Skip to main content
Erschienen in: European Journal of Epidemiology 1/2011

01.06.2011 | Supplement

Epidemiology and etiology of Parkinson’s disease: a review of the evidence

verfasst von: Karin Wirdefeldt, Hans-Olov Adami, Philip Cole, Dimitrios Trichopoulos, Jack Mandel

Erschienen in: European Journal of Epidemiology | Sonderheft 1/2011

Einloggen, um Zugang zu erhalten

Abstract

The etiology of Parkinson’s disease (PD) is not well understood but likely to involve both genetic and environmental factors. Incidence and prevalence estimates vary to a large extent—at least partly due to methodological differences between studies—but are consistently higher in men than in women. Several genes that cause familial as well as sporadic PD have been identified and familial aggregation studies support a genetic component. Despite a vast literature on lifestyle and environmental possible risk or protection factors, consistent findings are few. There is compelling evidence for protective effects of smoking and coffee, but the biologic mechanisms for these possibly causal relations are poorly understood. Uric acid also seems to be associated with lower PD risk. Evidence that one or several pesticides increase PD risk is suggestive but further research is needed to identify specific compounds that may play a causal role. Evidence is limited on the role of metals, other chemicals and magnetic fields. Important methodological limitations include crude classification of exposure, low frequency and intensity of exposure, inadequate sample size, potential for confounding, retrospective study designs and lack of consistent diagnostic criteria for PD. Studies that assessed possible shared etiological components between PD and other diseases show that REM sleep behavior disorder and mental illness increase PD risk and that PD patients have lower cancer risk, but methodological concerns exist. Future epidemiologic studies of PD should be large, include detailed quantifications of exposure, and collect information on environmental exposures as well as genetic polymorphisms.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Marsden CD. Movement disorders. In: Weatherall DJ, Ledingham JGG, Warrell DA, editors. Oxford textbook of medicine, vol. 3. New York: Oxford University Press Inc.; 1996. p. 3998–4022. Marsden CD. Movement disorders. In: Weatherall DJ, Ledingham JGG, Warrell DA, editors. Oxford textbook of medicine, vol. 3. New York: Oxford University Press Inc.; 1996. p. 3998–4022.
2.
Zurück zum Zitat Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:745–52.PubMedCrossRef Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:745–52.PubMedCrossRef
3.
Zurück zum Zitat McNaught KS, Olanow CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson’s disease. Ann Neurol. 2003;53:S73–84.PubMedCrossRef McNaught KS, Olanow CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson’s disease. Ann Neurol. 2003;53:S73–84.PubMedCrossRef
4.
Zurück zum Zitat Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–42.PubMed Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–42.PubMed
5.
Zurück zum Zitat Marttila RJ, Rinne UK. Epidemiology of Parkinson’s disease in Finland. Acta Neurol Scand. 1976;53:81–102.PubMedCrossRef Marttila RJ, Rinne UK. Epidemiology of Parkinson’s disease in Finland. Acta Neurol Scand. 1976;53:81–102.PubMedCrossRef
6.
Zurück zum Zitat Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology. 1985;35:841–5.PubMed Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology. 1985;35:841–5.PubMed
7.
Zurück zum Zitat Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson’s disease. Ann Neurol. 1992;32(Suppl):S125–7.PubMedCrossRef Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson’s disease. Ann Neurol. 1992;32(Suppl):S125–7.PubMedCrossRef
8.
Zurück zum Zitat Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33–9.PubMedCrossRef Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33–9.PubMedCrossRef
9.
Zurück zum Zitat Ward CD, Gibb WR. Research diagnostic criteria for Parkinson’s disease. Adv Neurol. 1990;53:245–9.PubMed Ward CD, Gibb WR. Research diagnostic criteria for Parkinson’s disease. Adv Neurol. 1990;53:245–9.PubMed
10.
Zurück zum Zitat Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism–a prospective study. Can J Neurol Sci. 1991;18:275–8.PubMed Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism–a prospective study. Can J Neurol Sci. 1991;18:275–8.PubMed
11.
Zurück zum Zitat Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–4.PubMedCrossRef Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–4.PubMedCrossRef
12.
Zurück zum Zitat Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology. 1992;42:1142–6.PubMed Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology. 1992;42:1142–6.PubMed
13.
Zurück zum Zitat Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology. 2001;57:1497–9.PubMed Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology. 2001;57:1497–9.PubMed
14.
Zurück zum Zitat Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861–70.PubMedCrossRef Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861–70.PubMedCrossRef
15.
Zurück zum Zitat Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998;55:969–78.PubMedCrossRef Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998;55:969–78.PubMedCrossRef
16.
Zurück zum Zitat Benito-Leon J, Bermejo-Pareja F, Rodriguez J, Molina JA, Gabriel R, Morales JM. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord. 2003;18:267–74.PubMedCrossRef Benito-Leon J, Bermejo-Pareja F, Rodriguez J, Molina JA, Gabriel R, Morales JM. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord. 2003;18:267–74.PubMedCrossRef
17.
Zurück zum Zitat de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, et al. Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:S21–3.PubMed de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, et al. Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:S21–3.PubMed
18.
Zurück zum Zitat de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62:10–5.PubMedCrossRef de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62:10–5.PubMedCrossRef
19.
Zurück zum Zitat Claveria LE, Duarte J, Sevillano MD, Perez-Sempere A, Cabezas C, Rodriguez F, et al. Prevalence of Parkinson’s disease in Cantalejo, Spain: a door-to-door survey. Mov Disord. 2002;17:242–9.PubMedCrossRef Claveria LE, Duarte J, Sevillano MD, Perez-Sempere A, Cabezas C, Rodriguez F, et al. Prevalence of Parkinson’s disease in Cantalejo, Spain: a door-to-door survey. Mov Disord. 2002;17:242–9.PubMedCrossRef
20.
Zurück zum Zitat Morgante L, Rocca WA, Di Rosa AE, De Domenico P, Grigoletto F, Meneghini F, et al. Prevalence of Parkinson’s disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology. 1992;42:1901–7.PubMed Morgante L, Rocca WA, Di Rosa AE, De Domenico P, Grigoletto F, Meneghini F, et al. Prevalence of Parkinson’s disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology. 1992;42:1901–7.PubMed
21.
Zurück zum Zitat Schoenberg BS, Osuntokun BO, Adeuja AO, Bademosi O, Nottidge V, Anderson DW, et al. Comparison of the prevalence of Parkinson’s disease in black populations in the rural United States and in rural Nigeria: door-to-door community studies. Neurology. 1988;38:645–6.PubMed Schoenberg BS, Osuntokun BO, Adeuja AO, Bademosi O, Nottidge V, Anderson DW, et al. Comparison of the prevalence of Parkinson’s disease in black populations in the rural United States and in rural Nigeria: door-to-door community studies. Neurology. 1988;38:645–6.PubMed
22.
Zurück zum Zitat Tison F, Dartigues JF, Dubes L, Zuber M, Alperovitch A, Henry P. Prevalence of Parkinson’s disease in the elderly: a population study in Gironde, France. Acta Neurol Scand. 1994;90:111–5.PubMedCrossRef Tison F, Dartigues JF, Dubes L, Zuber M, Alperovitch A, Henry P. Prevalence of Parkinson’s disease in the elderly: a population study in Gironde, France. Acta Neurol Scand. 1994;90:111–5.PubMedCrossRef
23.
Zurück zum Zitat Zhang ZX, Roman GC, Hong Z, Wu CB, Qu QM, Huang JB, et al. Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet. 2005;365:595–7.PubMed Zhang ZX, Roman GC, Hong Z, Wu CB, Qu QM, Huang JB, et al. Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet. 2005;365:595–7.PubMed
24.
Zurück zum Zitat Bermejo F, Gabriel R, Vega S, Morales JM, Rocca WA, Anderson DW. Problems and issues with door-to-door, two-phase surveys: an illustration from central Spain. Neuroepidemiology. 2001;20:225–31.PubMedCrossRef Bermejo F, Gabriel R, Vega S, Morales JM, Rocca WA, Anderson DW. Problems and issues with door-to-door, two-phase surveys: an illustration from central Spain. Neuroepidemiology. 2001;20:225–31.PubMedCrossRef
25.
Zurück zum Zitat de Rijk MC, Rocca WA, Anderson DW, Melcon MO, Breteler MM, Maraganore DM. A population perspective on diagnostic criteria for Parkinson’s disease. Neurology. 1997;48:1277–81.PubMed de Rijk MC, Rocca WA, Anderson DW, Melcon MO, Breteler MM, Maraganore DM. A population perspective on diagnostic criteria for Parkinson’s disease. Neurology. 1997;48:1277–81.PubMed
26.
Zurück zum Zitat Anderson DW, Rocca WA, de Rijk MC, Grigoletto F, Melcon MO, Breteler MM, et al. Case ascertainment uncertainties in prevalence surveys of Parkinson’s disease. Mov Disord. 1998;13:626–32.PubMedCrossRef Anderson DW, Rocca WA, de Rijk MC, Grigoletto F, Melcon MO, Breteler MM, et al. Case ascertainment uncertainties in prevalence surveys of Parkinson’s disease. Mov Disord. 1998;13:626–32.PubMedCrossRef
27.
Zurück zum Zitat Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson’s disease. Mov Disord. 2000;15:819–25.PubMedCrossRef Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson’s disease. Mov Disord. 2000;15:819–25.PubMedCrossRef
28.
Zurück zum Zitat Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E, et al. Parkinson’s disease and Parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology. 2000;55:1358–63.PubMed Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E, et al. Parkinson’s disease and Parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology. 2000;55:1358–63.PubMed
29.
Zurück zum Zitat Benito-Leon J, Bermejo-Pareja F, Morales-Gonzalez JM, Porta-Etessam J, Trincado R, Vega S, et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology. 2004;62:734–41.PubMed Benito-Leon J, Bermejo-Pareja F, Morales-Gonzalez JM, Porta-Etessam J, Trincado R, Vega S, et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology. 2004;62:734–41.PubMed
30.
Zurück zum Zitat Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology. 1999;52:1214–20.PubMed Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology. 1999;52:1214–20.PubMed
31.
Zurück zum Zitat Brewis M, Poskanzer DC, Rolland C, Miller H. Neurological disease in an English city. Acta Neurol Scand. 1966;42(Suppl 24):1–89.PubMed Brewis M, Poskanzer DC, Rolland C, Miller H. Neurological disease in an English city. Acta Neurol Scand. 1966;42(Suppl 24):1–89.PubMed
32.
Zurück zum Zitat Chen RC, Chang SF, Su CL, Chen TH, Yen MF, Wu HM, et al. Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology. 2001;57:1679–86.PubMed Chen RC, Chang SF, Su CL, Chen TH, Yen MF, Wu HM, et al. Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology. 2001;57:1679–86.PubMed
33.
Zurück zum Zitat de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology. 2004;63:1240–4.PubMed de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology. 2004;63:1240–4.PubMed
34.
Zurück zum Zitat Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009;72:432–8.PubMedCrossRef Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009;72:432–8.PubMedCrossRef
35.
Zurück zum Zitat Fall PA, Axelson O, Fredriksson M, Hansson G, Lindvall B, Olsson JE, et al. Age-standardized incidence and prevalence of Parkinson’s disease in a Swedish community. J Clin Epidemiol. 1996;49:637–41.PubMedCrossRef Fall PA, Axelson O, Fredriksson M, Hansson G, Lindvall B, Olsson JE, et al. Age-standardized incidence and prevalence of Parkinson’s disease in a Swedish community. J Clin Epidemiol. 1996;49:637–41.PubMedCrossRef
36.
Zurück zum Zitat Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain. 2004;127:550–60.PubMedCrossRef Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain. 2004;127:550–60.PubMedCrossRef
37.
Zurück zum Zitat Granieri E, Carreras M, Casetta I, Govoni V, Tola MR, Paolino E, et al. Parkinson’s disease in Ferrara, Italy, 1967 through 1987. Arch Neurol. 1991;48:854–7.PubMed Granieri E, Carreras M, Casetta I, Govoni V, Tola MR, Paolino E, et al. Parkinson’s disease in Ferrara, Italy, 1967 through 1987. Arch Neurol. 1991;48:854–7.PubMed
38.
Zurück zum Zitat Leentjens AF, Van den Akker M, Metsemakers JF, Troost J. The incidence of Parkinson’s disease in the Netherlands: results from a longitudinal general practice-based registration. Neuroepidemiology. 2003;22:311–2.PubMedCrossRef Leentjens AF, Van den Akker M, Metsemakers JF, Troost J. The incidence of Parkinson’s disease in the Netherlands: results from a longitudinal general practice-based registration. Neuroepidemiology. 2003;22:311–2.PubMedCrossRef
39.
Zurück zum Zitat MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain. 2000;123(Pt 4):665–76.PubMedCrossRef MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain. 2000;123(Pt 4):665–76.PubMedCrossRef
40.
Zurück zum Zitat Mayeux R, Marder K, Cote LJ, Denaro J, Hemenegildo N, Mejia H, et al. The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988–1993. Am J Epidemiol. 1995;142:820–7.PubMed Mayeux R, Marder K, Cote LJ, Denaro J, Hemenegildo N, Mejia H, et al. The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988–1993. Am J Epidemiol. 1995;142:820–7.PubMed
41.
Zurück zum Zitat Morens DM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR. Epidemiologic observations on Parkinson’s disease: incidence and mortality in a prospective study of middle-aged men. Neurology. 1996;46:1044–50.PubMed Morens DM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR. Epidemiologic observations on Parkinson’s disease: incidence and mortality in a prospective study of middle-aged men. Neurology. 1996;46:1044–50.PubMed
42.
Zurück zum Zitat Morioka S, Sakata K, Yoshida S, Nakai E, Shiba M, Yoshimura N, et al. Incidence of Parkinson disease in Wakayama, Japan. J Epidemiol. 2002;12:403–7.PubMed Morioka S, Sakata K, Yoshida S, Nakai E, Shiba M, Yoshimura N, et al. Incidence of Parkinson disease in Wakayama, Japan. J Epidemiol. 2002;12:403–7.PubMed
43.
Zurück zum Zitat Tan LC, Venketasubramanian N, Jamora RD, Heng D. Incidence of Parkinson’s disease in Singapore. Parkinsonism Relat Disord. 2007;13:40–3.PubMedCrossRef Tan LC, Venketasubramanian N, Jamora RD, Heng D. Incidence of Parkinson’s disease in Singapore. Parkinsonism Relat Disord. 2007;13:40–3.PubMedCrossRef
44.
Zurück zum Zitat Taylor KS, Counsell CE, Harris CE, Gordon JC, Smith WC. Pilot study of the incidence and prognosis of degenerative Parkinsonian disorders in Aberdeen, United Kingdom: methods and preliminary results. Mov Disord. 2006;21:976–82.PubMedCrossRef Taylor KS, Counsell CE, Harris CE, Gordon JC, Smith WC. Pilot study of the incidence and prognosis of degenerative Parkinsonian disorders in Aberdeen, United Kingdom: methods and preliminary results. Mov Disord. 2006;21:976–82.PubMedCrossRef
45.
Zurück zum Zitat Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157:1015–22.CrossRef Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157:1015–22.CrossRef
46.
Zurück zum Zitat Wang YS, Shi YM, Wu ZY, He YX, Zhang BZ. Parkinson’s disease in China. Coordinational Group of Neuroepidemiology, PLA. Chin Med J (Engl). 1991;104:960–4. Wang YS, Shi YM, Wu ZY, He YX, Zhang BZ. Parkinson’s disease in China. Coordinational Group of Neuroepidemiology, PLA. Chin Med J (Engl). 1991;104:960–4.
47.
Zurück zum Zitat Linder J, Stenlund H, Forsgren L. Incidence of Parkinson’s disease and parkinsonism in northern Sweden: a population-based study. Mov Disord. 2010;25:341–8.PubMed Linder J, Stenlund H, Forsgren L. Incidence of Parkinson’s disease and parkinsonism in northern Sweden: a population-based study. Mov Disord. 2010;25:341–8.PubMed
48.
Zurück zum Zitat Winter Y, Bezdolnyy Y, Katunina E, Avakjan G, Reese JP, Klotsche J, et al. Incidence of Parkinson’s disease and atypical parkinsonism: Russian population-based study. Mov Disord. 2010;25:349–56.PubMed Winter Y, Bezdolnyy Y, Katunina E, Avakjan G, Reese JP, Klotsche J, et al. Incidence of Parkinson’s disease and atypical parkinsonism: Russian population-based study. Mov Disord. 2010;25:349–56.PubMed
49.
Zurück zum Zitat Hristova D, Zachariev Z, Mateva N, Grozdev I. Incidence of Parkinson’s disease in Bulgaria. Neuroepidemiology. 2010;34:76–82.PubMedCrossRef Hristova D, Zachariev Z, Mateva N, Grozdev I. Incidence of Parkinson’s disease in Bulgaria. Neuroepidemiology. 2010;34:76–82.PubMedCrossRef
50.
Zurück zum Zitat Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson’s disease. Mov Disord. 2003;18:19–31.PubMedCrossRef Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson’s disease. Mov Disord. 2003;18:19–31.PubMedCrossRef
51.
Zurück zum Zitat Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the “common” neurologic disorders? Neurology. 2007;68:326–37.PubMedCrossRef Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the “common” neurologic disorders? Neurology. 2007;68:326–37.PubMedCrossRef
52.
Zurück zum Zitat Taba P, Asser T. Incidence of Parkinson’s disease in estonia. Neuroepidemiology. 2003;22:41–5.PubMedCrossRef Taba P, Asser T. Incidence of Parkinson’s disease in estonia. Neuroepidemiology. 2003;22:41–5.PubMedCrossRef
53.
Zurück zum Zitat Wermuth L, Bech S, Petersen MS, Joensen P, Weihe P, Grandjean P. Prevalence and incidence of Parkinson’s disease in The Faroe Islands. Acta Neurol Scand. 2008;118:126–31.PubMedCrossRef Wermuth L, Bech S, Petersen MS, Joensen P, Weihe P, Grandjean P. Prevalence and incidence of Parkinson’s disease in The Faroe Islands. Acta Neurol Scand. 2008;118:126–31.PubMedCrossRef
54.
Zurück zum Zitat Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Risk tables for parkinsonism and Parkinson’s disease. J Clin Epidemiol. 2002;55:25–31.PubMedCrossRef Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Risk tables for parkinsonism and Parkinson’s disease. J Clin Epidemiol. 2002;55:25–31.PubMedCrossRef
55.
Zurück zum Zitat Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry. 2004;75:637–9.PubMedCrossRef Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry. 2004;75:637–9.PubMedCrossRef
56.
Zurück zum Zitat Taylor KS, Cook JA, Counsell CE. Heterogeneity in male to female risk for Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78:905–6.PubMedCrossRef Taylor KS, Cook JA, Counsell CE. Heterogeneity in male to female risk for Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78:905–6.PubMedCrossRef
57.
Zurück zum Zitat Barbosa MT, Caramelli P, Maia DP, Cunningham MC, Guerra HL, Lima-Costa MF, et al. Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambui study). Mov Disord. 2006;21:800–8.PubMedCrossRef Barbosa MT, Caramelli P, Maia DP, Cunningham MC, Guerra HL, Lima-Costa MF, et al. Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambui study). Mov Disord. 2006;21:800–8.PubMedCrossRef
58.
Zurück zum Zitat Bergareche A, De La Puente E, Lopez de Munain A, Sarasqueta C, de Arce A, Poza JJ, et al. Prevalence of Parkinson’s disease and other types of Parkinsonism. A door-to-door survey in Bidasoa, Spain. J Neurol. 2004;251:340–5.PubMedCrossRef Bergareche A, De La Puente E, Lopez de Munain A, Sarasqueta C, de Arce A, Poza JJ, et al. Prevalence of Parkinson’s disease and other types of Parkinsonism. A door-to-door survey in Bidasoa, Spain. J Neurol. 2004;251:340–5.PubMedCrossRef
59.
Zurück zum Zitat Chan DK, Cordato D, Karr M, Ong B, Lei H, Liu J, et al. Prevalence of Parkinson’s disease in Sydney. Acta Neurol Scand. 2005;111:7–11.PubMedCrossRef Chan DK, Cordato D, Karr M, Ong B, Lei H, Liu J, et al. Prevalence of Parkinson’s disease in Sydney. Acta Neurol Scand. 2005;111:7–11.PubMedCrossRef
60.
Zurück zum Zitat de Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meche FG, et al. Prevalence of Parkinson’s disease in the elderly: the Rotterdam Study. Neurology. 1995;45:2143–6.PubMed de Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meche FG, et al. Prevalence of Parkinson’s disease in the elderly: the Rotterdam Study. Neurology. 1995;45:2143–6.PubMed
61.
Zurück zum Zitat Kis B, Schrag A, Ben-Shlomo Y, Klein C, Gasperi A, Spoegler F, et al. Novel three-stage ascertainment method: prevalence of PD and parkinsonism in South Tyrol, Italy. Neurology. 2002;58:1820–5.PubMed Kis B, Schrag A, Ben-Shlomo Y, Klein C, Gasperi A, Spoegler F, et al. Novel three-stage ascertainment method: prevalence of PD and parkinsonism in South Tyrol, Italy. Neurology. 2002;58:1820–5.PubMed
62.
Zurück zum Zitat Li SC, Schoenberg BS, Wang CC, Cheng XM, Rui DY, Bolis CL, et al. A prevalence survey of Parkinson’s disease and other movement disorders in the People’s Republic of China. Arch Neurol. 1985;42:655–7.PubMed Li SC, Schoenberg BS, Wang CC, Cheng XM, Rui DY, Bolis CL, et al. A prevalence survey of Parkinson’s disease and other movement disorders in the People’s Republic of China. Arch Neurol. 1985;42:655–7.PubMed
63.
Zurück zum Zitat Melcon MO, Anderson DW, Vergara RH, Rocca WA. Prevalence of Parkinson’s disease in Junin, Buenos Aires Province, Argentina. Mov Disord. 1997;12:197–205.PubMedCrossRef Melcon MO, Anderson DW, Vergara RH, Rocca WA. Prevalence of Parkinson’s disease in Junin, Buenos Aires Province, Argentina. Mov Disord. 1997;12:197–205.PubMedCrossRef
64.
Zurück zum Zitat Nicoletti A, Sofia V, Bartoloni A, Bartalesi F, Gamboa Barahon H, Giuffrida S, et al. Prevalence of Parkinson’s disease: a door-to-door survey in rural Bolivia. Parkinsonism Relat Disord. 2003;10:19–21.PubMedCrossRef Nicoletti A, Sofia V, Bartoloni A, Bartalesi F, Gamboa Barahon H, Giuffrida S, et al. Prevalence of Parkinson’s disease: a door-to-door survey in rural Bolivia. Parkinsonism Relat Disord. 2003;10:19–21.PubMedCrossRef
65.
Zurück zum Zitat Okada K, Kobayashi S, Tsunematsu T. Prevalence of Parkinson’s disease in Izumo City, Japan. Gerontology. 1990;36:340–4.PubMedCrossRef Okada K, Kobayashi S, Tsunematsu T. Prevalence of Parkinson’s disease in Izumo City, Japan. Gerontology. 1990;36:340–4.PubMedCrossRef
66.
Zurück zum Zitat Tan LC, Venketasubramanian N, Hong CY, Sahadevan S, Chin JJ, Krishnamoorthy ES, et al. Prevalence of Parkinson disease in Singapore: Chinese vs Malays vs Indians. Neurology. 2004;62:1999–2004.PubMed Tan LC, Venketasubramanian N, Hong CY, Sahadevan S, Chin JJ, Krishnamoorthy ES, et al. Prevalence of Parkinson disease in Singapore: Chinese vs Malays vs Indians. Neurology. 2004;62:1999–2004.PubMed
67.
Zurück zum Zitat Wang SJ, Fuh JL, Teng EL, Liu CY, Lin KP, Chen HM, et al. A door-to-door survey of Parkinson’s disease in a Chinese population in Kinmen. Arch Neurol. 1996;53:66–71.PubMed Wang SJ, Fuh JL, Teng EL, Liu CY, Lin KP, Chen HM, et al. A door-to-door survey of Parkinson’s disease in a Chinese population in Kinmen. Arch Neurol. 1996;53:66–71.PubMed
68.
Zurück zum Zitat Wirdefeldt K, Gatz M, Bakaysa SL, Fiske A, Flensburg M, Petzinger GM, et al. Complete ascertainment of Parkinson disease in the Swedish Twin Registry. Neurobiol Aging. 2008;29:1765–73.PubMedCrossRef Wirdefeldt K, Gatz M, Bakaysa SL, Fiske A, Flensburg M, Petzinger GM, et al. Complete ascertainment of Parkinson disease in the Swedish Twin Registry. Neurobiol Aging. 2008;29:1765–73.PubMedCrossRef
69.
Zurück zum Zitat Racette BA, Good LM, Kissel AM, Criswell SR, Perlmutter JS. A population-based study of parkinsonism in an Amish community. Neuroepidemiology. 2009;33:225–30.PubMedCrossRef Racette BA, Good LM, Kissel AM, Criswell SR, Perlmutter JS. A population-based study of parkinsonism in an Amish community. Neuroepidemiology. 2009;33:225–30.PubMedCrossRef
70.
Zurück zum Zitat Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384–6.PubMedCrossRef Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384–6.PubMedCrossRef
71.
Zurück zum Zitat Kessler II. Epidemiologic studies of Parkinson’s disease. II. A hospital-based survey. Am J Epidemiol. 1972;95:308–18.PubMed Kessler II. Epidemiologic studies of Parkinson’s disease. II. A hospital-based survey. Am J Epidemiol. 1972;95:308–18.PubMed
72.
Zurück zum Zitat Paddison RM, Griffith RP. Occurrence of Parkinson’s disease in black patients at Charity Hospital in New Orleans. Neurology. 1974;24:688–90.PubMed Paddison RM, Griffith RP. Occurrence of Parkinson’s disease in black patients at Charity Hospital in New Orleans. Neurology. 1974;24:688–90.PubMed
73.
Zurück zum Zitat Lombard A, Gelfand M. Parkinson’s disease in the African. Cent Afr J Med. 1978;24:5–8.PubMed Lombard A, Gelfand M. Parkinson’s disease in the African. Cent Afr J Med. 1978;24:5–8.PubMed
74.
Zurück zum Zitat Woo J, Lau E, Ziea E, Chan DK. Prevalence of Parkinson’s disease in a Chinese population. Acta Neurol Scand. 2004;109:228–31.PubMedCrossRef Woo J, Lau E, Ziea E, Chan DK. Prevalence of Parkinson’s disease in a Chinese population. Acta Neurol Scand. 2004;109:228–31.PubMedCrossRef
75.
Zurück zum Zitat Trenkwalder C, Schwarz J, Gebhard J, Ruland D, Trenkwalder P, Hense HW, et al. Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson’s disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol. 1995;52:1017–22.PubMed Trenkwalder C, Schwarz J, Gebhard J, Ruland D, Trenkwalder P, Hense HW, et al. Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson’s disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol. 1995;52:1017–22.PubMed
76.
Zurück zum Zitat Zhang ZX, Roman GC. Worldwide occurrence of Parkinson’s disease: an updated review. Neuroepidemiology. 1993;12:195–208.PubMedCrossRef Zhang ZX, Roman GC. Worldwide occurrence of Parkinson’s disease: an updated review. Neuroepidemiology. 1993;12:195–208.PubMedCrossRef
77.
Zurück zum Zitat McInerney-Leo A, Gwinn-Hardy K, Nussbaum RL. Prevalence of Parkinson’s disease in populations of African ancestry: a review. J Natl Med Assoc. 2004;96:974–9.PubMed McInerney-Leo A, Gwinn-Hardy K, Nussbaum RL. Prevalence of Parkinson’s disease in populations of African ancestry: a review. J Natl Med Assoc. 2004;96:974–9.PubMed
78.
Zurück zum Zitat Attia Romdhane N, Ben Hamida M, Mrabet A, Larnaout A, Samoud S, Ben Hamda A, et al. Prevalence study of neurologic disorders in Kelibia (Tunisia). Neuroepidemiology. 1993;12:285–99.PubMedCrossRef Attia Romdhane N, Ben Hamida M, Mrabet A, Larnaout A, Samoud S, Ben Hamda A, et al. Prevalence study of neurologic disorders in Kelibia (Tunisia). Neuroepidemiology. 1993;12:285–99.PubMedCrossRef
79.
Zurück zum Zitat Ashok PP, Radhakrishnan K, Sridharan R, Mousa ME. Epidemiology of Parkinson’s disease in Benghazi, North-East Libya. Clin Neurol Neurosurg. 1986;88:109–13.PubMedCrossRef Ashok PP, Radhakrishnan K, Sridharan R, Mousa ME. Epidemiology of Parkinson’s disease in Benghazi, North-East Libya. Clin Neurol Neurosurg. 1986;88:109–13.PubMedCrossRef
80.
Zurück zum Zitat Okubadejo NU, Bower JH, Rocca WA, Maraganore DM. Parkinson’s disease in Africa: a systematic review of epidemiologic and genetic studies. Mov Disord. 2006;21:2150–6.PubMedCrossRef Okubadejo NU, Bower JH, Rocca WA, Maraganore DM. Parkinson’s disease in Africa: a systematic review of epidemiologic and genetic studies. Mov Disord. 2006;21:2150–6.PubMedCrossRef
81.
Zurück zum Zitat D’Alessandro R, Gamberini G, Granieri E, Benassi G, Naccarato S, Manzaroli D. Prevalence of Parkinson’s disease in the Republic of San Marino. Neurology. 1987;37:1679–82.PubMed D’Alessandro R, Gamberini G, Granieri E, Benassi G, Naccarato S, Manzaroli D. Prevalence of Parkinson’s disease in the Republic of San Marino. Neurology. 1987;37:1679–82.PubMed
82.
Zurück zum Zitat Rosati G, Granieri E, Pinna L, Aiello I, De Bastiani P, Tola R, et al. Parkinson’s disease. Prevalence and incidence in the Province of Sassari, North Sardinia. Acta Neurol (Napoli). 1978;33:201–7. Rosati G, Granieri E, Pinna L, Aiello I, De Bastiani P, Tola R, et al. Parkinson’s disease. Prevalence and incidence in the Province of Sassari, North Sardinia. Acta Neurol (Napoli). 1978;33:201–7.
83.
Zurück zum Zitat Rosati G, Granieri E, Pinna L, Aiello I, Tola R, De Bastiani P, et al. The risk of Parkinson disease in Mediterranean people. Neurology. 1980;30:250–5.PubMed Rosati G, Granieri E, Pinna L, Aiello I, Tola R, De Bastiani P, et al. The risk of Parkinson disease in Mediterranean people. Neurology. 1980;30:250–5.PubMed
84.
Zurück zum Zitat Rosati G, Granieri E, Pinna L, Devoto MC. The frequency of Parkinson’s disease in the Province of Nuoro (Sardinia). Acta Neurol (Napoli). 1979;1:303–8. Rosati G, Granieri E, Pinna L, Devoto MC. The frequency of Parkinson’s disease in the Province of Nuoro (Sardinia). Acta Neurol (Napoli). 1979;1:303–8.
85.
Zurück zum Zitat Errea JM, Ara JR, Aibar C, de Pedro-Cuesta J. Prevalence of Parkinson’s disease in lower Aragon, Spain. Mov Disord. 1999;14:596–604.PubMedCrossRef Errea JM, Ara JR, Aibar C, de Pedro-Cuesta J. Prevalence of Parkinson’s disease in lower Aragon, Spain. Mov Disord. 1999;14:596–604.PubMedCrossRef
86.
Zurück zum Zitat Sutcliffe RL, Meara JR. Parkinson’s disease epidemiology in the Northampton District, England, 1992. Acta Neurol Scand. 1995;92:443–50.PubMedCrossRef Sutcliffe RL, Meara JR. Parkinson’s disease epidemiology in the Northampton District, England, 1992. Acta Neurol Scand. 1995;92:443–50.PubMedCrossRef
87.
Zurück zum Zitat Berger K, Breteler MM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, et al. Prognosis with Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:S24–7.PubMed Berger K, Breteler MM, Helmer C, Inzitari D, Fratiglioni L, Trenkwalder C, et al. Prognosis with Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:S24–7.PubMed
88.
Zurück zum Zitat Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A. Survival of Parkinson’s disease patients in a large prospective cohort of male health professionals. Mov Disord. 2006;21:1002–7.PubMedCrossRef Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A. Survival of Parkinson’s disease patients in a large prospective cohort of male health professionals. Mov Disord. 2006;21:1002–7.PubMedCrossRef
89.
Zurück zum Zitat D’Amelio M, Ragonese P, Morgante L, Reggio A, Callari G, Salemi G, et al. Long-term survival of Parkinson’s disease: a population-based study. J Neurol. 2006;253:33–7.PubMedCrossRef D’Amelio M, Ragonese P, Morgante L, Reggio A, Callari G, Salemi G, et al. Long-term survival of Parkinson’s disease: a population-based study. J Neurol. 2006;253:33–7.PubMedCrossRef
90.
Zurück zum Zitat de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol. 2005;62:1265–9.PubMedCrossRef de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol. 2005;62:1265–9.PubMedCrossRef
91.
Zurück zum Zitat Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology. 2008;70:1423–30.PubMedCrossRef Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology. 2008;70:1423–30.PubMedCrossRef
92.
Zurück zum Zitat Ebmeier KP, Calder SA, Crawford JR, Stewart L, Besson JA, Mutch WJ. Mortality and causes of death in idiopathic Parkinson’s disease: results from the Aberdeen whole population study. Scott Med J. 1990;35:173–5.PubMed Ebmeier KP, Calder SA, Crawford JR, Stewart L, Besson JA, Mutch WJ. Mortality and causes of death in idiopathic Parkinson’s disease: results from the Aberdeen whole population study. Scott Med J. 1990;35:173–5.PubMed
93.
Zurück zum Zitat Elbaz A, Bower JH, Peterson BJ, Maraganore DM, McDonnell SK, Ahlskog JE, et al. Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol. 2003;60:91–6.PubMedCrossRef Elbaz A, Bower JH, Peterson BJ, Maraganore DM, McDonnell SK, Ahlskog JE, et al. Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol. 2003;60:91–6.PubMedCrossRef
94.
Zurück zum Zitat Fall PA, Saleh A, Fredrickson M, Olsson JE, Granerus AK. Survival time, mortality, and cause of death in elderly patients with Parkinson’s disease: a 9-year follow-up. Mov Disord. 2003;18:1312–6.PubMedCrossRef Fall PA, Saleh A, Fredrickson M, Olsson JE, Granerus AK. Survival time, mortality, and cause of death in elderly patients with Parkinson’s disease: a 9-year follow-up. Mov Disord. 2003;18:1312–6.PubMedCrossRef
95.
Zurück zum Zitat Hely MA, Morris JG, Traficante R, Reid WG, O’Sullivan DJ, Williamson PM. The sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry. 1999;67:300–7.PubMedCrossRef Hely MA, Morris JG, Traficante R, Reid WG, O’Sullivan DJ, Williamson PM. The sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry. 1999;67:300–7.PubMedCrossRef
96.
Zurück zum Zitat Herlofson K, Lie SA, Arsland D, Larsen JP. Mortality and Parkinson disease: a community based study. Neurology. 2004;62:937–42.PubMed Herlofson K, Lie SA, Arsland D, Larsen JP. Mortality and Parkinson disease: a community based study. Neurology. 2004;62:937–42.PubMed
97.
Zurück zum Zitat Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson’s disease and its association with dementia and depression. Acta Neurol Scand. 2004;110:118–23.PubMedCrossRef Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson’s disease and its association with dementia and depression. Acta Neurol Scand. 2004;110:118–23.PubMedCrossRef
98.
Zurück zum Zitat Louis ED, Marder K, Cote L, Tang M, Mayeux R. Mortality from Parkinson disease. Arch Neurol. 1997;54:260–4.PubMed Louis ED, Marder K, Cote L, Tang M, Mayeux R. Mortality from Parkinson disease. Arch Neurol. 1997;54:260–4.PubMed
99.
Zurück zum Zitat Marttila RJ, Rinne UK, Siirtola T, Sonninen V. Mortality of patients with Parkinson’s disease treated with levodopa. J Neurol. 1977;216:147–53.PubMedCrossRef Marttila RJ, Rinne UK, Siirtola T, Sonninen V. Mortality of patients with Parkinson’s disease treated with levodopa. J Neurol. 1977;216:147–53.PubMedCrossRef
100.
Zurück zum Zitat Morgante L, Salemi G, Meneghini F, Di Rosa AE, Epifanio A, Grigoletto F, et al. Parkinson disease survival: a population-based study. Arch Neurol. 2000;57:507–12.PubMedCrossRef Morgante L, Salemi G, Meneghini F, Di Rosa AE, Epifanio A, Grigoletto F, et al. Parkinson disease survival: a population-based study. Arch Neurol. 2000;57:507–12.PubMedCrossRef
101.
Zurück zum Zitat Vanacore N, Bonifati V, Bellatreccia A, Edito F, Meco G. Mortality rates for Parkinson’s disease and parkinsonism in Italy (1969–1987). Neuroepidemiology. 1992;11:65–73.PubMedCrossRef Vanacore N, Bonifati V, Bellatreccia A, Edito F, Meco G. Mortality rates for Parkinson’s disease and parkinsonism in Italy (1969–1987). Neuroepidemiology. 1992;11:65–73.PubMedCrossRef
102.
Zurück zum Zitat Diem-Zangerl A, Seppi K, Oberaigner W, Poewe W. Mortality in Parkinson’s disease, a 20-year follow-up study. Mov Disord. 2010;25:661–2.PubMed Diem-Zangerl A, Seppi K, Oberaigner W, Poewe W. Mortality in Parkinson’s disease, a 20-year follow-up study. Mov Disord. 2010;25:661–2.PubMed
103.
Zurück zum Zitat Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD. Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. Neurology. 2001;57:2278–82.PubMed Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD. Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. Neurology. 2001;57:2278–82.PubMed
104.
Zurück zum Zitat Ishihara LS, Cheesbrough A, Brayne C, Schrag A. Estimated life expectancy of Parkinson’s patients compared with the UK population. J Neurol Neurosurg Psychiatry. 2007;78:1304–9.PubMedCrossRef Ishihara LS, Cheesbrough A, Brayne C, Schrag A. Estimated life expectancy of Parkinson’s patients compared with the UK population. J Neurol Neurosurg Psychiatry. 2007;78:1304–9.PubMedCrossRef
105.
Zurück zum Zitat Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry. 1995;58:293–9.PubMedCrossRef Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry. 1995;58:293–9.PubMedCrossRef
106.
Zurück zum Zitat Uitti RJ, Ahlskog JE, Maraganore DM, Muenter MD, Atkinson EJ, Cha RH, et al. Levodopa therapy and survival in idiopathic Parkinson’s disease: Olmsted County project. Neurology. 1993;43:1918–26.PubMed Uitti RJ, Ahlskog JE, Maraganore DM, Muenter MD, Atkinson EJ, Cha RH, et al. Levodopa therapy and survival in idiopathic Parkinson’s disease: Olmsted County project. Neurology. 1993;43:1918–26.PubMed
107.
Zurück zum Zitat Roos RA, Jongen JC, van der Velde EA. Clinical course of patients with idiopathic Parkinson’s disease. Mov Disord. 1996;11:236–42.PubMedCrossRef Roos RA, Jongen JC, van der Velde EA. Clinical course of patients with idiopathic Parkinson’s disease. Mov Disord. 1996;11:236–42.PubMedCrossRef
108.
Zurück zum Zitat Levy G, Tang MX, Louis ED, Cote LJ, Alfaro B, Mejia H, et al. The association of incident dementia with mortality in PD. Neurology. 2002;59:1708–13.PubMed Levy G, Tang MX, Louis ED, Cote LJ, Alfaro B, Mejia H, et al. The association of incident dementia with mortality in PD. Neurology. 2002;59:1708–13.PubMed
109.
Zurück zum Zitat Fahn S, Elton RL, the UPDRS Development Committee. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, editors. Recent developments in Parkinson’s disease, vol. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987. p. 153–63. Fahn S, Elton RL, the UPDRS Development Committee. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, editors. Recent developments in Parkinson’s disease, vol. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987. p. 153–63.
110.
Zurück zum Zitat Wermuth L, Stenager EN, Stenager E, Boldsen J. Mortality in patients with Parkinson’s disease. Acta Neurol Scand. 1995;92:55–8.PubMedCrossRef Wermuth L, Stenager EN, Stenager E, Boldsen J. Mortality in patients with Parkinson’s disease. Acta Neurol Scand. 1995;92:55–8.PubMedCrossRef
111.
Zurück zum Zitat Gorell JM, Johnson CC, Rybicki BA. Parkinson’s disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology. 1994;44:1865–8.PubMed Gorell JM, Johnson CC, Rybicki BA. Parkinson’s disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology. 1994;44:1865–8.PubMed
112.
Zurück zum Zitat Paulson GW, Gill WM. Are death certificates reliable to estimate the incidence of Parkinson’s disease? Mov Disord. 1995;10:678.PubMedCrossRef Paulson GW, Gill WM. Are death certificates reliable to estimate the incidence of Parkinson’s disease? Mov Disord. 1995;10:678.PubMedCrossRef
113.
114.
Zurück zum Zitat Marttila RJ, Kaprio J, Koskenvuo M, Rinne UK. Parkinson’s disease in a nationwide twin cohort. Neurology. 1988;38:1217–9.PubMed Marttila RJ, Kaprio J, Koskenvuo M, Rinne UK. Parkinson’s disease in a nationwide twin cohort. Neurology. 1988;38:1217–9.PubMed
115.
Zurück zum Zitat Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson’s disease in 65 pairs of twins and in a set of quadruplets. Neurology. 1983;33:815–24.PubMed Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson’s disease in 65 pairs of twins and in a set of quadruplets. Neurology. 1983;33:815–24.PubMed
116.
Zurück zum Zitat Vieregge P, Schiffke KA, Friedrich HJ, Muller B, Ludin HP. Parkinson’s disease in twins. Neurology. 1992;42:1453–61.PubMed Vieregge P, Schiffke KA, Friedrich HJ, Muller B, Ludin HP. Parkinson’s disease in twins. Neurology. 1992;42:1453–61.PubMed
117.
Zurück zum Zitat Vieregge P, Hagenah J, Heberlein I, Klein C, Ludin HP. Parkinson’s disease in twins: a follow-up study. Neurology. 1999;53:566–72.PubMed Vieregge P, Hagenah J, Heberlein I, Klein C, Ludin HP. Parkinson’s disease in twins: a follow-up study. Neurology. 1999;53:566–72.PubMed
118.
Zurück zum Zitat Johnson WG, Hodge SE, Duvoisin R. Twin studies and the genetics of Parkinson’s disease–a reappraisal. Mov Disord. 1990;5:187–94.PubMedCrossRef Johnson WG, Hodge SE, Duvoisin R. Twin studies and the genetics of Parkinson’s disease–a reappraisal. Mov Disord. 1990;5:187–94.PubMedCrossRef
119.
Zurück zum Zitat Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, et al. Parkinson disease in twins: an etiologic study. Jama. 1999;281:341–6.PubMedCrossRef Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, et al. Parkinson disease in twins: an etiologic study. Jama. 1999;281:341–6.PubMedCrossRef
120.
Zurück zum Zitat Wirdefeldt K, Gatz M, Schalling M, Pedersen NL. No evidence for heritability of Parkinson disease in Swedish twins. Neurology. 2004;63:305–11.PubMed Wirdefeldt K, Gatz M, Schalling M, Pedersen NL. No evidence for heritability of Parkinson disease in Swedish twins. Neurology. 2004;63:305–11.PubMed
121.
Zurück zum Zitat Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64:314–9.PubMedCrossRef Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64:314–9.PubMedCrossRef
122.
Zurück zum Zitat Burn DJ, Mark MH, Playford ED, Maraganore DM, Zimmerman TR Jr, Duvoisin RC, et al. Parkinson’s disease in twins studied with 18F-dopa and positron emission tomography. Neurology. 1992;42:1894–900.PubMed Burn DJ, Mark MH, Playford ED, Maraganore DM, Zimmerman TR Jr, Duvoisin RC, et al. Parkinson’s disease in twins studied with 18F-dopa and positron emission tomography. Neurology. 1992;42:1894–900.PubMed
123.
Zurück zum Zitat Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson’s disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 1999;45:577–82.PubMedCrossRef Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson’s disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 1999;45:577–82.PubMedCrossRef
124.
Zurück zum Zitat Holthoff VA, Vieregge P, Kessler J, Pietrzyk U, Herholz K, Bonner J, et al. Discordant twins with Parkinson’s disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol. 1994;36:176–82.PubMedCrossRef Holthoff VA, Vieregge P, Kessler J, Pietrzyk U, Herholz K, Bonner J, et al. Discordant twins with Parkinson’s disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol. 1994;36:176–82.PubMedCrossRef
125.
Zurück zum Zitat Laihinen A, Ruottinen H, Rinne JO, Haaparanta M, Bergman J, Solin O, et al. Risk for Parkinson’s disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET. J Neurol. 2000;247(Suppl 2):110–3. Laihinen A, Ruottinen H, Rinne JO, Haaparanta M, Bergman J, Solin O, et al. Risk for Parkinson’s disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET. J Neurol. 2000;247(Suppl 2):110–3.
126.
Zurück zum Zitat Martin WE, Young WI, Anderson VE. Parkinson’s disease. A genetic study. Brain. 1973;96:495–506.PubMedCrossRef Martin WE, Young WI, Anderson VE. Parkinson’s disease. A genetic study. Brain. 1973;96:495–506.PubMedCrossRef
127.
Zurück zum Zitat Barbeau A, Pourcher E. New data on the genetics of Parkinson’s disease. Can J Neurol Sci. 1982;9:53–60.PubMed Barbeau A, Pourcher E. New data on the genetics of Parkinson’s disease. Can J Neurol Sci. 1982;9:53–60.PubMed
128.
Zurück zum Zitat Alonso ME, Otero E, D’Regules R, Figueroa HH. Parkinson’s disease: a genetic study. Can J Neurol Sci. 1986;13:248–51.PubMed Alonso ME, Otero E, D’Regules R, Figueroa HH. Parkinson’s disease: a genetic study. Can J Neurol Sci. 1986;13:248–51.PubMed
129.
Zurück zum Zitat Marttila RJ, Rinne UK. Parkinson’s disease and essential tremor in families of patients with early-onset Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:429–31.PubMedCrossRef Marttila RJ, Rinne UK. Parkinson’s disease and essential tremor in families of patients with early-onset Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:429–31.PubMedCrossRef
130.
Zurück zum Zitat Mickel SF, Broste SK, Hiner BC. Lack of overlap in genetic risks for Alzheimer’s disease and Parkinson’s disease. Neurology. 1997;48:942–9.PubMed Mickel SF, Broste SK, Hiner BC. Lack of overlap in genetic risks for Alzheimer’s disease and Parkinson’s disease. Neurology. 1997;48:942–9.PubMed
131.
Zurück zum Zitat Taylor CA, Saint-Hilaire MH, Cupples LA, Thomas CA, Burchard AE, Feldman RG, et al. Environmental, medical, and family history risk factors for Parkinson’s disease: a New England-based case control study. Am J Med Genet. 1999;88:742–9.PubMedCrossRef Taylor CA, Saint-Hilaire MH, Cupples LA, Thomas CA, Burchard AE, Feldman RG, et al. Environmental, medical, and family history risk factors for Parkinson’s disease: a New England-based case control study. Am J Med Genet. 1999;88:742–9.PubMedCrossRef
132.
Zurück zum Zitat Semchuk KM, Love EJ, Lee RG. Parkinson’s disease: a test of the multifactorial etiologic hypothesis. Neurology. 1993;43:1173–80.PubMed Semchuk KM, Love EJ, Lee RG. Parkinson’s disease: a test of the multifactorial etiologic hypothesis. Neurology. 1993;43:1173–80.PubMed
133.
Zurück zum Zitat Payami H, Larsen K, Bernard S, Nutt J. Increased risk of Parkinson’s disease in parents and siblings of patients. Ann Neurol. 1994;36:659–61.PubMedCrossRef Payami H, Larsen K, Bernard S, Nutt J. Increased risk of Parkinson’s disease in parents and siblings of patients. Ann Neurol. 1994;36:659–61.PubMedCrossRef
134.
Zurück zum Zitat Payami H, Zareparsi S, James D, Nutt J. Familial aggregation of Parkinson disease: a comparative study of early-onset and late-onset disease. Arch Neurol. 2002;59:848–50.PubMedCrossRef Payami H, Zareparsi S, James D, Nutt J. Familial aggregation of Parkinson disease: a comparative study of early-onset and late-onset disease. Arch Neurol. 2002;59:848–50.PubMedCrossRef
135.
Zurück zum Zitat de la Fuente-Fernandez R. Maternal effect on Parkinson’s disease. Ann Neurol. 2000;48:782–7.CrossRef de la Fuente-Fernandez R. Maternal effect on Parkinson’s disease. Ann Neurol. 2000;48:782–7.CrossRef
136.
Zurück zum Zitat Preux PM, Condet A, Anglade C, Druet-Cabanac M, Debrock C, Macharia W, et al. Parkinson’s disease and environmental factors. Matched case-control study in the Limousin region, France. Neuroepidemiology. 2000;19:333–7.PubMedCrossRef Preux PM, Condet A, Anglade C, Druet-Cabanac M, Debrock C, Macharia W, et al. Parkinson’s disease and environmental factors. Matched case-control study in the Limousin region, France. Neuroepidemiology. 2000;19:333–7.PubMedCrossRef
137.
Zurück zum Zitat Herishanu YO, Medvedovski M, Goldsmith JR, Kordysh E. A case-control study of Parkinson’s disease in urban population of southern Israel. Can J Neurol Sci. 2001;28:144–7.PubMed Herishanu YO, Medvedovski M, Goldsmith JR, Kordysh E. A case-control study of Parkinson’s disease in urban population of southern Israel. Can J Neurol Sci. 2001;28:144–7.PubMed
138.
Zurück zum Zitat Marder K, Levy G, Louis ED, Mejia-Santana H, Cote L, Andrews H, et al. Familial aggregation of early- and late-onset Parkinson’s disease. Ann Neurol. 2003;54:507–13.PubMedCrossRef Marder K, Levy G, Louis ED, Mejia-Santana H, Cote L, Andrews H, et al. Familial aggregation of early- and late-onset Parkinson’s disease. Ann Neurol. 2003;54:507–13.PubMedCrossRef
139.
Zurück zum Zitat Bonifati V, Fabrizio E, Vanacore N, De Mari M, Meco G. Familial Parkinson’s disease: a clinical genetic analysis. Can J Neurol Sci. 1995;22:272–9.PubMed Bonifati V, Fabrizio E, Vanacore N, De Mari M, Meco G. Familial Parkinson’s disease: a clinical genetic analysis. Can J Neurol Sci. 1995;22:272–9.PubMed
140.
Zurück zum Zitat De Michele G, Filla A, Volpe G, De Marco V, Gogliettino A, Ambrosio G, et al. Environmental and genetic risk factors in Parkinson’s disease: a case-control study in southern Italy. Mov Disord. 1996;11:17–23.PubMedCrossRef De Michele G, Filla A, Volpe G, De Marco V, Gogliettino A, Ambrosio G, et al. Environmental and genetic risk factors in Parkinson’s disease: a case-control study in southern Italy. Mov Disord. 1996;11:17–23.PubMedCrossRef
141.
Zurück zum Zitat McCann SJ, LeCouteur DG, Green AC, Brayne C, Johnson AG, Chan D, et al. The epidemiology of Parkinson’s disease in an Australian population. Neuroepidemiology. 1998;17:310–7.PubMedCrossRef McCann SJ, LeCouteur DG, Green AC, Brayne C, Johnson AG, Chan D, et al. The epidemiology of Parkinson’s disease in an Australian population. Neuroepidemiology. 1998;17:310–7.PubMedCrossRef
142.
Zurück zum Zitat Morano A, Jimenez-Jimenez FJ, Molina JA, Antolin MA. Risk-factors for Parkinson’s disease: case-control study in the province of Caceres, Spain. Acta Neurol Scand. 1994;89:164–70.PubMedCrossRef Morano A, Jimenez-Jimenez FJ, Molina JA, Antolin MA. Risk-factors for Parkinson’s disease: case-control study in the province of Caceres, Spain. Acta Neurol Scand. 1994;89:164–70.PubMedCrossRef
143.
Zurück zum Zitat Behari M, Srivastava AK, Das RR, Pandey RM. Risk factors of Parkinson’s disease in Indian patients. J Neurol Sci. 2001;190:49–55.PubMedCrossRef Behari M, Srivastava AK, Das RR, Pandey RM. Risk factors of Parkinson’s disease in Indian patients. J Neurol Sci. 2001;190:49–55.PubMedCrossRef
144.
Zurück zum Zitat Chan DK, Woo J, Ho SC, Pang CP, Law LK, Ng PW, et al. Genetic and environmental risk factors for Parkinson’s disease in a Chinese population. J Neurol Neurosurg Psychiatry. 1998;65:781–4.PubMedCrossRef Chan DK, Woo J, Ho SC, Pang CP, Law LK, Ng PW, et al. Genetic and environmental risk factors for Parkinson’s disease in a Chinese population. J Neurol Neurosurg Psychiatry. 1998;65:781–4.PubMedCrossRef
145.
Zurück zum Zitat Werneck AL, Alvarenga H. Genetics, drugs and environmental factors in Parkinson’s disease. A case-control study. Arq Neuropsiquiatr. 1999;57:347–55.PubMedCrossRef Werneck AL, Alvarenga H. Genetics, drugs and environmental factors in Parkinson’s disease. A case-control study. Arq Neuropsiquiatr. 1999;57:347–55.PubMedCrossRef
146.
Zurück zum Zitat Wang WZ, Fang XH, Cheng XM, Jiang DH, Lin ZJ. A case-control study on the environmental risk factors of Parkinson’s disease in Tianjin, China. Neuroepidemiology. 1993;12:209–18.PubMedCrossRef Wang WZ, Fang XH, Cheng XM, Jiang DH, Lin ZJ. A case-control study on the environmental risk factors of Parkinson’s disease in Tianjin, China. Neuroepidemiology. 1993;12:209–18.PubMedCrossRef
147.
Zurück zum Zitat Zorzon M, Capus L, Pellegrino A, Cazzato G, Zivadinov R. Familial and environmental risk factors in Parkinson’s disease: a case-control study in north-east Italy. Acta Neurol Scand. 2002;105:77–82.PubMedCrossRef Zorzon M, Capus L, Pellegrino A, Cazzato G, Zivadinov R. Familial and environmental risk factors in Parkinson’s disease: a case-control study in north-east Italy. Acta Neurol Scand. 2002;105:77–82.PubMedCrossRef
148.
Zurück zum Zitat Rybicki BA, Johnson CC, Peterson EL, Kortsha GX, Gorell JM. A family history of Parkinson’s disease and its effect on other PD risk factors. Neuroepidemiology. 1999;18:270–8.PubMedCrossRef Rybicki BA, Johnson CC, Peterson EL, Kortsha GX, Gorell JM. A family history of Parkinson’s disease and its effect on other PD risk factors. Neuroepidemiology. 1999;18:270–8.PubMedCrossRef
149.
Zurück zum Zitat Korchounov A, Schipper HI, Preobrazhenskaya IS, Kessler KR, Yakhno NN. Differences in age at onset and familial aggregation between clinical types of idiopathic Parkinson’s disease. Mov Disord. 2004;19:1059–64.PubMedCrossRef Korchounov A, Schipper HI, Preobrazhenskaya IS, Kessler KR, Yakhno NN. Differences in age at onset and familial aggregation between clinical types of idiopathic Parkinson’s disease. Mov Disord. 2004;19:1059–64.PubMedCrossRef
150.
Zurück zum Zitat Spanaki C, Plaitakis A. Bilineal transmission of Parkinson disease on Crete suggests a complex inheritance. Neurology. 2004;62:815–7.PubMed Spanaki C, Plaitakis A. Bilineal transmission of Parkinson disease on Crete suggests a complex inheritance. Neurology. 2004;62:815–7.PubMed
151.
Zurück zum Zitat Marttila RJ, Rinne UK. Arteriosclerosis, heredity, and some previous infections in the etiology of Parkinson’s disease. A case-control study. Clin Neurol Neurosurg. 1976;79:46–56.PubMedCrossRef Marttila RJ, Rinne UK. Arteriosclerosis, heredity, and some previous infections in the etiology of Parkinson’s disease. A case-control study. Clin Neurol Neurosurg. 1976;79:46–56.PubMedCrossRef
152.
Zurück zum Zitat Rossi P, Albanese A, Moro E, Genvardi M, Tonali P. Clinical genetic study of familial Parkinson’s disease in Italy. Adv Neurol. 1999;80:181–6.PubMed Rossi P, Albanese A, Moro E, Genvardi M, Tonali P. Clinical genetic study of familial Parkinson’s disease in Italy. Adv Neurol. 1999;80:181–6.PubMed
153.
Zurück zum Zitat Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG. Environmental antecedents of young-onset Parkinson’s disease. Neurology. 1993;43:1150–8.PubMed Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG. Environmental antecedents of young-onset Parkinson’s disease. Neurology. 1993;43:1150–8.PubMed
154.
Zurück zum Zitat Seidler A, Hellenbrand W, Robra BP, Vieregge P, Nischan P, Joerg J, et al. Possible environmental, occupational, and other etiologic factors for Parkinson’s disease: a case-control study in Germany. Neurology. 1996;46:1275–84.PubMed Seidler A, Hellenbrand W, Robra BP, Vieregge P, Nischan P, Joerg J, et al. Possible environmental, occupational, and other etiologic factors for Parkinson’s disease: a case-control study in Germany. Neurology. 1996;46:1275–84.PubMed
155.
Zurück zum Zitat Autere JM, Moilanen JS, Myllyla VV, Majamaa K. Familial aggregation of Parkinson’s disease in a Finnish population. J Neurol Neurosurg Psychiatry. 2000;69:107–9.PubMedCrossRef Autere JM, Moilanen JS, Myllyla VV, Majamaa K. Familial aggregation of Parkinson’s disease in a Finnish population. J Neurol Neurosurg Psychiatry. 2000;69:107–9.PubMedCrossRef
156.
Zurück zum Zitat Duzcan F, Zencir M, Ozdemir F, Cetin GO, Bagci H, Heutink P, et al. Familial influence on parkinsonism in a rural area of Turkey (Kizilcaboluk-Denizli): a community-based case-control study. Mov Disord. 2003;18:799–804.PubMedCrossRef Duzcan F, Zencir M, Ozdemir F, Cetin GO, Bagci H, Heutink P, et al. Familial influence on parkinsonism in a rural area of Turkey (Kizilcaboluk-Denizli): a community-based case-control study. Mov Disord. 2003;18:799–804.PubMedCrossRef
157.
Zurück zum Zitat Elbaz A, Grigoletto F, Baldereschi M, Breteler MM, Manubens-Bertran JM, Lopez-Pousa S, et al. Familial aggregation of Parkinson’s disease: a population-based case-control study in Europe. EUROPARKINSON Study Group. Neurology. 1999;52:1876–82.PubMed Elbaz A, Grigoletto F, Baldereschi M, Breteler MM, Manubens-Bertran JM, Lopez-Pousa S, et al. Familial aggregation of Parkinson’s disease: a population-based case-control study in Europe. EUROPARKINSON Study Group. Neurology. 1999;52:1876–82.PubMed
158.
Zurück zum Zitat Kuopio A, Marttila RJ, Helenius H, Rinne UK. Familial occurrence of Parkinson’s disease in a community-based case-control study. Parkinsonism Relat Disord. 2001;7:297–303.PubMedCrossRef Kuopio A, Marttila RJ, Helenius H, Rinne UK. Familial occurrence of Parkinson’s disease in a community-based case-control study. Parkinsonism Relat Disord. 2001;7:297–303.PubMedCrossRef
159.
Zurück zum Zitat Kurz M, Alves G, Aarsland D, Larsen JP. Familial Parkinson’s disease: a community-based study. Eur J Neurol. 2003;10:159–63.PubMedCrossRef Kurz M, Alves G, Aarsland D, Larsen JP. Familial Parkinson’s disease: a community-based study. Eur J Neurol. 2003;10:159–63.PubMedCrossRef
160.
Zurück zum Zitat Marder K, Tang MX, Mejia H, Alfaro B, Cote L, Louis E, et al. Risk of Parkinson’s disease among first-degree relatives: a community-based study. Neurology. 1996;47:155–60.PubMed Marder K, Tang MX, Mejia H, Alfaro B, Cote L, Louis E, et al. Risk of Parkinson’s disease among first-degree relatives: a community-based study. Neurology. 1996;47:155–60.PubMed
161.
Zurück zum Zitat Rocca WA, McDonnell SK, Strain KJ, Bower JH, Ahlskog JE, Elbaz A, et al. Familial aggregation of Parkinson’s disease: the Mayo Clinic family study. Ann Neurol. 2004;56:495–502.PubMedCrossRef Rocca WA, McDonnell SK, Strain KJ, Bower JH, Ahlskog JE, Elbaz A, et al. Familial aggregation of Parkinson’s disease: the Mayo Clinic family study. Ann Neurol. 2004;56:495–502.PubMedCrossRef
162.
Zurück zum Zitat Sundquist K, Li X, Hemminki K. Familial risks of hospitalization for Parkinson’s disease in first-degree relatives: a nationwide follow-up study from Sweden. Neurogenetics. 2006;7:231–7.PubMedCrossRef Sundquist K, Li X, Hemminki K. Familial risks of hospitalization for Parkinson’s disease in first-degree relatives: a nationwide follow-up study from Sweden. Neurogenetics. 2006;7:231–7.PubMedCrossRef
163.
Zurück zum Zitat Sveinbjornsdottir S, Hicks AA, Jonsson T, Petursson H, Gugmundsson G, Frigge ML, et al. Familial aggregation of Parkinson’s disease in Iceland. N Engl J Med. 2000;343:1765–70.PubMedCrossRef Sveinbjornsdottir S, Hicks AA, Jonsson T, Petursson H, Gugmundsson G, Frigge ML, et al. Familial aggregation of Parkinson’s disease in Iceland. N Engl J Med. 2000;343:1765–70.PubMedCrossRef
164.
Zurück zum Zitat Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson’s disease. Neurotoxicology. 1999;20:239–47.PubMed Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson’s disease. Neurotoxicology. 1999;20:239–47.PubMed
165.
Zurück zum Zitat Khoury MJ, Beaty TH, Cohen BH. Fundamentals of genetic epidemiology. New York: Oxford University Press; 1993. Khoury MJ, Beaty TH, Cohen BH. Fundamentals of genetic epidemiology. New York: Oxford University Press; 1993.
166.
Zurück zum Zitat Elbaz A, McDonnell SK, Maraganore DM, Strain KJ, Schaid DJ, Bower JH, et al. Validity of family history data on PD: evidence for a family information bias. Neurology. 2003;61:11–7.PubMed Elbaz A, McDonnell SK, Maraganore DM, Strain KJ, Schaid DJ, Bower JH, et al. Validity of family history data on PD: evidence for a family information bias. Neurology. 2003;61:11–7.PubMed
167.
Zurück zum Zitat Thacker EL, Ascherio A. Familial aggregation of Parkinson’s disease: a meta-analysis. Mov Disord. 2008;23:1174–83.PubMedCrossRef Thacker EL, Ascherio A. Familial aggregation of Parkinson’s disease: a meta-analysis. Mov Disord. 2008;23:1174–83.PubMedCrossRef
168.
Zurück zum Zitat Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256–9.PubMedCrossRef Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256–9.PubMedCrossRef
169.
Zurück zum Zitat Gasser T, Muller-Myhsok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V, et al. A susceptibility locus for Parkinson’s disease maps to chromosome 2p13. Nat Genet. 1998;18:262–5.PubMedCrossRef Gasser T, Muller-Myhsok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V, et al. A susceptibility locus for Parkinson’s disease maps to chromosome 2p13. Nat Genet. 1998;18:262–5.PubMedCrossRef
170.
Zurück zum Zitat Hicks AA, Petursson H, Jonsson T, Stefansson H, Johannsdottir HS, Sainz J, et al. A susceptibility gene for late-onset idiopathic Parkinson’s disease. Ann Neurol. 2002;52:549–55.PubMedCrossRef Hicks AA, Petursson H, Jonsson T, Stefansson H, Johannsdottir HS, Sainz J, et al. A susceptibility gene for late-onset idiopathic Parkinson’s disease. Ann Neurol. 2002;52:549–55.PubMedCrossRef
171.
Zurück zum Zitat Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605–8.PubMedCrossRef Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605–8.PubMedCrossRef
172.
Zurück zum Zitat Lautier C, Goldwurm S, Durr A, Giovannone B, Tsiaras WG, Pezzoli G, et al. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet. 2008;82:822–33.PubMedCrossRef Lautier C, Goldwurm S, Durr A, Giovannone B, Tsiaras WG, Pezzoli G, et al. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet. 2008;82:822–33.PubMedCrossRef
173.
Zurück zum Zitat Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, et al. The ubiquitin pathway in Parkinson’s disease. Nature. 1998;395:451–2.PubMedCrossRef Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, et al. The ubiquitin pathway in Parkinson’s disease. Nature. 1998;395:451–2.PubMedCrossRef
174.
Zurück zum Zitat Paisan-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW, et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol. 2009;65:19–23.PubMedCrossRef Paisan-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW, et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol. 2009;65:19–23.PubMedCrossRef
175.
Zurück zum Zitat Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron. 2004;44:595–600.PubMedCrossRef Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron. 2004;44:595–600.PubMedCrossRef
176.
Zurück zum Zitat Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, et al. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet. 2002;71:124–35.PubMedCrossRef Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, et al. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet. 2002;71:124–35.PubMedCrossRef
177.
Zurück zum Zitat Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A, et al. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Mol Genet. 2003;12:2599–608.PubMedCrossRef Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A, et al. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Mol Genet. 2003;12:2599–608.PubMedCrossRef
178.
Zurück zum Zitat Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045–7.PubMedCrossRef Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045–7.PubMedCrossRef
179.
Zurück zum Zitat Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006;38:1184–91.PubMedCrossRef Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006;38:1184–91.PubMedCrossRef
180.
Zurück zum Zitat Shojaee S, Sina F, Banihosseini SS, Kazemi MH, Kalhor R, Shahidi GA, et al. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. Am J Hum Genet. 2008;82:1375–84.PubMedCrossRef Shojaee S, Sina F, Banihosseini SS, Kazemi MH, Kalhor R, Shahidi GA, et al. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. Am J Hum Genet. 2008;82:1375–84.PubMedCrossRef
181.
Zurück zum Zitat Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. Alpha-Synuclein locus triplication causes Parkinson’s disease. Science. 2003;302:841.PubMedCrossRef Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. Alpha-Synuclein locus triplication causes Parkinson’s disease. Science. 2003;302:841.PubMedCrossRef
182.
Zurück zum Zitat Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease. Hum Mol Genet. 2005;14:2099–111.PubMedCrossRef Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease. Hum Mol Genet. 2005;14:2099–111.PubMedCrossRef
183.
Zurück zum Zitat Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science. 2004;304:1158–60.PubMedCrossRef Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science. 2004;304:1158–60.PubMedCrossRef
184.
Zurück zum Zitat Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–7.PubMedCrossRef Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–7.PubMedCrossRef
185.
Zurück zum Zitat Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med. 2004;351:1972–7.PubMedCrossRef Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med. 2004;351:1972–7.PubMedCrossRef
186.
Zurück zum Zitat Payami H, Nutt J, Gancher S, Bird T, McNeal MG, Seltzer WK, et al. SCA2 may present as levodopa-responsive parkinsonism. Mov Disord. 2003;18:425–9.PubMedCrossRef Payami H, Nutt J, Gancher S, Bird T, McNeal MG, Seltzer WK, et al. SCA2 may present as levodopa-responsive parkinsonism. Mov Disord. 2003;18:425–9.PubMedCrossRef
187.
Zurück zum Zitat Berg D, Niwar M, Maass S, Zimprich A, Moller JC, Wuellner U, et al. Alpha-synuclein and Parkinson’s disease: implications from the screening of more than 1, 900 patients. Mov Disord. 2005;20:1191–4.PubMedCrossRef Berg D, Niwar M, Maass S, Zimprich A, Moller JC, Wuellner U, et al. Alpha-synuclein and Parkinson’s disease: implications from the screening of more than 1, 900 patients. Mov Disord. 2005;20:1191–4.PubMedCrossRef
188.
Zurück zum Zitat Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet. 1998;18:106–8.PubMedCrossRef Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet. 1998;18:106–8.PubMedCrossRef
189.
Zurück zum Zitat Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55:164–73.PubMedCrossRef Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55:164–73.PubMedCrossRef
190.
Zurück zum Zitat Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisin RC. A large kindred with autosomal dominant Parkinson’s disease. Ann Neurol. 1990;27:276–82.PubMedCrossRef Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisin RC. A large kindred with autosomal dominant Parkinson’s disease. Ann Neurol. 1990;27:276–82.PubMedCrossRef
191.
Zurück zum Zitat Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol. 2001;49:313–9.PubMedCrossRef Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol. 2001;49:313–9.PubMedCrossRef
192.
Zurück zum Zitat Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet. 2004;364:1167–9.PubMedCrossRef Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet. 2004;364:1167–9.PubMedCrossRef
193.
Zurück zum Zitat Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, Schule B, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology. 2007;68:916–22.PubMedCrossRef Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, Schule B, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology. 2007;68:916–22.PubMedCrossRef
194.
Zurück zum Zitat Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson’s disease. Lancet. 2004;364:1169–71.PubMedCrossRef Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson’s disease. Lancet. 2004;364:1169–71.PubMedCrossRef
195.
Zurück zum Zitat Nishioka K, Hayashi S, Farrer MJ, Singleton AB, Yoshino H, Imai H, et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson’s disease. Ann Neurol. 2006;59:298–309.PubMedCrossRef Nishioka K, Hayashi S, Farrer MJ, Singleton AB, Yoshino H, Imai H, et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson’s disease. Ann Neurol. 2006;59:298–309.PubMedCrossRef
196.
Zurück zum Zitat Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol. 2008;63:743–50.PubMedCrossRef Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol. 2008;63:743–50.PubMedCrossRef
197.
Zurück zum Zitat Ahn TB, Kim SY, Kim JY, Park SS, Lee DS, Min HJ, et al. Alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology. 2008;70:43–9.PubMedCrossRef Ahn TB, Kim SY, Kim JY, Park SS, Lee DS, Min HJ, et al. Alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology. 2008;70:43–9.PubMedCrossRef
198.
Zurück zum Zitat Brueggemann N, Odin P, Gruenewald A, Tadic V, Hagenah J, Seidel G, et al. Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology. 2008;71:1294.PubMedCrossRef Brueggemann N, Odin P, Gruenewald A, Tadic V, Hagenah J, Seidel G, et al. Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology. 2008;71:1294.PubMedCrossRef
199.
Zurück zum Zitat Troiano AR, Cazeneuve C, Le Ber I, Bonnet AM, Lesage S, Brice A. Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology. 2008;71:1295.PubMedCrossRef Troiano AR, Cazeneuve C, Le Ber I, Bonnet AM, Lesage S, Brice A. Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology. 2008;71:1295.PubMedCrossRef
200.
Zurück zum Zitat Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad Sci USA. 1998;95:6469–73.PubMedCrossRef Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad Sci USA. 1998;95:6469–73.PubMedCrossRef
201.
Zurück zum Zitat Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–40.PubMedCrossRef Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–40.PubMedCrossRef
202.
Zurück zum Zitat West AB, Zimprich A, Lockhart PJ, Farrer M, Singleton A, Holtom B, et al. Refinement of the PARK3 locus on chromosome 2p13 and the analysis of 14 candidate genes. Eur J Hum Genet. 2001;9:659–66.PubMedCrossRef West AB, Zimprich A, Lockhart PJ, Farrer M, Singleton A, Holtom B, et al. Refinement of the PARK3 locus on chromosome 2p13 and the analysis of 14 candidate genes. Eur J Hum Genet. 2001;9:659–66.PubMedCrossRef
203.
Zurück zum Zitat DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M, et al. PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am J Hum Genet. 2002;70:1089–95.PubMedCrossRef DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M, et al. PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am J Hum Genet. 2002;70:1089–95.PubMedCrossRef
204.
Zurück zum Zitat Pankratz N, Uniacke SK, Halter CA, Rudolph A, Shults CW, Conneally PM, et al. Genes influencing Parkinson disease onset: replication of PARK3 and identification of novel loci. Neurology. 2004;62:1616–8.PubMed Pankratz N, Uniacke SK, Halter CA, Rudolph A, Shults CW, Conneally PM, et al. Genes influencing Parkinson disease onset: replication of PARK3 and identification of novel loci. Neurology. 2004;62:1616–8.PubMed
205.
Zurück zum Zitat Martinez M, Brice A, Vaughan JR, Zimprich A, Breteler MM, Meco G, et al. Genome-wide scan linkage analysis for Parkinson’s disease: the European genetic study of Parkinson’s disease. J Med Genet. 2004;41:900–7.PubMedCrossRef Martinez M, Brice A, Vaughan JR, Zimprich A, Breteler MM, Meco G, et al. Genome-wide scan linkage analysis for Parkinson’s disease: the European genetic study of Parkinson’s disease. J Med Genet. 2004;41:900–7.PubMedCrossRef
206.
Zurück zum Zitat Karamohamed S, DeStefano AL, Wilk JB, Shoemaker CM, Golbe LI, Mark MH, et al. A haplotype at the PARK3 locus influences onset age for Parkinson’s disease: the GenePD study. Neurology. 2003;61:1557–61.PubMed Karamohamed S, DeStefano AL, Wilk JB, Shoemaker CM, Golbe LI, Mark MH, et al. A haplotype at the PARK3 locus influences onset age for Parkinson’s disease: the GenePD study. Neurology. 2003;61:1557–61.PubMed
207.
Zurück zum Zitat Sharma M, Mueller JC, Zimprich A, Lichtner P, Hofer A, Leitner P, et al. The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson’s disease in European populations. J Med Genet. 2006;43:557–62.PubMedCrossRef Sharma M, Mueller JC, Zimprich A, Lichtner P, Hofer A, Leitner P, et al. The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson’s disease in European populations. J Med Genet. 2006;43:557–62.PubMedCrossRef
208.
Zurück zum Zitat Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2–q13.1. Ann Neurol. 2002;51:296–301.PubMedCrossRef Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2–q13.1. Ann Neurol. 2002;51:296–301.PubMedCrossRef
209.
Zurück zum Zitat Farrer M, Stone J, Mata IF, Lincoln S, Kachergus J, Hulihan M, et al. LRRK2 mutations in Parkinson disease. Neurology. 2005;65:738–40.PubMedCrossRef Farrer M, Stone J, Mata IF, Lincoln S, Kachergus J, Hulihan M, et al. LRRK2 mutations in Parkinson disease. Neurology. 2005;65:738–40.PubMedCrossRef
210.
Zurück zum Zitat Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, et al. LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N Engl J Med. 2006;354:422–3.PubMedCrossRef Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, et al. LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N Engl J Med. 2006;354:422–3.PubMedCrossRef
211.
Zurück zum Zitat Paisan-Ruiz C, Nath P, Washecka N, Gibbs JR, Singleton AB. Comprehensive analysis of LRRK2 in publicly available Parkinson’s disease cases and neurologically normal controls. Hum Mutat. 2008;29:485–90.PubMedCrossRef Paisan-Ruiz C, Nath P, Washecka N, Gibbs JR, Singleton AB. Comprehensive analysis of LRRK2 in publicly available Parkinson’s disease cases and neurologically normal controls. Hum Mutat. 2008;29:485–90.PubMedCrossRef
212.
Zurück zum Zitat Lesage S, Brice A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009;18:R48–59.PubMedCrossRef Lesage S, Brice A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009;18:R48–59.PubMedCrossRef
213.
Zurück zum Zitat Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, et al. LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. N Engl J Med. 2006;354:424–5.PubMedCrossRef Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, et al. LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. N Engl J Med. 2006;354:424–5.PubMedCrossRef
214.
Zurück zum Zitat Lu CS, Simons EJ, Wu-Chou YH, Fonzo AD, Chang HC, Chen RS, et al. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson’s disease. Parkinsonism Relat Disord. 2005;11:521–2.PubMedCrossRef Lu CS, Simons EJ, Wu-Chou YH, Fonzo AD, Chang HC, Chen RS, et al. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson’s disease. Parkinsonism Relat Disord. 2005;11:521–2.PubMedCrossRef
215.
Zurück zum Zitat Tan EK, Shen H, Tan LC, Farrer M, Yew K, Chua E, et al. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson’s disease patients. Neurosci Lett. 2005;384:327–9.PubMedCrossRef Tan EK, Shen H, Tan LC, Farrer M, Yew K, Chua E, et al. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson’s disease patients. Neurosci Lett. 2005;384:327–9.PubMedCrossRef
216.
Zurück zum Zitat Okubadejo N, Britton A, Crews C, Akinyemi R, Hardy J, Singleton A, et al. Analysis of Nigerians with apparently sporadic Parkinson disease for mutations in LRRK2, PRKN and ATXN3. PLoS One. 2008;3:e3421.PubMedCrossRef Okubadejo N, Britton A, Crews C, Akinyemi R, Hardy J, Singleton A, et al. Analysis of Nigerians with apparently sporadic Parkinson disease for mutations in LRRK2, PRKN and ATXN3. PLoS One. 2008;3:e3421.PubMedCrossRef
217.
Zurück zum Zitat Healy DG, Falchi M, O’Sullivan SS, Bonifati V, Durr A, Bressman S, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol. 2008;7:583–90.PubMedCrossRef Healy DG, Falchi M, O’Sullivan SS, Bonifati V, Durr A, Bressman S, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol. 2008;7:583–90.PubMedCrossRef
218.
Zurück zum Zitat Ishikawa A, Tsuji S. Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. Neurology. 1996;47:160–6.PubMed Ishikawa A, Tsuji S. Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. Neurology. 1996;47:160–6.PubMed
219.
Zurück zum Zitat Takahashi H, Ohama E, Suzuki S, Horikawa Y, Ishikawa A, Morita T, et al. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology. 1994;44:437–41.PubMed Takahashi H, Ohama E, Suzuki S, Horikawa Y, Ishikawa A, Morita T, et al. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology. 1994;44:437–41.PubMed
220.
Zurück zum Zitat Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol. 2001;50:293–300.PubMedCrossRef Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol. 2001;50:293–300.PubMedCrossRef
221.
Zurück zum Zitat Pramstaller PP, Schlossmacher MG, Jacques TS, Scaravilli F, Eskelson C, Pepivani I, et al. Lewy body Parkinson’s disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol. 2005;58:411–22.PubMedCrossRef Pramstaller PP, Schlossmacher MG, Jacques TS, Scaravilli F, Eskelson C, Pepivani I, et al. Lewy body Parkinson’s disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol. 2005;58:411–22.PubMedCrossRef
222.
223.
Zurück zum Zitat Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology. 2003;60:796–801.PubMed Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology. 2003;60:796–801.PubMed
224.
Zurück zum Zitat Dekker MC, Bonifati V, van Duijn CM. Parkinson’s disease: piecing together a genetic jigsaw. Brain. 2003;126:1722–33.PubMedCrossRef Dekker MC, Bonifati V, van Duijn CM. Parkinson’s disease: piecing together a genetic jigsaw. Brain. 2003;126:1722–33.PubMedCrossRef
225.
Zurück zum Zitat Clark LN, Afridi S, Karlins E, Wang Y, Mejia-Santana H, Harris J, et al. Case-control study of the parkin gene in early-onset Parkinson disease. Arch Neurol. 2006;63:548–52.PubMedCrossRef Clark LN, Afridi S, Karlins E, Wang Y, Mejia-Santana H, Harris J, et al. Case-control study of the parkin gene in early-onset Parkinson disease. Arch Neurol. 2006;63:548–52.PubMedCrossRef
226.
Zurück zum Zitat Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol. 2007;6:652–62.PubMedCrossRef Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol. 2007;6:652–62.PubMedCrossRef
227.
Zurück zum Zitat Sun M, Latourelle JC, Wooten GF, Lew MF, Klein C, Shill HA, et al. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol. 2006;63:826–32.PubMedCrossRef Sun M, Latourelle JC, Wooten GF, Lew MF, Klein C, Shill HA, et al. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol. 2006;63:826–32.PubMedCrossRef
228.
Zurück zum Zitat Lesage S, Lohmann E, Tison F, Durif F, Durr A, Brice A. Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. J Med Genet. 2008;45:43–6.PubMedCrossRef Lesage S, Lohmann E, Tison F, Durif F, Durr A, Brice A. Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. J Med Genet. 2008;45:43–6.PubMedCrossRef
229.
Zurück zum Zitat Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science. 2001;293:263–9.PubMedCrossRef Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science. 2001;293:263–9.PubMedCrossRef
230.
Zurück zum Zitat Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35–p36. Am J Hum Genet. 2001;68:895–900.PubMedCrossRef Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35–p36. Am J Hum Genet. 2001;68:895–900.PubMedCrossRef
231.
Zurück zum Zitat Valente EM, Salvi S, Ialongo T, Marongiu R, Elia AE, Caputo V, et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol. 2004;56:336–41.PubMedCrossRef Valente EM, Salvi S, Ialongo T, Marongiu R, Elia AE, Caputo V, et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol. 2004;56:336–41.PubMedCrossRef
232.
Zurück zum Zitat Bonifati V, Rohe CF, Breedveld GJ, Fabrizio E, De Mari M, Tassorelli C, et al. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology. 2005;65:87–95.PubMedCrossRef Bonifati V, Rohe CF, Breedveld GJ, Fabrizio E, De Mari M, Tassorelli C, et al. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology. 2005;65:87–95.PubMedCrossRef
233.
Zurück zum Zitat Healy DG, Abou-Sleiman PM, Gibson JM, Ross OA, Jain S, Gandhi S, et al. PINK1 (PARK6) associated Parkinson disease in Ireland. Neurology. 2004;63:1486–8.PubMed Healy DG, Abou-Sleiman PM, Gibson JM, Ross OA, Jain S, Gandhi S, et al. PINK1 (PARK6) associated Parkinson disease in Ireland. Neurology. 2004;63:1486–8.PubMed
234.
Zurück zum Zitat Li Y, Tomiyama H, Sato K, Hatano Y, Yoshino H, Atsumi M, et al. Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism. Neurology. 2005;64:1955–7.PubMedCrossRef Li Y, Tomiyama H, Sato K, Hatano Y, Yoshino H, Atsumi M, et al. Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism. Neurology. 2005;64:1955–7.PubMedCrossRef
235.
Zurück zum Zitat Rogaeva E, Johnson J, Lang AE, Gulick C, Gwinn-Hardy K, Kawarai T, et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol. 2004;61:1898–904.PubMedCrossRef Rogaeva E, Johnson J, Lang AE, Gulick C, Gwinn-Hardy K, Kawarai T, et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol. 2004;61:1898–904.PubMedCrossRef
236.
Zurück zum Zitat Tan EK, Yew K, Chua E, Puvan K, Shen H, Lee E, et al. PINK1 mutations in sporadic early-onset Parkinson’s disease. Mov Disord. 2006;21:789–93.PubMedCrossRef Tan EK, Yew K, Chua E, Puvan K, Shen H, Lee E, et al. PINK1 mutations in sporadic early-onset Parkinson’s disease. Mov Disord. 2006;21:789–93.PubMedCrossRef
237.
Zurück zum Zitat Clark LN, Afridi S, Mejia-Santana H, Harris J, Louis ED, Cote LJ, et al. Analysis of an early-onset Parkinson’s disease cohort for DJ-1 mutations. Mov Disord. 2004;19:796–800.PubMedCrossRef Clark LN, Afridi S, Mejia-Santana H, Harris J, Louis ED, Cote LJ, et al. Analysis of an early-onset Parkinson’s disease cohort for DJ-1 mutations. Mov Disord. 2004;19:796–800.PubMedCrossRef
238.
Zurück zum Zitat Hedrich K, Djarmati A, Schafer N, Hering R, Wellenbrock C, Weiss PH, et al. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology. 2004;62:389–94.PubMed Hedrich K, Djarmati A, Schafer N, Hering R, Wellenbrock C, Weiss PH, et al. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology. 2004;62:389–94.PubMed
239.
Zurück zum Zitat Hering R, Strauss KM, Tao X, Bauer A, Woitalla D, Mietz EM, et al. Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum Mutat. 2004;24:321–9.PubMedCrossRef Hering R, Strauss KM, Tao X, Bauer A, Woitalla D, Mietz EM, et al. Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum Mutat. 2004;24:321–9.PubMedCrossRef
240.
Zurück zum Zitat Lockhart PJ, Lincoln S, Hulihan M, Kachergus J, Wilkes K, Bisceglio G, et al. DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function. J Med Genet. 2004;41:e22.PubMedCrossRef Lockhart PJ, Lincoln S, Hulihan M, Kachergus J, Wilkes K, Bisceglio G, et al. DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function. J Med Genet. 2004;41:e22.PubMedCrossRef
241.
Zurück zum Zitat Tan EK, Tan C, Zhao Y, Yew K, Shen H, Chandran VR, et al. Genetic analysis of DJ-1 in a cohort Parkinson’s disease patients of different ethnicity. Neurosci Lett. 2004;367:109–12.PubMedCrossRef Tan EK, Tan C, Zhao Y, Yew K, Shen H, Chandran VR, et al. Genetic analysis of DJ-1 in a cohort Parkinson’s disease patients of different ethnicity. Neurosci Lett. 2004;367:109–12.PubMedCrossRef
242.
Zurück zum Zitat Mitsumoto A, Nakagawa Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic Res. 2001;35:885–93.PubMedCrossRef Mitsumoto A, Nakagawa Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic Res. 2001;35:885–93.PubMedCrossRef
243.
Zurück zum Zitat Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 2004;5:213–8.PubMedCrossRef Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 2004;5:213–8.PubMedCrossRef
244.
Zurück zum Zitat Najim al-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor–Rakeb syndrome. Acta Neurol Scand. 1994;89:347–52.PubMedCrossRef Najim al-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor–Rakeb syndrome. Acta Neurol Scand. 1994;89:347–52.PubMedCrossRef
245.
Zurück zum Zitat Ning YP, Kanai K, Tomiyama H, Li Y, Funayama M, Yoshino H, et al. PARK9-linked parkinsonism in eastern Asia: mutation detection in ATP13A2 and clinical phenotype. Neurology. 2008;70:1491–3.PubMedCrossRef Ning YP, Kanai K, Tomiyama H, Li Y, Funayama M, Yoshino H, et al. PARK9-linked parkinsonism in eastern Asia: mutation detection in ATP13A2 and clinical phenotype. Neurology. 2008;70:1491–3.PubMedCrossRef
246.
Zurück zum Zitat Di Fonzo A, Chien HF, Socal M, Giraudo S, Tassorelli C, Iliceto G, et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology. 2007;68:1557–62.PubMedCrossRef Di Fonzo A, Chien HF, Socal M, Giraudo S, Tassorelli C, Iliceto G, et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology. 2007;68:1557–62.PubMedCrossRef
247.
Zurück zum Zitat Lin CH, Tan EK, Chen ML, Tan LC, Lim HQ, Chen GS, et al. Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore. Neurology. 2008;71:1727–32.PubMedCrossRef Lin CH, Tan EK, Chen ML, Tan LC, Lim HQ, Chen GS, et al. Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore. Neurology. 2008;71:1727–32.PubMedCrossRef
248.
Zurück zum Zitat Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA, et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002;70:985–93.PubMedCrossRef Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA, et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002;70:985–93.PubMedCrossRef
249.
Zurück zum Zitat DeStefano AL, Latourelle J, Lew MF, Suchowersky O, Klein C, Golbe LI, et al. Replication of association between ELAVL4 and Parkinson disease: the GenePD study. Hum Genet. 2008;124:95–9.PubMedCrossRef DeStefano AL, Latourelle J, Lew MF, Suchowersky O, Klein C, Golbe LI, et al. Replication of association between ELAVL4 and Parkinson disease: the GenePD study. Hum Genet. 2008;124:95–9.PubMedCrossRef
250.
Zurück zum Zitat Haugarvoll K, Toft M, Ross OA, Stone JT, Heckman MG, White LR, et al. ELAVL4, PARK10, and the Celts. Mov Disord. 2007;22:585–7.PubMedCrossRef Haugarvoll K, Toft M, Ross OA, Stone JT, Heckman MG, White LR, et al. ELAVL4, PARK10, and the Celts. Mov Disord. 2007;22:585–7.PubMedCrossRef
251.
Zurück zum Zitat Noureddine MA, Qin XJ, Oliveira SA, Skelly TJ, van der Walt J, Hauser MA, et al. Association between the neuron-specific RNA-binding protein ELAVL4 and Parkinson disease. Hum Genet. 2005;117:27–33.PubMedCrossRef Noureddine MA, Qin XJ, Oliveira SA, Skelly TJ, van der Walt J, Hauser MA, et al. Association between the neuron-specific RNA-binding protein ELAVL4 and Parkinson disease. Hum Genet. 2005;117:27–33.PubMedCrossRef
252.
Zurück zum Zitat Maraganore DM, de Andrade M, Lesnick TG, Strain KJ, Farrer MJ, Rocca WA, et al. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet. 2005;77:685–93.PubMedCrossRef Maraganore DM, de Andrade M, Lesnick TG, Strain KJ, Farrer MJ, Rocca WA, et al. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet. 2005;77:685–93.PubMedCrossRef
253.
Zurück zum Zitat Prestel J, Sharma M, Leitner P, Zimprich A, Vaughan JR, Durr A, et al. PARK11 is not linked with Parkinson’s disease in European families. Eur J Hum Genet. 2005;13:193–7.PubMedCrossRef Prestel J, Sharma M, Leitner P, Zimprich A, Vaughan JR, Durr A, et al. PARK11 is not linked with Parkinson’s disease in European families. Eur J Hum Genet. 2005;13:193–7.PubMedCrossRef
254.
Zurück zum Zitat Nichols WC, Kissell DK, Pankratz N, Pauciulo MW, Elsaesser VE, Clark KA, et al. Variation in GIGYF2 is not associated with Parkinson disease. Neurology. 2009;72:1886–92.PubMedCrossRef Nichols WC, Kissell DK, Pankratz N, Pauciulo MW, Elsaesser VE, Clark KA, et al. Variation in GIGYF2 is not associated with Parkinson disease. Neurology. 2009;72:1886–92.PubMedCrossRef
255.
Zurück zum Zitat Meeus B, Nuytemans K, Crosiers D, Engelborghs S, Pals P, Pickut B, et al. GIGYF2 has no major role in Parkinson genetic etiology in a Belgian population. Neurobiol Aging. 2011;32:308–12.PubMedCrossRef Meeus B, Nuytemans K, Crosiers D, Engelborghs S, Pals P, Pickut B, et al. GIGYF2 has no major role in Parkinson genetic etiology in a Belgian population. Neurobiol Aging. 2011;32:308–12.PubMedCrossRef
256.
Zurück zum Zitat Bras J, Simon-Sanchez J, Federoff M, Morgadinho A, Januario C, Ribeiro M, et al. Lack of replication of association between GIGYF2 variants and Parkinson disease. Hum Mol Genet. 2009;18:341–6.PubMedCrossRef Bras J, Simon-Sanchez J, Federoff M, Morgadinho A, Januario C, Ribeiro M, et al. Lack of replication of association between GIGYF2 variants and Parkinson disease. Hum Mol Genet. 2009;18:341–6.PubMedCrossRef
257.
Zurück zum Zitat Di Fonzo A, Fabrizio E, Thomas A, Fincati E, Marconi R, Tinazzi M, et al. GIGYF2 mutations are not a frequent cause of familial Parkinson’s disease. Parkinsonism Relat Disord. 2009;15:703–5.PubMedCrossRef Di Fonzo A, Fabrizio E, Thomas A, Fincati E, Marconi R, Tinazzi M, et al. GIGYF2 mutations are not a frequent cause of familial Parkinson’s disease. Parkinsonism Relat Disord. 2009;15:703–5.PubMedCrossRef
258.
Zurück zum Zitat Vilarino-Guell C, Ross OA, Soto AI, Farrer MJ, Haugarvoll K, Aasly JO, et al. Reported mutations in GIGYF2 are not a common cause of Parkinson’s disease. Mov Disord. 2009;24:619–20.PubMedCrossRef Vilarino-Guell C, Ross OA, Soto AI, Farrer MJ, Haugarvoll K, Aasly JO, et al. Reported mutations in GIGYF2 are not a common cause of Parkinson’s disease. Mov Disord. 2009;24:619–20.PubMedCrossRef
259.
Zurück zum Zitat Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. Jama. 2001;286:2239–44.PubMedCrossRef Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. Jama. 2001;286:2239–44.PubMedCrossRef
260.
Zurück zum Zitat Morgan NV, Westaway SK, Morton JE, Gregory A, Gissen P, Sonek S, et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet. 2006;38:752–4.PubMedCrossRef Morgan NV, Westaway SK, Morton JE, Gregory A, Gissen P, Sonek S, et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet. 2006;38:752–4.PubMedCrossRef
261.
Zurück zum Zitat Di Fonzo A, Dekker MC, Montagna P, Baruzzi A, Yonova EH, Correia Guedes L, et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology. 2009;72:240–5.PubMedCrossRef Di Fonzo A, Dekker MC, Montagna P, Baruzzi A, Yonova EH, Correia Guedes L, et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology. 2009;72:240–5.PubMedCrossRef
262.
Zurück zum Zitat Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet. 2009;41:1303–7.PubMedCrossRef Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet. 2009;41:1303–7.PubMedCrossRef
263.
Zurück zum Zitat Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet. 2009;41:1308–12.PubMedCrossRef Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet. 2009;41:1308–12.PubMedCrossRef
264.
Zurück zum Zitat Tan EK, Kwok HK, Tan LC, Zhao WT, Prakash KM, Au WL, et al. Analysis of GWAS-linked loci in Parkinson disease reaffirms PARK16 as a susceptibility locus. Neurology. 2010;75:508–12.PubMedCrossRef Tan EK, Kwok HK, Tan LC, Zhao WT, Prakash KM, Au WL, et al. Analysis of GWAS-linked loci in Parkinson disease reaffirms PARK16 as a susceptibility locus. Neurology. 2010;75:508–12.PubMedCrossRef
265.
Zurück zum Zitat Lill CM, Bagade S, McQueen MB, Roehr JT, Kavvoura F, Schjeide BMM, et al. The PDGene Database. Alzheimer Research Forum. 2010. http://www.pdgene.org/. Accessed 23 Sept 2010. Lill CM, Bagade S, McQueen MB, Roehr JT, Kavvoura F, Schjeide BMM, et al. The PDGene Database. Alzheimer Research Forum. 2010. http://​www.​pdgene.​org/​. Accessed 23 Sept 2010.
266.
Zurück zum Zitat Grabowski GA. Gaucher disease. Enzymology, genetics, and treatment. Adv Hum Genet. 1993;21:377–441.PubMed Grabowski GA. Gaucher disease. Enzymology, genetics, and treatment. Adv Hum Genet. 1993;21:377–441.PubMed
267.
Zurück zum Zitat Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med. 2009;361:1651–61.PubMedCrossRef Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med. 2009;361:1651–61.PubMedCrossRef
268.
Zurück zum Zitat Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology. 2006;67:908–10.PubMedCrossRef Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology. 2006;67:908–10.PubMedCrossRef
269.
Zurück zum Zitat Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol. 2008;65:1353–7.PubMedCrossRef Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol. 2008;65:1353–7.PubMedCrossRef
270.
Zurück zum Zitat McCulloch CC, Kay DM, Factor SA, Samii A, Nutt JG, Higgins DS, et al. Exploring gene-environment interactions in Parkinson’s disease. Hum Genet. 2008;123:257–65.PubMedCrossRef McCulloch CC, Kay DM, Factor SA, Samii A, Nutt JG, Higgins DS, et al. Exploring gene-environment interactions in Parkinson’s disease. Hum Genet. 2008;123:257–65.PubMedCrossRef
271.
Zurück zum Zitat Gatto NM, Rhodes SL, Manthripragada AD, Bronstein J, Cockburn M, Farrer M, et al. Alpha-Synuclein gene may interact with environmental factors in increasing risk of Parkinson’s disease. Neuroepidemiology. 2010;35:191–5.PubMedCrossRef Gatto NM, Rhodes SL, Manthripragada AD, Bronstein J, Cockburn M, Farrer M, et al. Alpha-Synuclein gene may interact with environmental factors in increasing risk of Parkinson’s disease. Neuroepidemiology. 2010;35:191–5.PubMedCrossRef
272.
Zurück zum Zitat Brighina L, Frigerio R, Schneider NK, Lesnick TG, de Andrade M, Cunningham JM, et al. Alpha-synuclein, pesticides, and Parkinson disease: a case-control study. Neurology. 2008;70:1461–9.PubMedCrossRef Brighina L, Frigerio R, Schneider NK, Lesnick TG, de Andrade M, Cunningham JM, et al. Alpha-synuclein, pesticides, and Parkinson disease: a case-control study. Neurology. 2008;70:1461–9.PubMedCrossRef
273.
Zurück zum Zitat Brighina L, Schneider NK, Lesnick TG, de Andrade M, Cunningham JM, Mrazek D, et al. Alpha-Synuclein, alcohol use disorders, and Parkinson disease: a case-control study. Parkinsonism Relat Disord. 2009;15:430–4.PubMedCrossRef Brighina L, Schneider NK, Lesnick TG, de Andrade M, Cunningham JM, Mrazek D, et al. Alpha-Synuclein, alcohol use disorders, and Parkinson disease: a case-control study. Parkinsonism Relat Disord. 2009;15:430–4.PubMedCrossRef
274.
Zurück zum Zitat Elbaz A, Levecque C, Clavel J, Vidal JS, Richard F, Amouyel P, et al. CYP2D6 polymorphism, pesticide exposure, and Parkinson’s disease. Ann Neurol. 2004;55:430–4.PubMedCrossRef Elbaz A, Levecque C, Clavel J, Vidal JS, Richard F, Amouyel P, et al. CYP2D6 polymorphism, pesticide exposure, and Parkinson’s disease. Ann Neurol. 2004;55:430–4.PubMedCrossRef
275.
Zurück zum Zitat Deng Y, Newman B, Dunne MP, Silburn PA, Mellick GD. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson’s disease. Ann Neurol. 2004;55:897.PubMedCrossRef Deng Y, Newman B, Dunne MP, Silburn PA, Mellick GD. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson’s disease. Ann Neurol. 2004;55:897.PubMedCrossRef
276.
Zurück zum Zitat Dick FD, De Palma G, Ahmadi A, Osborne A, Scott NW, Prescott GJ, et al. Gene-environment interactions in parkinsonism and Parkinson’s disease: the Geoparkinson study. Occup Environ Med. 2007;64:673–80.PubMedCrossRef Dick FD, De Palma G, Ahmadi A, Osborne A, Scott NW, Prescott GJ, et al. Gene-environment interactions in parkinsonism and Parkinson’s disease: the Geoparkinson study. Occup Environ Med. 2007;64:673–80.PubMedCrossRef
277.
Zurück zum Zitat Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702–5.PubMedCrossRef Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702–5.PubMedCrossRef
278.
Zurück zum Zitat Checkoway H, Franklin GM, Costa-Mallen P, Smith-Weller T, Dilley J, Swanson PD, et al. A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson’s disease. Neurology. 1998;50:1458–61.PubMed Checkoway H, Franklin GM, Costa-Mallen P, Smith-Weller T, Dilley J, Swanson PD, et al. A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson’s disease. Neurology. 1998;50:1458–61.PubMed
279.
Zurück zum Zitat Mellick GD, McCann SJ, Le Couter DG. Parkinson’s disease, MAOB, and smoking. Neurology. 1999;53:658.PubMed Mellick GD, McCann SJ, Le Couter DG. Parkinson’s disease, MAOB, and smoking. Neurology. 1999;53:658.PubMed
280.
Zurück zum Zitat Hernan MA, Checkoway H, O’Brien R, Costa-Mallen P, De Vivo I, Colditz GA, et al. MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD. Neurology. 2002;58:1381–7.PubMed Hernan MA, Checkoway H, O’Brien R, Costa-Mallen P, De Vivo I, Colditz GA, et al. MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD. Neurology. 2002;58:1381–7.PubMed
281.
Zurück zum Zitat Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979–80.PubMedCrossRef Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979–80.PubMedCrossRef
282.
Zurück zum Zitat Barbeau A, Roy M, Bernier G, Campanella G, Paris S. Ecogenetics of Parkinson’s disease: prevalence and environmental aspects in rural areas. Can J Neurol Sci. 1987;14:36–41.PubMed Barbeau A, Roy M, Bernier G, Campanella G, Paris S. Ecogenetics of Parkinson’s disease: prevalence and environmental aspects in rural areas. Can J Neurol Sci. 1987;14:36–41.PubMed
283.
Zurück zum Zitat Bhatt MH, Elias MA, Mankodi AK. Acute and reversible parkinsonism due to organophosphate pesticide intoxication: five cases. Neurology. 1999;52:1467–71.PubMed Bhatt MH, Elias MA, Mankodi AK. Acute and reversible parkinsonism due to organophosphate pesticide intoxication: five cases. Neurology. 1999;52:1467–71.PubMed
284.
Zurück zum Zitat Meco G, Bonifati V, Vanacore N, Fabrizio E. Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate). Scand J Work Environ Health. 1994;20:301–5.PubMed Meco G, Bonifati V, Vanacore N, Fabrizio E. Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate). Scand J Work Environ Health. 1994;20:301–5.PubMed
285.
Zurück zum Zitat Sechi GP, Agnetti V, Piredda M, Canu M, Deserra F, Omar HA, et al. Acute and persistent parkinsonism after use of diquat. Neurology. 1992;42:261–3.PubMed Sechi GP, Agnetti V, Piredda M, Canu M, Deserra F, Omar HA, et al. Acute and persistent parkinsonism after use of diquat. Neurology. 1992;42:261–3.PubMed
286.
Zurück zum Zitat Muller-Vahl KR, Kolbe H, Dengler R. Transient severe parkinsonism after acute organophosphate poisoning. J Neurol Neurosurg Psychiatry. 1999;66:253–4.PubMedCrossRef Muller-Vahl KR, Kolbe H, Dengler R. Transient severe parkinsonism after acute organophosphate poisoning. J Neurol Neurosurg Psychiatry. 1999;66:253–4.PubMedCrossRef
287.
288.
Zurück zum Zitat Sanchez-Ramos JR, Hefti F, Weiner WJ. Paraquat and Parkinson’s disease. Neurology. 1987;37:728.PubMed Sanchez-Ramos JR, Hefti F, Weiner WJ. Paraquat and Parkinson’s disease. Neurology. 1987;37:728.PubMed
289.
Zurück zum Zitat Golbe LI, Farrell TM, Davis PH. Follow-up study of early-life protective and risk factors in Parkinson’s disease. Mov Disord. 1990;5:66–70.PubMedCrossRef Golbe LI, Farrell TM, Davis PH. Follow-up study of early-life protective and risk factors in Parkinson’s disease. Mov Disord. 1990;5:66–70.PubMedCrossRef
290.
Zurück zum Zitat Semchuk KM, Love EJ, Lee RG. Parkinson’s disease and exposure to agricultural work and pesticide chemicals. Neurology. 1992;42:1328–35.PubMed Semchuk KM, Love EJ, Lee RG. Parkinson’s disease and exposure to agricultural work and pesticide chemicals. Neurology. 1992;42:1328–35.PubMed
291.
Zurück zum Zitat Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC. Risk factors for Parkinson’s disease. Neurology. 1993;43:1693–7.PubMed Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC. Risk factors for Parkinson’s disease. Neurology. 1993;43:1693–7.PubMed
292.
Zurück zum Zitat Hertzman C, Wiens M, Snow B, Kelly S, Calne D. A case-control study of Parkinson’s disease in a horticultural region of British Columbia. Mov Disord. 1994;9:69–75.PubMedCrossRef Hertzman C, Wiens M, Snow B, Kelly S, Calne D. A case-control study of Parkinson’s disease in a horticultural region of British Columbia. Mov Disord. 1994;9:69–75.PubMedCrossRef
293.
Zurück zum Zitat Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, et al. Environmental risk factors and Parkinson’s disease: a case-control study in Taiwan. Neurology. 1997;48:1583–8.PubMed Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, et al. Environmental risk factors and Parkinson’s disease: a case-control study in Taiwan. Neurology. 1997;48:1583–8.PubMed
294.
Zurück zum Zitat Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson’s disease, pesticides, and glutathione transferase polymorphisms. Lancet. 1998;352:1344–6.PubMedCrossRef Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson’s disease, pesticides, and glutathione transferase polymorphisms. Lancet. 1998;352:1344–6.PubMedCrossRef
295.
Zurück zum Zitat Fall PA, Fredrikson M, Axelson O, Granerus AK. Nutritional and occupational factors influencing the risk of Parkinson’s disease: a case-control study in southeastern Sweden. Mov Disord. 1999;14:28–37.PubMedCrossRef Fall PA, Fredrikson M, Axelson O, Granerus AK. Nutritional and occupational factors influencing the risk of Parkinson’s disease: a case-control study in southeastern Sweden. Mov Disord. 1999;14:28–37.PubMedCrossRef
296.
Zurück zum Zitat Baldereschi M, Di Carlo A, Vanni P, Ghetti A, Carbonin P, Amaducci L, et al. Lifestyle-related risk factors for Parkinson’s disease: a population-based study. Acta Neurol Scand. 2003;108:239–44.PubMedCrossRef Baldereschi M, Di Carlo A, Vanni P, Ghetti A, Carbonin P, Amaducci L, et al. Lifestyle-related risk factors for Parkinson’s disease: a population-based study. Acta Neurol Scand. 2003;108:239–44.PubMedCrossRef
297.
Zurück zum Zitat Baldi I, Cantagrel A, Lebailly P, Tison F, Dubroca B, Chrysostome V, et al. Association between Parkinson’s disease and exposure to pesticides in southwestern France. Neuroepidemiology. 2003;22:305–10.PubMedCrossRef Baldi I, Cantagrel A, Lebailly P, Tison F, Dubroca B, Chrysostome V, et al. Association between Parkinson’s disease and exposure to pesticides in southwestern France. Neuroepidemiology. 2003;22:305–10.PubMedCrossRef
298.
Zurück zum Zitat Galanaud JP, Elbaz A, Clavel J, Vidal JS, Correze JR, Alperovitch A, et al. Cigarette smoking and Parkinson’s disease: a case-control study in a population characterized by a high prevalence of pesticide exposure. Mov Disord. 2005;20:181–9.PubMedCrossRef Galanaud JP, Elbaz A, Clavel J, Vidal JS, Correze JR, Alperovitch A, et al. Cigarette smoking and Parkinson’s disease: a case-control study in a population characterized by a high prevalence of pesticide exposure. Mov Disord. 2005;20:181–9.PubMedCrossRef
299.
Zurück zum Zitat Frigerio R, Sanft KR, Grossardt BR, Peterson BJ, Elbaz A, Bower JH, et al. Chemical exposures and Parkinson’s disease: a population-based case-control study. Mov Disord. 2006;21:1688–92.PubMedCrossRef Frigerio R, Sanft KR, Grossardt BR, Peterson BJ, Elbaz A, Bower JH, et al. Chemical exposures and Parkinson’s disease: a population-based case-control study. Mov Disord. 2006;21:1688–92.PubMedCrossRef
300.
Zurück zum Zitat Dick FD, De Palma G, Ahmadi A, Scott NW, Prescott GJ, Bennett J, et al. Environmental risk factors for Parkinson’s disease and parkinsonism: the Geoparkinson study. Occup Environ Med. 2007;64:666–72.PubMedCrossRef Dick FD, De Palma G, Ahmadi A, Scott NW, Prescott GJ, Bennett J, et al. Environmental risk factors for Parkinson’s disease and parkinsonism: the Geoparkinson study. Occup Environ Med. 2007;64:666–72.PubMedCrossRef
301.
Zurück zum Zitat Dhillon AS, Tarbutton GL, Levin JL, Plotkin GM, Lowry LK, Nalbone JT, et al. Pesticide/environmental exposures and Parkinson’s disease in East Texas. J Agromed. 2008;13:37–48.CrossRef Dhillon AS, Tarbutton GL, Levin JL, Plotkin GM, Lowry LK, Nalbone JT, et al. Pesticide/environmental exposures and Parkinson’s disease in East Texas. J Agromed. 2008;13:37–48.CrossRef
302.
Zurück zum Zitat Hancock DB, Martin ER, Mayhew GM, Stajich JM, Jewett R, Stacy MA, et al. Pesticide exposure and risk of Parkinson’s disease: a family-based case-control study. BMC Neurol. 2008;8:6.PubMedCrossRef Hancock DB, Martin ER, Mayhew GM, Stajich JM, Jewett R, Stacy MA, et al. Pesticide exposure and risk of Parkinson’s disease: a family-based case-control study. BMC Neurol. 2008;8:6.PubMedCrossRef
303.
Zurück zum Zitat Ho SC, Woo J, Lee CM. Epidemiologic study of Parkinson’s disease in Hong Kong. Neurology. 1989;39:1314–8.PubMed Ho SC, Woo J, Lee CM. Epidemiologic study of Parkinson’s disease in Hong Kong. Neurology. 1989;39:1314–8.PubMed
304.
Zurück zum Zitat Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, et al. Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol. 2009;66:1106–13.PubMedCrossRef Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, et al. Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol. 2009;66:1106–13.PubMedCrossRef
305.
Zurück zum Zitat Koller W, Vetere-Overfield B, Gray C, Alexander C, Chin T, Dolezal J, et al. Environmental risk factors in Parkinson’s disease. Neurology. 1990;40:1218–21.PubMed Koller W, Vetere-Overfield B, Gray C, Alexander C, Chin T, Dolezal J, et al. Environmental risk factors in Parkinson’s disease. Neurology. 1990;40:1218–21.PubMed
306.
Zurück zum Zitat Wechsler LS, Checkoway H, Franklin GM, Costa LG. A pilot study of occupational and environmental risk factors for Parkinson’s disease. Neurotoxicology. 1991;12:387–92.PubMed Wechsler LS, Checkoway H, Franklin GM, Costa LG. A pilot study of occupational and environmental risk factors for Parkinson’s disease. Neurotoxicology. 1991;12:387–92.PubMed
307.
Zurück zum Zitat Jimenez-Jimenez FJ, Mateo D, Gimenez-Roldan S. Exposure to well water and pesticides in Parkinson’s disease: a case-control study in the Madrid area. Mov Disord. 1992;7:149–52.PubMedCrossRef Jimenez-Jimenez FJ, Mateo D, Gimenez-Roldan S. Exposure to well water and pesticides in Parkinson’s disease: a case-control study in the Madrid area. Mov Disord. 1992;7:149–52.PubMedCrossRef
308.
Zurück zum Zitat Chaturvedi S, Ostbye T, Stoessl AJ, Merskey H, Hachinski V. Environmental exposures in elderly Canadians with Parkinson’s disease. Can J Neurol Sci. 1995;22:232–4.PubMed Chaturvedi S, Ostbye T, Stoessl AJ, Merskey H, Hachinski V. Environmental exposures in elderly Canadians with Parkinson’s disease. Can J Neurol Sci. 1995;22:232–4.PubMed
309.
Zurück zum Zitat Smargiassi A, Mutti A, De Rosa A, De Palma G, Negrotti A, Calzetti S. A case-control study of occupational and environmental risk factors for Parkinson’s disease in the Emilia-Romagna region of Italy. Neurotoxicology. 1998;19:709–12.PubMed Smargiassi A, Mutti A, De Rosa A, De Palma G, Negrotti A, Calzetti S. A case-control study of occupational and environmental risk factors for Parkinson’s disease in the Emilia-Romagna region of Italy. Neurotoxicology. 1998;19:709–12.PubMed
310.
Zurück zum Zitat Dong JQ, Zhang ZX, Zhang KL. Parkinson’s disease and smoking: an integral part of PD’s etiological study. Biomed Environ Sci. 2003;16:173–9.PubMed Dong JQ, Zhang ZX, Zhang KL. Parkinson’s disease and smoking: an integral part of PD’s etiological study. Biomed Environ Sci. 2003;16:173–9.PubMed
311.
Zurück zum Zitat Nuti A, Ceravolo R, Dell’Agnello G, Gambaccini G, Bellini G, Kiferle L, et al. Environmental factors and Parkinson’s disease: a case-control study in the Tuscany region of Italy. Parkinsonism Relat Disord. 2004;10:481–5.PubMedCrossRef Nuti A, Ceravolo R, Dell’Agnello G, Gambaccini G, Bellini G, Kiferle L, et al. Environmental factors and Parkinson’s disease: a case-control study in the Tuscany region of Italy. Parkinsonism Relat Disord. 2004;10:481–5.PubMedCrossRef
312.
Zurück zum Zitat Wright JM, Keller-Byrne J. Environmental determinants of Parkinson’s disease. Arch Environ Occup Health. 2005;60:32–8.PubMedCrossRef Wright JM, Keller-Byrne J. Environmental determinants of Parkinson’s disease. Arch Environ Occup Health. 2005;60:32–8.PubMedCrossRef
313.
Zurück zum Zitat Petersen MS, Halling J, Bech S, Wermuth L, Weihe P, Nielsen F, et al. Impact of dietary exposure to food contaminants on the risk of Parkinson’s disease. Neurotoxicology. 2008;29:584–90.PubMedCrossRef Petersen MS, Halling J, Bech S, Wermuth L, Weihe P, Nielsen F, et al. Impact of dietary exposure to food contaminants on the risk of Parkinson’s disease. Neurotoxicology. 2008;29:584–90.PubMedCrossRef
314.
Zurück zum Zitat Wong GF, Gray CS, Hassanein RS, Koller WC. Environmental risk factors in siblings with Parkinson’s disease. Arch Neurol. 1991;48:287–9.PubMed Wong GF, Gray CS, Hassanein RS, Koller WC. Environmental risk factors in siblings with Parkinson’s disease. Arch Neurol. 1991;48:287–9.PubMed
315.
Zurück zum Zitat Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Environmental risk factors in Parkinson’s disease. Mov Disord. 1999;14:928–39.PubMedCrossRef Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Environmental risk factors in Parkinson’s disease. Mov Disord. 1999;14:928–39.PubMedCrossRef
316.
Zurück zum Zitat Firestone JA, Smith-Weller T, Franklin G, Swanson P, Longstreth WT Jr, Checkoway H. Pesticides and risk of Parkinson disease: a population-based case-control study. Arch Neurol. 2005;62:91–5.PubMedCrossRef Firestone JA, Smith-Weller T, Franklin G, Swanson P, Longstreth WT Jr, Checkoway H. Pesticides and risk of Parkinson disease: a population-based case-control study. Arch Neurol. 2005;62:91–5.PubMedCrossRef
317.
Zurück zum Zitat Firestone JA, Lundin JI, Powers KM, Smith-Weller T, Franklin GM, Swanson PD, et al. Occupational factors and risk of Parkinson’s disease: a population-based case-control study. Am J Ind Med. 2010;53:217–23.PubMed Firestone JA, Lundin JI, Powers KM, Smith-Weller T, Franklin GM, Swanson PD, et al. Occupational factors and risk of Parkinson’s disease: a population-based case-control study. Am J Ind Med. 2010;53:217–23.PubMed
318.
Zurück zum Zitat Polder A, Skaare JU, Skjerve E, Loken KB, Eggesbo M. Levels of chlorinated pesticides and polychlorinated biphenyls in Norwegian breast milk (2002–2006), and factors that may predict the level of contamination. Sci Total Environ. 2009;407:4584–90.PubMedCrossRef Polder A, Skaare JU, Skjerve E, Loken KB, Eggesbo M. Levels of chlorinated pesticides and polychlorinated biphenyls in Norwegian breast milk (2002–2006), and factors that may predict the level of contamination. Sci Total Environ. 2009;407:4584–90.PubMedCrossRef
319.
Zurück zum Zitat Baldi I, Lebailly P, Mohammed-Brahim B, Letenneur L, Dartigues JF, Brochard P. Neurodegenerative diseases and exposure to pesticides in the elderly. Am J Epidemiol. 2003;157:409–14.PubMedCrossRef Baldi I, Lebailly P, Mohammed-Brahim B, Letenneur L, Dartigues JF, Brochard P. Neurodegenerative diseases and exposure to pesticides in the elderly. Am J Epidemiol. 2003;157:409–14.PubMedCrossRef
320.
Zurück zum Zitat Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S. A meta-analysis of Parkinson’s disease and exposure to pesticides. Neurotoxicology. 2000;21:435–40.PubMed Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S. A meta-analysis of Parkinson’s disease and exposure to pesticides. Neurotoxicology. 2000;21:435–40.PubMed
321.
Zurück zum Zitat Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology. 1998;50:1346–50.PubMed Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology. 1998;50:1346–50.PubMed
322.
Zurück zum Zitat Gorell JM, Peterson EL, Rybicki BA, Johnson CC. Multiple risk factors for Parkinson’s disease. J Neurol Sci. 2004;217:169–74.PubMedCrossRef Gorell JM, Peterson EL, Rybicki BA, Johnson CC. Multiple risk factors for Parkinson’s disease. J Neurol Sci. 2004;217:169–74.PubMedCrossRef
323.
Zurück zum Zitat Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B. Parkinson’s disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol. 2009;169:919–26.PubMedCrossRef Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B. Parkinson’s disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol. 2009;169:919–26.PubMedCrossRef
324.
Zurück zum Zitat Elbaz A, Clavel J, Rathouz PJ, Moisan F, Galanaud JP, Delemotte B, et al. Professional exposure to pesticides and Parkinson disease. Ann Neurol. 2009;66:494–504.PubMedCrossRef Elbaz A, Clavel J, Rathouz PJ, Moisan F, Galanaud JP, Delemotte B, et al. Professional exposure to pesticides and Parkinson disease. Ann Neurol. 2009;66:494–504.PubMedCrossRef
325.
Zurück zum Zitat Stern M, Dulaney E, Gruber SB, Golbe L, Bergen M, Hurtig H, et al. The epidemiology of Parkinson’s disease. A case-control study of young-onset and old-onset patients. Arch Neurol. 1991;48:903–7.PubMed Stern M, Dulaney E, Gruber SB, Golbe L, Bergen M, Hurtig H, et al. The epidemiology of Parkinson’s disease. A case-control study of young-onset and old-onset patients. Arch Neurol. 1991;48:903–7.PubMed
326.
Zurück zum Zitat Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR. Parkinson’s disease and brain levels of organochlorine pesticides. Ann Neurol. 1994;36:100–3.PubMedCrossRef Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR. Parkinson’s disease and brain levels of organochlorine pesticides. Ann Neurol. 1994;36:100–3.PubMedCrossRef
327.
Zurück zum Zitat Corrigan FM, Wienburg CL, Shore RF, Daniel SE, Mann D. Organochlorine insecticides in substantia nigra in Parkinson’s disease. J Toxicol Environ Health A. 2000;59:229–34.PubMedCrossRef Corrigan FM, Wienburg CL, Shore RF, Daniel SE, Mann D. Organochlorine insecticides in substantia nigra in Parkinson’s disease. J Toxicol Environ Health A. 2000;59:229–34.PubMedCrossRef
328.
Zurück zum Zitat Koldkjaer OG, Wermuth L, Bjerregaard P. Parkinson’s disease among Inuit in Greenland: organochlorines as risk factors. Int J Circumpolar Health. 2004;63(Suppl 2):366–8.PubMed Koldkjaer OG, Wermuth L, Bjerregaard P. Parkinson’s disease among Inuit in Greenland: organochlorines as risk factors. Int J Circumpolar Health. 2004;63(Suppl 2):366–8.PubMed
329.
Zurück zum Zitat Weisskopf MG, Knekt P, O’Reilly EJ, Lyytinen J, Reunanen A, Laden F, et al. Persistent organochlorine pesticides in serum and risk of Parkinson disease. Neurology. 2010;74:1055–61.PubMedCrossRef Weisskopf MG, Knekt P, O’Reilly EJ, Lyytinen J, Reunanen A, Laden F, et al. Persistent organochlorine pesticides in serum and risk of Parkinson disease. Neurology. 2010;74:1055–61.PubMedCrossRef
330.
Zurück zum Zitat Ascherio A, Chen H, Weisskopf MG, O’Reilly E, McCullough ML, Calle EE, et al. Pesticide exposure and risk for Parkinson’s disease. Ann Neurol. 2006;60:197–203.PubMedCrossRef Ascherio A, Chen H, Weisskopf MG, O’Reilly E, McCullough ML, Calle EE, et al. Pesticide exposure and risk for Parkinson’s disease. Ann Neurol. 2006;60:197–203.PubMedCrossRef
331.
Zurück zum Zitat Petrovitch H, Ross GW, Abbott RD, Sanderson WT, Sharp DS, Tanner CM, et al. Plantation work and risk of Parkinson disease in a population-based longitudinal study. Arch Neurol. 2002;59:1787–92.PubMedCrossRef Petrovitch H, Ross GW, Abbott RD, Sanderson WT, Sharp DS, Tanner CM, et al. Plantation work and risk of Parkinson disease in a population-based longitudinal study. Arch Neurol. 2002;59:1787–92.PubMedCrossRef
332.
Zurück zum Zitat Kamel F, Tanner C, Umbach D, Hoppin J, Alavanja M, Blair A, et al. Pesticide exposure and self-reported Parkinson’s disease in the agricultural health study. Am J Epidemiol. 2007;165:364–74.PubMedCrossRef Kamel F, Tanner C, Umbach D, Hoppin J, Alavanja M, Blair A, et al. Pesticide exposure and self-reported Parkinson’s disease in the agricultural health study. Am J Epidemiol. 2007;165:364–74.PubMedCrossRef
333.
Zurück zum Zitat Dosemeci M, Alavanja MC, Rowland AS, Mage D, Zahm SH, Rothman N, et al. A quantitative approach for estimating exposure to pesticides in the Agricultural Health Study. Ann Occup Hyg. 2002;46:245–60.PubMedCrossRef Dosemeci M, Alavanja MC, Rowland AS, Mage D, Zahm SH, Rothman N, et al. A quantitative approach for estimating exposure to pesticides in the Agricultural Health Study. Ann Occup Hyg. 2002;46:245–60.PubMedCrossRef
334.
Zurück zum Zitat Acquavella JF, Alexander BH, Mandel JS, Burns CJ, Gustin C. Exposure misclassification in studies of agricultural pesticides: insights from biomonitoring. Epidemiology. 2006;17:69–74.PubMedCrossRef Acquavella JF, Alexander BH, Mandel JS, Burns CJ, Gustin C. Exposure misclassification in studies of agricultural pesticides: insights from biomonitoring. Epidemiology. 2006;17:69–74.PubMedCrossRef
335.
Zurück zum Zitat Wang SJ, Fuh JL, Liu CY, Lin KP, Chang R, Yih JS, et al. Parkinson’s disease in Kin-Hu, Kinmen: a community survey by neurologists. Neuroepidemiology. 1994;13:69–74.PubMedCrossRef Wang SJ, Fuh JL, Liu CY, Lin KP, Chang R, Yih JS, et al. Parkinson’s disease in Kin-Hu, Kinmen: a community survey by neurologists. Neuroepidemiology. 1994;13:69–74.PubMedCrossRef
336.
Zurück zum Zitat Svenson LW, Platt GH, Woodhead SE. Geographic variations in the prevalence rates of Parkinson’s disease in Alberta. Can J Neurol Sci. 1993;20:307–11.PubMed Svenson LW, Platt GH, Woodhead SE. Geographic variations in the prevalence rates of Parkinson’s disease in Alberta. Can J Neurol Sci. 1993;20:307–11.PubMed
337.
Zurück zum Zitat Tandberg E, Larsen JP, Nessler EG, Riise T, Aarli JA. The epidemiology of Parkinson’s disease in the county of Rogaland, Norway. Mov Disord. 1995;10:541–9.PubMedCrossRef Tandberg E, Larsen JP, Nessler EG, Riise T, Aarli JA. The epidemiology of Parkinson’s disease in the county of Rogaland, Norway. Mov Disord. 1995;10:541–9.PubMedCrossRef
338.
Zurück zum Zitat Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Changing epidemiology of Parkinson’s disease in southwestern Finland. Neurology. 1999;52:302–8.PubMed Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Changing epidemiology of Parkinson’s disease in southwestern Finland. Neurology. 1999;52:302–8.PubMed
339.
Zurück zum Zitat Yesalis CE 3rd, Lemke JH, Wallace RB, Kohout FJ, Morris MC. Health status of the rural elderly according to farm work history: the Iowa 65+ rural health study. Arch Environ Health. 1985;40:245–53.PubMed Yesalis CE 3rd, Lemke JH, Wallace RB, Kohout FJ, Morris MC. Health status of the rural elderly according to farm work history: the Iowa 65+ rural health study. Arch Environ Health. 1985;40:245–53.PubMed
340.
Zurück zum Zitat Imaizumi Y. Geographical variations in mortality from Parkinson’s disease in Japan, 1977–1985. Acta Neurol Scand. 1995;91:311–6.PubMedCrossRef Imaizumi Y. Geographical variations in mortality from Parkinson’s disease in Japan, 1977–1985. Acta Neurol Scand. 1995;91:311–6.PubMedCrossRef
341.
Zurück zum Zitat Sethi KD, Meador KJ, Loring D, Meador MP. Neuroepidemiology of Parkinson’s disease: analysis of mortality data for the USA and Georgia. Int J Neurosci. 1989;46:87–92.PubMedCrossRef Sethi KD, Meador KJ, Loring D, Meador MP. Neuroepidemiology of Parkinson’s disease: analysis of mortality data for the USA and Georgia. Int J Neurosci. 1989;46:87–92.PubMedCrossRef
342.
Zurück zum Zitat Strickland D, Bertoni JM, Pfeiffer RF. Descriptive epidemiology of Parkinson’s disease through proxy measures. Can J Neurol Sci. 1996;23:279–84.PubMed Strickland D, Bertoni JM, Pfeiffer RF. Descriptive epidemiology of Parkinson’s disease through proxy measures. Can J Neurol Sci. 1996;23:279–84.PubMed
343.
Zurück zum Zitat Ritz B, Yu F. Parkinson’s disease mortality and pesticide exposure in California 1984–1994. Int J Epidemiol. 2000;29:323–9.PubMedCrossRef Ritz B, Yu F. Parkinson’s disease mortality and pesticide exposure in California 1984–1994. Int J Epidemiol. 2000;29:323–9.PubMedCrossRef
344.
Zurück zum Zitat Hertzman C, Wiens M, Bowering D, Snow B, Calne D. Parkinson’s disease: a case-control study of occupational and environmental risk factors. Am J Ind Med. 1990;17:349–55.PubMedCrossRef Hertzman C, Wiens M, Bowering D, Snow B, Calne D. Parkinson’s disease: a case-control study of occupational and environmental risk factors. Am J Ind Med. 1990;17:349–55.PubMedCrossRef
345.
Zurück zum Zitat Frigerio R, Elbaz A, Sanft KR, Peterson BJ, Bower JH, Ahlskog JE, et al. Education and occupations preceding Parkinson disease: a population-based case-control study. Neurology. 2005;65:1575–83.PubMedCrossRef Frigerio R, Elbaz A, Sanft KR, Peterson BJ, Bower JH, Ahlskog JE, et al. Education and occupations preceding Parkinson disease: a population-based case-control study. Neurology. 2005;65:1575–83.PubMedCrossRef
346.
Zurück zum Zitat Park J, Yoo CI, Sim CS, Kim HK, Kim JW, Jeon BS, et al. Occupations and Parkinson’s disease: a multi-center case-control study in South Korea. Neurotoxicology. 2005;26:99–105.PubMedCrossRef Park J, Yoo CI, Sim CS, Kim HK, Kim JW, Jeon BS, et al. Occupations and Parkinson’s disease: a multi-center case-control study in South Korea. Neurotoxicology. 2005;26:99–105.PubMedCrossRef
347.
Zurück zum Zitat Kirkey KL, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Gorell JM. Occupational categories at risk for Parkinson’s disease. Am J Ind Med. 2001;39:564–71.PubMedCrossRef Kirkey KL, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Gorell JM. Occupational categories at risk for Parkinson’s disease. Am J Ind Med. 2001;39:564–71.PubMedCrossRef
348.
Zurück zum Zitat Tsui JK, Calne DB, Wang Y, Schulzer M, Marion SA. Occupational risk factors in Parkinson’s disease. Can J Public Health. 1999;90:334–7.PubMed Tsui JK, Calne DB, Wang Y, Schulzer M, Marion SA. Occupational risk factors in Parkinson’s disease. Can J Public Health. 1999;90:334–7.PubMed
349.
Zurück zum Zitat Rocca WA, Anderson DW, Meneghini F, Grigoletto F, Morgante L, Reggio A, et al. Occupation, education, and Parkinson’s disease: a case-control study in an Italian population. Mov Disord. 1996;11:201–6.PubMedCrossRef Rocca WA, Anderson DW, Meneghini F, Grigoletto F, Morgante L, Reggio A, et al. Occupation, education, and Parkinson’s disease: a case-control study in an Italian population. Mov Disord. 1996;11:201–6.PubMedCrossRef
350.
Zurück zum Zitat Tanner CM, Chen B, Wang W, Peng M, Liu Z, Liang X, et al. Environmental factors and Parkinson’s disease: a case-control study in China. Neurology. 1989;39:660–4.PubMed Tanner CM, Chen B, Wang W, Peng M, Liu Z, Liang X, et al. Environmental factors and Parkinson’s disease: a case-control study in China. Neurology. 1989;39:660–4.PubMed
351.
Zurück zum Zitat Park J, Yoo CI, Sim CS, Kim JW, Yi Y, Jung KY, et al. Occupations and Parkinson’s disease: a case-control study in South Korea. Ind Health. 2004;42:352–8.PubMedCrossRef Park J, Yoo CI, Sim CS, Kim JW, Yi Y, Jung KY, et al. Occupations and Parkinson’s disease: a case-control study in South Korea. Ind Health. 2004;42:352–8.PubMedCrossRef
352.
Zurück zum Zitat Goldman SM, Tanner CM, Olanow CW, Watts RL, Field RD, Langston JW. Occupation and parkinsonism in three movement disorders clinics. Neurology. 2005;65:1430–5.PubMedCrossRef Goldman SM, Tanner CM, Olanow CW, Watts RL, Field RD, Langston JW. Occupation and parkinsonism in three movement disorders clinics. Neurology. 2005;65:1430–5.PubMedCrossRef
353.
Zurück zum Zitat Lee E, Burnett CA, Lalich N, Cameron LL, Sestito JP. Proportionate mortality of crop and livestock farmers in the United States, 1984–1993. Am J Ind Med. 2002;42:410–20.PubMedCrossRef Lee E, Burnett CA, Lalich N, Cameron LL, Sestito JP. Proportionate mortality of crop and livestock farmers in the United States, 1984–1993. Am J Ind Med. 2002;42:410–20.PubMedCrossRef
354.
Zurück zum Zitat Tuchsen F, Jensen AA. Agricultural work and the risk of Parkinson’s disease in Denmark, 1981–1993. Scand J Work Environ Health. 2000;26:359–62.PubMed Tuchsen F, Jensen AA. Agricultural work and the risk of Parkinson’s disease in Denmark, 1981–1993. Scand J Work Environ Health. 2000;26:359–62.PubMed
355.
Zurück zum Zitat Tsai CH, Lo SK, See LC, Chen HZ, Chen RS, Weng YH, et al. Environmental risk factors of young onset Parkinson’s disease: a case-control study. Clin Neurol Neurosurg. 2002;104:328–33.PubMedCrossRef Tsai CH, Lo SK, See LC, Chen HZ, Chen RS, Weng YH, et al. Environmental risk factors of young onset Parkinson’s disease: a case-control study. Clin Neurol Neurosurg. 2002;104:328–33.PubMedCrossRef
356.
Zurück zum Zitat Semchuk KM, Love EJ, Lee RG. Parkinson’s disease and exposure to rural environmental factors: a population based case-control study. Can J Neurol Sci. 1991;18:279–86.PubMed Semchuk KM, Love EJ, Lee RG. Parkinson’s disease and exposure to rural environmental factors: a population based case-control study. Can J Neurol Sci. 1991;18:279–86.PubMed
357.
Zurück zum Zitat Marder K, Logroscino G, Alfaro B, Mejia H, Halim A, Louis E, et al. Environmental risk factors for Parkinson’s disease in an urban multiethnic community. Neurology. 1998;50:279–81.PubMed Marder K, Logroscino G, Alfaro B, Mejia H, Halim A, Louis E, et al. Environmental risk factors for Parkinson’s disease in an urban multiethnic community. Neurology. 1998;50:279–81.PubMed
358.
Zurück zum Zitat Tan EK, Tan C, Fook-Chong SM, Lum SY, Chai A, Chung H, et al. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson’s disease: a study in ethnic Chinese. J Neurol Sci. 2003;216:163–7.PubMedCrossRef Tan EK, Tan C, Fook-Chong SM, Lum SY, Chai A, Chung H, et al. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson’s disease: a study in ethnic Chinese. J Neurol Sci. 2003;216:163–7.PubMedCrossRef
359.
Zurück zum Zitat Gatto NM, Cockburn M, Bronstein J, Manthripragada AD, Ritz B. Well-water consumption and Parkinson’s disease in rural California. Environ Health Persp. 2009;117:1912–8. Gatto NM, Cockburn M, Bronstein J, Manthripragada AD, Ritz B. Well-water consumption and Parkinson’s disease in rural California. Environ Health Persp. 2009;117:1912–8.
360.
Zurück zum Zitat Rybicki BA, Johnson CC, Uman J, Gorell JM. Parkinson’s disease mortality and the industrial use of heavy metals in Michigan. Mov Disord. 1993;8:87–92.PubMedCrossRef Rybicki BA, Johnson CC, Uman J, Gorell JM. Parkinson’s disease mortality and the industrial use of heavy metals in Michigan. Mov Disord. 1993;8:87–92.PubMedCrossRef
361.
Zurück zum Zitat Hatcher JM, Pennell KD, Miller GW. Parkinson’s disease and pesticides: a toxicological perspective. Trends Pharmacol Sci. 2008;29:322–9.PubMedCrossRef Hatcher JM, Pennell KD, Miller GW. Parkinson’s disease and pesticides: a toxicological perspective. Trends Pharmacol Sci. 2008;29:322–9.PubMedCrossRef
362.
363.
Zurück zum Zitat Brown TP, Rumsby PC, Capleton AC, Rushton L, Levy LS. Pesticides and Parkinson’s disease—is there a link? Environ Health Persp. 2006;114:156–64.CrossRef Brown TP, Rumsby PC, Capleton AC, Rushton L, Levy LS. Pesticides and Parkinson’s disease—is there a link? Environ Health Persp. 2006;114:156–64.CrossRef
364.
Zurück zum Zitat Li AA, Mink PJ, McIntosh LJ, Teta MJ, Finley B. Evaluation of epidemiologic and animal data associating pesticides with Parkinson’s disease. J Occup Environ Med. 2005;47:1059–87.PubMedCrossRef Li AA, Mink PJ, McIntosh LJ, Teta MJ, Finley B. Evaluation of epidemiologic and animal data associating pesticides with Parkinson’s disease. J Occup Environ Med. 2005;47:1059–87.PubMedCrossRef
365.
Zurück zum Zitat Di Monte DA. The environment and Parkinson’s disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2003;2:531–8.PubMedCrossRef Di Monte DA. The environment and Parkinson’s disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2003;2:531–8.PubMedCrossRef
366.
Zurück zum Zitat Sherer TB, Betarbet R, Greenamyre JT. Environment, mitochondria, and Parkinson’s disease. Neuroscientist. 2002;8:192–7.PubMed Sherer TB, Betarbet R, Greenamyre JT. Environment, mitochondria, and Parkinson’s disease. Neuroscientist. 2002;8:192–7.PubMed
367.
Zurück zum Zitat Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci. 2000;3:1301–6.PubMedCrossRef Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci. 2000;3:1301–6.PubMedCrossRef
368.
Zurück zum Zitat McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, et al. Environmental risk factors and Parkinson’s disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis. 2002;10:119–27.PubMedCrossRef McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, et al. Environmental risk factors and Parkinson’s disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis. 2002;10:119–27.PubMedCrossRef
369.
Zurück zum Zitat Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory-Slechta DA. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson’s disease. J Neurosci. 2000;20:9207–14.PubMed Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory-Slechta DA. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson’s disease. J Neurosci. 2000;20:9207–14.PubMed
370.
Zurück zum Zitat Uversky VN, Li J, Fink AL. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson’s disease. FEBS Lett. 2001;500:105–8.PubMedCrossRef Uversky VN, Li J, Fink AL. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson’s disease. FEBS Lett. 2001;500:105–8.PubMedCrossRef
371.
Zurück zum Zitat Hatcher JM, Richardson JR, Guillot TS, McCormack AL, Di Monte DA, Jones DP, et al. Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. Exp Neurol. 2007;204:619–30.PubMedCrossRef Hatcher JM, Richardson JR, Guillot TS, McCormack AL, Di Monte DA, Jones DP, et al. Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. Exp Neurol. 2007;204:619–30.PubMedCrossRef
372.
Zurück zum Zitat Le Couteur DG, McLean AJ, Taylor MC, Woodham BL, Board PG. Pesticides and Parkinson’s disease. Biomed Pharmacother. 1999;53:122–30.PubMedCrossRef Le Couteur DG, McLean AJ, Taylor MC, Woodham BL, Board PG. Pesticides and Parkinson’s disease. Biomed Pharmacother. 1999;53:122–30.PubMedCrossRef
373.
Zurück zum Zitat Di Monte DA, Lavasani M, Manning-Bog AB. Environmental factors in Parkinson’s disease. Neurotoxicology. 2002;23:487–502.PubMedCrossRef Di Monte DA, Lavasani M, Manning-Bog AB. Environmental factors in Parkinson’s disease. Neurotoxicology. 2002;23:487–502.PubMedCrossRef
374.
Zurück zum Zitat Elbaz A, Tranchant C. Epidemiologic studies of environmental exposures in Parkinson’s disease. J Neurol Sci. 2007;262:37–44.PubMedCrossRef Elbaz A, Tranchant C. Epidemiologic studies of environmental exposures in Parkinson’s disease. J Neurol Sci. 2007;262:37–44.PubMedCrossRef
375.
Zurück zum Zitat Jankovic J. Searching for a relationship between manganese and welding and Parkinson’s disease. Neurology. 2005;64:2021–8.PubMedCrossRef Jankovic J. Searching for a relationship between manganese and welding and Parkinson’s disease. Neurology. 2005;64:2021–8.PubMedCrossRef
376.
Zurück zum Zitat Kuhn W, Winkel R, Woitalla D, Meves S, Przuntek H, Muller T. High prevalence of parkinsonism after occupational exposure to lead-sulfate batteries. Neurology. 1998;50:1885–6.PubMed Kuhn W, Winkel R, Woitalla D, Meves S, Przuntek H, Muller T. High prevalence of parkinsonism after occupational exposure to lead-sulfate batteries. Neurology. 1998;50:1885–6.PubMed
377.
Zurück zum Zitat Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet. 1987;2:1219–20.PubMedCrossRef Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet. 1987;2:1219–20.PubMedCrossRef
378.
Zurück zum Zitat Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. Brain. 1991;114(Pt 4):1953–75.PubMedCrossRef Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. Brain. 1991;114(Pt 4):1953–75.PubMedCrossRef
379.
Zurück zum Zitat Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem. 1989;52:515–20.PubMedCrossRef Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem. 1989;52:515–20.PubMedCrossRef
380.
Zurück zum Zitat Ngim CH, Devathasan G. Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson’s disease. Neuroepidemiology. 1989;8:128–41.PubMedCrossRef Ngim CH, Devathasan G. Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson’s disease. Neuroepidemiology. 1989;8:128–41.PubMedCrossRef
381.
Zurück zum Zitat McDonnell L, Maginnis C, Lewis S, Pickering N, Antoniak M, Hubbard R, et al. Occupational exposure to solvents and metals and Parkinson’s disease. Neurology. 2003;61:716–7.PubMed McDonnell L, Maginnis C, Lewis S, Pickering N, Antoniak M, Hubbard R, et al. Occupational exposure to solvents and metals and Parkinson’s disease. Neurology. 2003;61:716–7.PubMed
382.
Zurück zum Zitat Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, et al. Occupational exposures to metals as risk factors for Parkinson’s disease. Neurology. 1997;48:650–8.PubMed Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, et al. Occupational exposures to metals as risk factors for Parkinson’s disease. Neurology. 1997;48:650–8.PubMed
383.
Zurück zum Zitat Coon S, Stark A, Peterson E, Gloi A, Kortsha G, Pounds J, et al. Whole-body lifetime occupational lead exposure and risk of Parkinson’s disease. Environ Health Persp. 2006;114:1872–6. Coon S, Stark A, Peterson E, Gloi A, Kortsha G, Pounds J, et al. Whole-body lifetime occupational lead exposure and risk of Parkinson’s disease. Environ Health Persp. 2006;114:1872–6.
384.
Zurück zum Zitat Jimenez-Jimenez FJ, Molina JA, Aguilar MV, Arrieta FJ, Jorge-Santamaria A, Cabrera-Valdivia F, et al. Serum and urinary manganese levels in patients with Parkinson’s disease. Acta Neurol Scand. 1995;91:317–20.PubMedCrossRef Jimenez-Jimenez FJ, Molina JA, Aguilar MV, Arrieta FJ, Jorge-Santamaria A, Cabrera-Valdivia F, et al. Serum and urinary manganese levels in patients with Parkinson’s disease. Acta Neurol Scand. 1995;91:317–20.PubMedCrossRef
385.
Zurück zum Zitat Park J, Yoo CI, Sim CS, Kim JW, Yi Y, Shin YC, et al. A retrospective cohort study of Parkinson’s disease in Korean shipbuilders. Neurotoxicology. 2006;27:445–9.PubMedCrossRef Park J, Yoo CI, Sim CS, Kim JW, Yi Y, Shin YC, et al. A retrospective cohort study of Parkinson’s disease in Korean shipbuilders. Neurotoxicology. 2006;27:445–9.PubMedCrossRef
386.
Zurück zum Zitat Finkelstein MM, Jerrett M. A study of the relationships between Parkinson’s disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. Environ Res. 2007;104:420–32.PubMedCrossRef Finkelstein MM, Jerrett M. A study of the relationships between Parkinson’s disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. Environ Res. 2007;104:420–32.PubMedCrossRef
387.
Zurück zum Zitat Fryzek JP, Hansen J, Cohen S, Bonde JP, Llambias MT, Kolstad HA, et al. A cohort study of Parkinson’s disease and other neurodegenerative disorders in Danish welders. J Occup Environ Med. 2005;47:466–72.PubMedCrossRef Fryzek JP, Hansen J, Cohen S, Bonde JP, Llambias MT, Kolstad HA, et al. A cohort study of Parkinson’s disease and other neurodegenerative disorders in Danish welders. J Occup Environ Med. 2005;47:466–72.PubMedCrossRef
388.
Zurück zum Zitat Fored CM, Fryzek JP, Brandt L, Nise G, Sjogren B, McLaughlin JK, et al. Parkinson’s disease and other basal ganglia or movement disorders in a large nationwide cohort of Swedish welders. Occup Environ Med. 2006;63:135–40.PubMedCrossRef Fored CM, Fryzek JP, Brandt L, Nise G, Sjogren B, McLaughlin JK, et al. Parkinson’s disease and other basal ganglia or movement disorders in a large nationwide cohort of Swedish welders. Occup Environ Med. 2006;63:135–40.PubMedCrossRef
389.
Zurück zum Zitat Stampfer MJ. Welding occupations and mortality from Parkinson’s disease and other neurodegenerative diseases among United States men, 1985–1999. J Occup Environ Hyg. 2009;6:267–72.PubMedCrossRef Stampfer MJ. Welding occupations and mortality from Parkinson’s disease and other neurodegenerative diseases among United States men, 1985–1999. J Occup Environ Hyg. 2009;6:267–72.PubMedCrossRef
390.
Zurück zum Zitat Marsh GM, Gula MJ. Employment as a welder and Parkinson disease among heavy equipment manufacturing workers. J Occup Environ Med. 2006;48:1031–46.PubMedCrossRef Marsh GM, Gula MJ. Employment as a welder and Parkinson disease among heavy equipment manufacturing workers. J Occup Environ Med. 2006;48:1031–46.PubMedCrossRef
391.
Zurück zum Zitat Logroscino G, Chen H, Wing A, Ascherio A. Blood donations, iron stores, and risk of Parkinson’s disease. Mov Disord. 2006;21:835–8.PubMedCrossRef Logroscino G, Chen H, Wing A, Ascherio A. Blood donations, iron stores, and risk of Parkinson’s disease. Mov Disord. 2006;21:835–8.PubMedCrossRef
392.
Zurück zum Zitat Marder K, Logroscino G, Tang MX, Graziano J, Cote L, Louis E, et al. Systemic iron metabolism and mortality from Parkinson’s disease. Neurology. 1998;50:1138–40.PubMed Marder K, Logroscino G, Tang MX, Graziano J, Cote L, Louis E, et al. Systemic iron metabolism and mortality from Parkinson’s disease. Neurology. 1998;50:1138–40.PubMed
393.
Zurück zum Zitat Ohlson CG, Hogstedt C. Parkinson’s disease and occupational exposure to organic solvents, agricultural chemicals and mercury—a case-referent study. Scand J Work Environ Health. 1981;7:252–6.PubMed Ohlson CG, Hogstedt C. Parkinson’s disease and occupational exposure to organic solvents, agricultural chemicals and mercury—a case-referent study. Scand J Work Environ Health. 1981;7:252–6.PubMed
394.
Zurück zum Zitat Savitz DA, Checkoway H, Loomis DP. Magnetic field exposure and neurodegenerative disease mortality among electric utility workers. Epidemiology. 1998;9:398–404.PubMedCrossRef Savitz DA, Checkoway H, Loomis DP. Magnetic field exposure and neurodegenerative disease mortality among electric utility workers. Epidemiology. 1998;9:398–404.PubMedCrossRef
395.
Zurück zum Zitat Johansen C. Exposure to electromagnetic fields and risk of central nervous system disease in utility workers. Epidemiology. 2000;11:539–43.PubMedCrossRef Johansen C. Exposure to electromagnetic fields and risk of central nervous system disease in utility workers. Epidemiology. 2000;11:539–43.PubMedCrossRef
396.
Zurück zum Zitat Noonan CW, Reif JS, Yost M, Touchstone J. Occupational exposure to magnetic fields in case-referent studies of neurodegenerative diseases. Scand J Work Environ Health. 2002;28:42–8.PubMed Noonan CW, Reif JS, Yost M, Touchstone J. Occupational exposure to magnetic fields in case-referent studies of neurodegenerative diseases. Scand J Work Environ Health. 2002;28:42–8.PubMed
397.
Zurück zum Zitat Li X, Sundquist J, Sundquist K. Socioeconomic and occupational groups and Parkinson’s disease: a nationwide study based on hospitalizations in Sweden. Int Arch Occup Environ Health. 2009;82:235–41.PubMedCrossRef Li X, Sundquist J, Sundquist K. Socioeconomic and occupational groups and Parkinson’s disease: a nationwide study based on hospitalizations in Sweden. Int Arch Occup Environ Health. 2009;82:235–41.PubMedCrossRef
398.
Zurück zum Zitat Dorn HF. Tobacco consumption and mortality from cancer and other diseases. Public Health Rep. 1959;74:581–93.PubMed Dorn HF. Tobacco consumption and mortality from cancer and other diseases. Public Health Rep. 1959;74:581–93.PubMed
399.
Zurück zum Zitat Kahn HA. The Dorn study of smoking and mortality among U.S. veterans: report on eight and one-half years of observation. Natl Cancer Inst Monogr. 1966;19:1–125.PubMed Kahn HA. The Dorn study of smoking and mortality among U.S. veterans: report on eight and one-half years of observation. Natl Cancer Inst Monogr. 1966;19:1–125.PubMed
400.
Zurück zum Zitat Hammond EC. Smoking in relation to the death rates of one million men and women. Natl Cancer Inst Monogr. 1966;19:127–204.PubMed Hammond EC. Smoking in relation to the death rates of one million men and women. Natl Cancer Inst Monogr. 1966;19:127–204.PubMed
401.
Zurück zum Zitat Doll R, Peto R. Mortality in relation to smoking: 20 years’ observations on male British doctors. Br Med J. 1976;2:1525–36.PubMedCrossRef Doll R, Peto R. Mortality in relation to smoking: 20 years’ observations on male British doctors. Br Med J. 1976;2:1525–36.PubMedCrossRef
402.
Zurück zum Zitat Shahi GS, Moochhala SM. Smoking and Parkinson’s disease—a new perspective. Rev Environ Health. 1991;9:123–36.PubMedCrossRef Shahi GS, Moochhala SM. Smoking and Parkinson’s disease—a new perspective. Rev Environ Health. 1991;9:123–36.PubMedCrossRef
403.
Zurück zum Zitat Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson’s disease: false association or etiologic clue? Neurology. 1995;45:1041–51.PubMed Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson’s disease: false association or etiologic clue? Neurology. 1995;45:1041–51.PubMed
404.
Zurück zum Zitat Nefzger MD, Quadfasel FA, Karl VC. A retrospective study of smoking in Parkinson’s disease. Am J Epidemiol. 1968;88:149–58.PubMed Nefzger MD, Quadfasel FA, Karl VC. A retrospective study of smoking in Parkinson’s disease. Am J Epidemiol. 1968;88:149–58.PubMed
405.
Zurück zum Zitat Kessler II, Diamond EL. Epidemiologic studies of Parkinson’s disease. I. Smoking and Parkinson’s disease: a survey and explanatory hypothesis. Am J Epidemiol. 1971;94:16–25.PubMed Kessler II, Diamond EL. Epidemiologic studies of Parkinson’s disease. I. Smoking and Parkinson’s disease: a survey and explanatory hypothesis. Am J Epidemiol. 1971;94:16–25.PubMed
406.
Zurück zum Zitat Marttila RJ, Rinne UK. Smoking and Parkinson’s disease. Acta Neurol Scand. 1980;62:322–5.PubMedCrossRef Marttila RJ, Rinne UK. Smoking and Parkinson’s disease. Acta Neurol Scand. 1980;62:322–5.PubMedCrossRef
407.
Zurück zum Zitat Haack DG, Baumann RJ, McKean HE, Jameson HD, Turbek JA. Nicotine exposure and Parkinson disease. Am J Epidemiol. 1981;114:191–200.PubMed Haack DG, Baumann RJ, McKean HE, Jameson HD, Turbek JA. Nicotine exposure and Parkinson disease. Am J Epidemiol. 1981;114:191–200.PubMed
408.
Zurück zum Zitat Godwin-Austen RB, Lee PN, Marmot MG, Stern GM. Smoking and Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1982;45:577–81.PubMedCrossRef Godwin-Austen RB, Lee PN, Marmot MG, Stern GM. Smoking and Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1982;45:577–81.PubMedCrossRef
409.
Zurück zum Zitat Rajput AH, Offord KP, Beard CM, Kurland LT. A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson’s disease. Neurology. 1987;37:226–32.PubMed Rajput AH, Offord KP, Beard CM, Kurland LT. A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson’s disease. Neurology. 1987;37:226–32.PubMed
410.
Zurück zum Zitat Mayeux R, Tang MX, Marder K, Cote LJ, Stern Y. Smoking and Parkinson’s disease. Mov Disord. 1994;9:207–12.PubMedCrossRef Mayeux R, Tang MX, Marder K, Cote LJ, Stern Y. Smoking and Parkinson’s disease. Mov Disord. 1994;9:207–12.PubMedCrossRef
411.
Zurück zum Zitat Martyn CN, Osmond C. Parkinson’s disease and the environment in early life. J Neurol Sci. 1995;132:201–6.PubMedCrossRef Martyn CN, Osmond C. Parkinson’s disease and the environment in early life. J Neurol Sci. 1995;132:201–6.PubMedCrossRef
412.
Zurück zum Zitat Hellenbrand W, Seidler A, Robra BP, Vieregge P, Oertel WH, Joerg J, et al. Smoking and Parkinson’s disease: a case-control study in Germany. Int J Epidemiol. 1997;26:328–39.PubMedCrossRef Hellenbrand W, Seidler A, Robra BP, Vieregge P, Oertel WH, Joerg J, et al. Smoking and Parkinson’s disease: a case-control study in Germany. Int J Epidemiol. 1997;26:328–39.PubMedCrossRef
413.
Zurück zum Zitat Gorell JM, Rybicki BA, Johnson CC, Peterson EL. Smoking and Parkinson’s disease: a dose-response relationship. Neurology. 1999;52:115–9.PubMed Gorell JM, Rybicki BA, Johnson CC, Peterson EL. Smoking and Parkinson’s disease: a dose-response relationship. Neurology. 1999;52:115–9.PubMed
414.
Zurück zum Zitat Vanacore N, Bonifati V, Fabbrini G, Colosimo C, Marconi R, Nicholl D, et al. Smoking habits in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical Parkinsonisms. Neurology. 2000;54:114–9.PubMed Vanacore N, Bonifati V, Fabbrini G, Colosimo C, Marconi R, Nicholl D, et al. Smoking habits in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical Parkinsonisms. Neurology. 2000;54:114–9.PubMed
415.
Zurück zum Zitat Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD. Parkinson’s disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol. 2002;155:732–8.PubMedCrossRef Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD. Parkinson’s disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol. 2002;155:732–8.PubMedCrossRef
416.
Zurück zum Zitat Powers KM, Kay DM, Factor SA, Zabetian CP, Higgins DS, Samii A, et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson’s disease risk. Mov Disord. 2008;23:88–95.PubMedCrossRef Powers KM, Kay DM, Factor SA, Zabetian CP, Higgins DS, Samii A, et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson’s disease risk. Mov Disord. 2008;23:88–95.PubMedCrossRef
417.
Zurück zum Zitat Evans AH, Lawrence AD, Potts J, MacGregor L, Katzenschlager R, Shaw K, et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2006;77:317–21.PubMedCrossRef Evans AH, Lawrence AD, Potts J, MacGregor L, Katzenschlager R, Shaw K, et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2006;77:317–21.PubMedCrossRef
418.
Zurück zum Zitat Elbaz A, Manubens-Bertran JM, Baldereschi M, Breteler MM, Grigoletto F, Lopez-Pousa S, et al. Parkinson’s disease, smoking, and family history. EUROPARKINSON Study Group. J Neurol. 2000;247:793–8.PubMedCrossRef Elbaz A, Manubens-Bertran JM, Baldereschi M, Breteler MM, Grigoletto F, Lopez-Pousa S, et al. Parkinson’s disease, smoking, and family history. EUROPARKINSON Study Group. J Neurol. 2000;247:793–8.PubMedCrossRef
419.
Zurück zum Zitat Tanner CM, Chen B, Wang WZ, Peng ML, Liu ZL, Liang XL, et al. Environmental factors in the etiology of Parkinson’s disease. Can J Neurol Sci. 1987;14:419–23.PubMed Tanner CM, Chen B, Wang WZ, Peng ML, Liu ZL, Liang XL, et al. Environmental factors in the etiology of Parkinson’s disease. Can J Neurol Sci. 1987;14:419–23.PubMed
420.
Zurück zum Zitat Hofman A, Collette HJ, Bartelds AI. Incidence and risk factors of Parkinson’s disease in The Netherlands. Neuroepidemiology. 1989;8:296–9.PubMedCrossRef Hofman A, Collette HJ, Bartelds AI. Incidence and risk factors of Parkinson’s disease in The Netherlands. Neuroepidemiology. 1989;8:296–9.PubMedCrossRef
421.
Zurück zum Zitat Jimenez-Jimenez FJ, Mateo D, Gimenez-Roldan S. Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson’s disease: a case-control study. Mov Disord. 1992;7:339–44.PubMedCrossRef Jimenez-Jimenez FJ, Mateo D, Gimenez-Roldan S. Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson’s disease: a case-control study. Mov Disord. 1992;7:339–44.PubMedCrossRef
422.
Zurück zum Zitat Tzourio C, Rocca WA, Breteler MM, Baldereschi M, Dartigues JF, Lopez-Pousa S, et al. Smoking and Parkinson’s disease. An age-dependent risk effect? The EUROPARKINSON Study Group. Neurology. 1997;49:1267–72.PubMed Tzourio C, Rocca WA, Breteler MM, Baldereschi M, Dartigues JF, Lopez-Pousa S, et al. Smoking and Parkinson’s disease. An age-dependent risk effect? The EUROPARKINSON Study Group. Neurology. 1997;49:1267–72.PubMed
423.
Zurück zum Zitat Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Smoking, alcohol, and coffee consumption preceding Parkinson’s disease: a case-control study. Neurology. 2000;55:1350–8.PubMed Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Smoking, alcohol, and coffee consumption preceding Parkinson’s disease: a case-control study. Neurology. 2000;55:1350–8.PubMed
424.
Zurück zum Zitat Ragonese P, Salemi G, Morgante L, Aridon P, Epifanio A, Buffa D, et al. A case-control study on cigarette, alcohol, and coffee consumption preceding Parkinson’s disease. Neuroepidemiology. 2003;22:297–304.PubMedCrossRef Ragonese P, Salemi G, Morgante L, Aridon P, Epifanio A, Buffa D, et al. A case-control study on cigarette, alcohol, and coffee consumption preceding Parkinson’s disease. Neuroepidemiology. 2003;22:297–304.PubMedCrossRef
425.
Zurück zum Zitat Duvoisin RC, Eldridge R, Williams A, Nutt J, Calne D. Twin study of Parkinson disease. Neurology. 1981;31:77–80.PubMed Duvoisin RC, Eldridge R, Williams A, Nutt J, Calne D. Twin study of Parkinson disease. Neurology. 1981;31:77–80.PubMed
426.
Zurück zum Zitat Bharucha NE, Stokes L, Schoenberg BS, Ward C, Ince S, Nutt JG, et al. A case-control study of twin pairs discordant for Parkinson’s disease: a search for environmental risk factors. Neurology. 1986;36:284–8.PubMed Bharucha NE, Stokes L, Schoenberg BS, Ward C, Ince S, Nutt JG, et al. A case-control study of twin pairs discordant for Parkinson’s disease: a search for environmental risk factors. Neurology. 1986;36:284–8.PubMed
427.
Zurück zum Zitat Tanner CM, Goldman SM, Aston DA, Ottman R, Ellenberg J, Mayeux R, et al. Smoking and Parkinson’s disease in twins. Neurology. 2002;58:581–8.PubMed Tanner CM, Goldman SM, Aston DA, Ottman R, Ellenberg J, Mayeux R, et al. Smoking and Parkinson’s disease in twins. Neurology. 2002;58:581–8.PubMed
428.
Zurück zum Zitat Hernan MA, Zhang SM, Rueda-deCastro AM, Colditz GA, Speizer FE, Ascherio A. Cigarette smoking and the incidence of Parkinson’s disease in two prospective studies. Ann Neurol. 2001;50:780–6.PubMedCrossRef Hernan MA, Zhang SM, Rueda-deCastro AM, Colditz GA, Speizer FE, Ascherio A. Cigarette smoking and the incidence of Parkinson’s disease in two prospective studies. Ann Neurol. 2001;50:780–6.PubMedCrossRef
429.
Zurück zum Zitat Thacker EL, O’Reilly EJ, Weisskopf MG, Chen H, Schwarzschild MA, McCullough ML, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology. 2007;68:764–8.PubMedCrossRef Thacker EL, O’Reilly EJ, Weisskopf MG, Chen H, Schwarzschild MA, McCullough ML, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology. 2007;68:764–8.PubMedCrossRef
430.
Zurück zum Zitat Chen H, Huang X, Guo X, Mailman RB, Park Y, Kamel F, et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology. 2010;74:878–84.PubMedCrossRef Chen H, Huang X, Guo X, Mailman RB, Park Y, Kamel F, et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology. 2010;74:878–84.PubMedCrossRef
431.
Zurück zum Zitat Tan LC, Koh WP, Yuan JM, Wang R, Au WL, Tan JH, et al. Differential effects of black versus green tea on risk of Parkinson’s disease in the Singapore Chinese Health Study. Am J Epidemiol. 2008;167:553–60.PubMedCrossRef Tan LC, Koh WP, Yuan JM, Wang R, Au WL, Tan JH, et al. Differential effects of black versus green tea on risk of Parkinson’s disease in the Singapore Chinese Health Study. Am J Epidemiol. 2008;167:553–60.PubMedCrossRef
432.
Zurück zum Zitat Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson’s disease. Am J Epidemiol. 1994;139:1129–38.PubMed Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson’s disease. Am J Epidemiol. 1994;139:1129–38.PubMed
433.
Zurück zum Zitat Sasco AJ, Paffenbarger RS Jr. Smoking and Parkinson’s disease. Epidemiology. 1990;1:460–5.PubMedCrossRef Sasco AJ, Paffenbarger RS Jr. Smoking and Parkinson’s disease. Epidemiology. 1990;1:460–5.PubMedCrossRef
434.
Zurück zum Zitat Paganini-Hill A. Risk factors for parkinson’s disease: the leisure world cohort study. Neuroepidemiology. 2001;20:118–24.PubMedCrossRef Paganini-Hill A. Risk factors for parkinson’s disease: the leisure world cohort study. Neuroepidemiology. 2001;20:118–24.PubMedCrossRef
435.
Zurück zum Zitat Wirdefeldt K, Gatz M, Pawitan Y, Pedersen NL. Risk and protective factors for Parkinson’s disease: a study in Swedish twins. Ann Neurol. 2005;57:27–33.PubMedCrossRef Wirdefeldt K, Gatz M, Pawitan Y, Pedersen NL. Risk and protective factors for Parkinson’s disease: a study in Swedish twins. Ann Neurol. 2005;57:27–33.PubMedCrossRef
436.
Zurück zum Zitat Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol. 2002;52:276–84.PubMedCrossRef Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol. 2002;52:276–84.PubMedCrossRef
437.
Zurück zum Zitat Sugita M, Izuno T, Tatemichi M, Otahara Y. Meta-analysis for epidemiologic studies on the relationship between smoking and Parkinson’s disease. J Epidemiol. 2001;11:87–94.PubMed Sugita M, Izuno T, Tatemichi M, Otahara Y. Meta-analysis for epidemiologic studies on the relationship between smoking and Parkinson’s disease. J Epidemiol. 2001;11:87–94.PubMed
438.
Zurück zum Zitat Allam MF, Campbell MJ, Hofman A, Del Castillo AS, Fernandez-Crehuet Navajas R. Smoking and Parkinson’s disease: systematic review of prospective studies. Mov Disord. 2004;19:614–21.PubMedCrossRef Allam MF, Campbell MJ, Hofman A, Del Castillo AS, Fernandez-Crehuet Navajas R. Smoking and Parkinson’s disease: systematic review of prospective studies. Mov Disord. 2004;19:614–21.PubMedCrossRef
439.
Zurück zum Zitat Allam MF, Del Castillo AS, Navajas RF. Parkinson’s disease, smoking and family history: meta-analysis. Eur J Neurol. 2003;10:59–62.PubMedCrossRef Allam MF, Del Castillo AS, Navajas RF. Parkinson’s disease, smoking and family history: meta-analysis. Eur J Neurol. 2003;10:59–62.PubMedCrossRef
440.
Zurück zum Zitat Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol. 2007;64:990–7.PubMedCrossRef Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol. 2007;64:990–7.PubMedCrossRef
441.
Zurück zum Zitat Fratiglioni L, Wang HX. Smoking and Parkinson’s and Alzheimer’s disease: review of the epidemiological studies. Behav Brain Res. 2000;113:117–20.PubMedCrossRef Fratiglioni L, Wang HX. Smoking and Parkinson’s and Alzheimer’s disease: review of the epidemiological studies. Behav Brain Res. 2000;113:117–20.PubMedCrossRef
442.
Zurück zum Zitat Golbe LI, Cody RA, Duvoisin RC. Smoking and Parkinson’s disease. Search for a dose-response relationship. Arch Neurol. 1986;43:774–8.PubMed Golbe LI, Cody RA, Duvoisin RC. Smoking and Parkinson’s disease. Search for a dose-response relationship. Arch Neurol. 1986;43:774–8.PubMed
443.
Zurück zum Zitat Riggs JE. Cigarette smoking and Parkinson disease: the illusion of a neuroprotective effect. Clin Neuropharmacol. 1992;15:88–99.PubMedCrossRef Riggs JE. Cigarette smoking and Parkinson disease: the illusion of a neuroprotective effect. Clin Neuropharmacol. 1992;15:88–99.PubMedCrossRef
444.
Zurück zum Zitat Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB, et al. Parkinson’s disease in twins. Adv Neurol. 1984;40:341–4.PubMed Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB, et al. Parkinson’s disease in twins. Adv Neurol. 1984;40:341–4.PubMed
445.
Zurück zum Zitat Ogawa T. Personality characteristics of Parkinson’s disease. Percept Mot Skills. 1981;52:375–8.PubMed Ogawa T. Personality characteristics of Parkinson’s disease. Percept Mot Skills. 1981;52:375–8.PubMed
446.
Zurück zum Zitat Poewe W, Gerstenbrand F, Ransmayr G, Plorer S. Premorbid personality of Parkinson patients. J Neural Transm Suppl. 1983;19:215–24.PubMed Poewe W, Gerstenbrand F, Ransmayr G, Plorer S. Premorbid personality of Parkinson patients. J Neural Transm Suppl. 1983;19:215–24.PubMed
447.
Zurück zum Zitat Scott WK, Zhang F, Stajich JM, Scott BL, Stacy MA, Vance JM. Family-based case-control study of cigarette smoking and Parkinson disease. Neurology. 2005;64:442–7.PubMed Scott WK, Zhang F, Stajich JM, Scott BL, Stacy MA, Vance JM. Family-based case-control study of cigarette smoking and Parkinson disease. Neurology. 2005;64:442–7.PubMed
448.
Zurück zum Zitat Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol. 2007;64:576–80.PubMedCrossRef Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol. 2007;64:576–80.PubMedCrossRef
449.
Zurück zum Zitat O’Reilly EJ, Chen H, Gardener H, Gao X, Schwarzschild MA, Ascherio A. Smoking and Parkinson’s disease: using parental smoking as a proxy to explore causality. Am J Epidemiol. 2009;169:678–82.PubMedCrossRef O’Reilly EJ, Chen H, Gardener H, Gao X, Schwarzschild MA, Ascherio A. Smoking and Parkinson’s disease: using parental smoking as a proxy to explore causality. Am J Epidemiol. 2009;169:678–82.PubMedCrossRef
450.
Zurück zum Zitat Morozova N, O’Reilly EJ, Ascherio A. Variations in gender ratios support the connection between smoking and Parkinson’s disease. Mov Disord. 2008;23:1414–9.PubMedCrossRef Morozova N, O’Reilly EJ, Ascherio A. Variations in gender ratios support the connection between smoking and Parkinson’s disease. Mov Disord. 2008;23:1414–9.PubMedCrossRef
451.
Zurück zum Zitat Kandinov B, Giladi N, Korczyn AD. Smoking and tea consumption delay onset of Parkinson’s disease. Parkinsonism Relat Disord. 2009;15:41–6.PubMedCrossRef Kandinov B, Giladi N, Korczyn AD. Smoking and tea consumption delay onset of Parkinson’s disease. Parkinsonism Relat Disord. 2009;15:41–6.PubMedCrossRef
452.
Zurück zum Zitat De Reuck J, De Weweire M, Van Maele G, Santens P. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson’s disease. J Neurol Sci. 2005;231:35–9.PubMedCrossRef De Reuck J, De Weweire M, Van Maele G, Santens P. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson’s disease. J Neurol Sci. 2005;231:35–9.PubMedCrossRef
453.
Zurück zum Zitat Alves G, Kurz M, Lie SA, Larsen JP. Cigarette smoking in Parkinson’s disease: influence on disease progression. Mov Disord. 2004;19:1087–92.PubMedCrossRef Alves G, Kurz M, Lie SA, Larsen JP. Cigarette smoking in Parkinson’s disease: influence on disease progression. Mov Disord. 2004;19:1087–92.PubMedCrossRef
454.
Zurück zum Zitat Kandinov B, Giladi N, Korczyn AD. The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:243–5.PubMedCrossRef Kandinov B, Giladi N, Korczyn AD. The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:243–5.PubMedCrossRef
455.
Zurück zum Zitat O’Reilly EJ, McCullough ML, Chao A, Henley SJ, Calle EE, Thun MJ, et al. Smokeless tobacco use and the risk of Parkinson’s disease mortality. Mov Disord. 2005;20:1383–4.PubMedCrossRef O’Reilly EJ, McCullough ML, Chao A, Henley SJ, Calle EE, Thun MJ, et al. Smokeless tobacco use and the risk of Parkinson’s disease mortality. Mov Disord. 2005;20:1383–4.PubMedCrossRef
456.
457.
Zurück zum Zitat Hong DP, Fink AL, Uversky VN. Smoking and Parkinson’s disease: does nicotine affect alpha-synuclein fibrillation? Biochim Biophys Acta. 2009;1794:282–90.PubMed Hong DP, Fink AL, Uversky VN. Smoking and Parkinson’s disease: does nicotine affect alpha-synuclein fibrillation? Biochim Biophys Acta. 2009;1794:282–90.PubMed
458.
Zurück zum Zitat Hellenbrand W, Seidler A, Boeing H, Robra BP, Vieregge P, Nischan P, et al. Diet and Parkinson’s disease. I: a possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology. 1996;47:636–43.PubMed Hellenbrand W, Seidler A, Boeing H, Robra BP, Vieregge P, Nischan P, et al. Diet and Parkinson’s disease. I: a possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology. 1996;47:636–43.PubMed
459.
Zurück zum Zitat Hernan MA, Chen H, Schwarzschild MA, Ascherio A. Alcohol consumption and the incidence of Parkinson’s disease. Ann Neurol. 2003;54:170–5.PubMedCrossRef Hernan MA, Chen H, Schwarzschild MA, Ascherio A. Alcohol consumption and the incidence of Parkinson’s disease. Ann Neurol. 2003;54:170–5.PubMedCrossRef
460.
Zurück zum Zitat Fertl E, Doppelbauer A, Auff E. Physical activity and sports in patients suffering from Parkinson’s disease in comparison with healthy seniors. J Neural Transm Park Dis Dement Sect. 1993;5:157–61.PubMedCrossRef Fertl E, Doppelbauer A, Auff E. Physical activity and sports in patients suffering from Parkinson’s disease in comparison with healthy seniors. J Neural Transm Park Dis Dement Sect. 1993;5:157–61.PubMedCrossRef
461.
Zurück zum Zitat Sasco AJ, Paffenbarger RS Jr, Gendre I, Wing AL. The role of physical exercise in the occurrence of Parkinson’s disease. Arch Neurol. 1992;49:360–5.PubMed Sasco AJ, Paffenbarger RS Jr, Gendre I, Wing AL. The role of physical exercise in the occurrence of Parkinson’s disease. Arch Neurol. 1992;49:360–5.PubMed
462.
Zurück zum Zitat Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A. Physical activity and the risk of Parkinson disease. Neurology. 2005;64:664–9.PubMed Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A. Physical activity and the risk of Parkinson disease. Neurology. 2005;64:664–9.PubMed
463.
Zurück zum Zitat Logroscino G, Sesso HD, Paffenbarger RS Jr, Lee IM. Physical activity and risk of Parkinson’s disease: a prospective cohort study. J Neurol Neurosurg Psychiatry. 2006;77:1318–22.PubMedCrossRef Logroscino G, Sesso HD, Paffenbarger RS Jr, Lee IM. Physical activity and risk of Parkinson’s disease: a prospective cohort study. J Neurol Neurosurg Psychiatry. 2006;77:1318–22.PubMedCrossRef
464.
Zurück zum Zitat Thacker EL, Chen H, Patel AV, McCullough ML, Calle EE, Thun MJ, et al. Recreational physical activity and risk of Parkinson’s disease. Mov Disord. 2008;23:69–74.PubMedCrossRef Thacker EL, Chen H, Patel AV, McCullough ML, Calle EE, Thun MJ, et al. Recreational physical activity and risk of Parkinson’s disease. Mov Disord. 2008;23:69–74.PubMedCrossRef
465.
Zurück zum Zitat Ragonese P, D’Amelio M, Callari G, Di Benedetto N, Palmeri B, Mazzola MA, et al. Body mass index does not change before Parkinson’s disease onset. Eur J Neurol. 2008;15:965–8.PubMedCrossRef Ragonese P, D’Amelio M, Callari G, Di Benedetto N, Palmeri B, Mazzola MA, et al. Body mass index does not change before Parkinson’s disease onset. Eur J Neurol. 2008;15:965–8.PubMedCrossRef
466.
Zurück zum Zitat Ma L, Zhang L, Gao XH, Chen W, Wu YP, Wang Y, et al. Dietary factors and smoking as risk factors for PD in a rural population in China: a nested case-control study. Acta Neurol Scand. 2006;113:278–81.PubMedCrossRef Ma L, Zhang L, Gao XH, Chen W, Wu YP, Wang Y, et al. Dietary factors and smoking as risk factors for PD in a rural population in China: a nested case-control study. Acta Neurol Scand. 2006;113:278–81.PubMedCrossRef
467.
Zurück zum Zitat Abbott RD, Ross GW, White LR, Nelson JS, Masaki KH, Tanner CM, et al. Midlife adiposity and the future risk of Parkinson’s disease. Neurology. 2002;59:1051–7.PubMed Abbott RD, Ross GW, White LR, Nelson JS, Masaki KH, Tanner CM, et al. Midlife adiposity and the future risk of Parkinson’s disease. Neurology. 2002;59:1051–7.PubMed
468.
Zurück zum Zitat Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, Tuomilehto J. Body mass index and the risk of Parkinson disease. Neurology. 2006;67:1955–9.PubMedCrossRef Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, Tuomilehto J. Body mass index and the risk of Parkinson disease. Neurology. 2006;67:1955–9.PubMedCrossRef
469.
Zurück zum Zitat Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Willett WC, Ascherio A. Obesity and the risk of Parkinson’s disease. Am J Epidemiol. 2004;159:547–55.PubMedCrossRef Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Willett WC, Ascherio A. Obesity and the risk of Parkinson’s disease. Am J Epidemiol. 2004;159:547–55.PubMedCrossRef
470.
Zurück zum Zitat Logroscino G, Sesso HD, Paffenbarger RS Jr, Lee IM. Body mass index and risk of Parkinson’s disease: a prospective cohort study. Am J Epidemiol. 2007;166:1186–90.PubMedCrossRef Logroscino G, Sesso HD, Paffenbarger RS Jr, Lee IM. Body mass index and risk of Parkinson’s disease: a prospective cohort study. Am J Epidemiol. 2007;166:1186–90.PubMedCrossRef
471.
Zurück zum Zitat Golbe LI, Farrell TM, Davis PH. Case-control study of early life dietary factors in Parkinson’s disease. Arch Neurol. 1988;45:1350–3.PubMed Golbe LI, Farrell TM, Davis PH. Case-control study of early life dietary factors in Parkinson’s disease. Arch Neurol. 1988;45:1350–3.PubMed
472.
Zurück zum Zitat Vieregge P, von Maravic C, Friedrich HJ. Life-style and dietary factors early and late in Parkinson’s disease. Can J Neurol Sci. 1992;19:170–3.PubMed Vieregge P, von Maravic C, Friedrich HJ. Life-style and dietary factors early and late in Parkinson’s disease. Can J Neurol Sci. 1992;19:170–3.PubMed
473.
Zurück zum Zitat Kondo K, Watanabe K. Lifestyles, risk factors, and inherited predispositions in Parkinson’s disease. Preliminary report of a case-control study. Adv Neurol. 1993;60:346–51.PubMed Kondo K, Watanabe K. Lifestyles, risk factors, and inherited predispositions in Parkinson’s disease. Preliminary report of a case-control study. Adv Neurol. 1993;60:346–51.PubMed
474.
Zurück zum Zitat Ayuso-Peralta L, Jimenez-Jimenez FJ, Cabrera-Valdivia F, Molina J, Javier MR, Almazan J, et al. Premorbid dietetic habits and risk for Parkinson’s disease. Parkinsonism Relat Disord. 1997;3:55–61.PubMedCrossRef Ayuso-Peralta L, Jimenez-Jimenez FJ, Cabrera-Valdivia F, Molina J, Javier MR, Almazan J, et al. Premorbid dietetic habits and risk for Parkinson’s disease. Parkinsonism Relat Disord. 1997;3:55–61.PubMedCrossRef
475.
Zurück zum Zitat Ross GW, Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson’s disease. Drugs Aging. 2001;18:797–806.PubMedCrossRef Ross GW, Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson’s disease. Drugs Aging. 2001;18:797–806.PubMedCrossRef
476.
Zurück zum Zitat Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson’s disease. Trends Neurosci. 2006;29:647–54.PubMedCrossRef Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson’s disease. Trends Neurosci. 2006;29:647–54.PubMedCrossRef
477.
Zurück zum Zitat Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. Jama. 2000;283:2674–9.PubMedCrossRef Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. Jama. 2000;283:2674–9.PubMedCrossRef
478.
Zurück zum Zitat Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, et al. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol. 2001;50:56–63.PubMedCrossRef Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, et al. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol. 2001;50:56–63.PubMedCrossRef
479.
Zurück zum Zitat Ascherio A, Weisskopf MG, O’Reilly EJ, McCullough ML, Calle EE, Rodriguez C, et al. Coffee consumption, gender, and Parkinson’s disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol. 2004;160:977–84.PubMedCrossRef Ascherio A, Weisskopf MG, O’Reilly EJ, McCullough ML, Calle EE, Rodriguez C, et al. Coffee consumption, gender, and Parkinson’s disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol. 2004;160:977–84.PubMedCrossRef
480.
Zurück zum Zitat Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, et al. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson’s disease. J Neurosci. 2006;26:535–41.PubMedCrossRef Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, et al. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson’s disease. J Neurosci. 2006;26:535–41.PubMedCrossRef
481.
Zurück zum Zitat Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson’s disease. Mov Disord. 2007;22:2242–8.PubMedCrossRef Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson’s disease. Mov Disord. 2007;22:2242–8.PubMedCrossRef
482.
Zurück zum Zitat Saaksjarvi K, Knekt P, Rissanen H, Laaksonen MA, Reunanen A, Mannisto S. Prospective study of coffee consumption and risk of Parkinson’s disease. Eur J Clin Nutr. 2008;62:908–15.PubMedCrossRef Saaksjarvi K, Knekt P, Rissanen H, Laaksonen MA, Reunanen A, Mannisto S. Prospective study of coffee consumption and risk of Parkinson’s disease. Eur J Clin Nutr. 2008;62:908–15.PubMedCrossRef
483.
Zurück zum Zitat Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A. Diet and Parkinson’s disease: a potential role of dairy products in men. Ann Neurol. 2002;52:793–801.PubMedCrossRef Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A. Diet and Parkinson’s disease: a potential role of dairy products in men. Ann Neurol. 2002;52:793–801.PubMedCrossRef
484.
Zurück zum Zitat Park M, Ross GW, Petrovitch H, White LR, Masaki KH, Nelson JS, et al. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology. 2005;64:1047–51.PubMed Park M, Ross GW, Petrovitch H, White LR, Masaki KH, Nelson JS, et al. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology. 2005;64:1047–51.PubMed
485.
Zurück zum Zitat Chen H, O’Reilly E, McCullough ML, Rodriguez C, Schwarzschild MA, Calle EE, et al. Consumption of dairy products and risk of Parkinson’s disease. Am J Epidemiol. 2007;165:998–1006.PubMedCrossRef Chen H, O’Reilly E, McCullough ML, Rodriguez C, Schwarzschild MA, Calle EE, et al. Consumption of dairy products and risk of Parkinson’s disease. Am J Epidemiol. 2007;165:998–1006.PubMedCrossRef
486.
Zurück zum Zitat Hellenbrand W, Boeing H, Robra BP, Seidler A, Vieregge P, Nischan P, et al. Diet and Parkinson’s disease. II: a possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology. 1996;47:644–50.PubMed Hellenbrand W, Boeing H, Robra BP, Seidler A, Vieregge P, Nischan P, et al. Diet and Parkinson’s disease. II: a possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology. 1996;47:644–50.PubMed
487.
Zurück zum Zitat Logroscino G, Marder K, Cote L, Tang MX, Shea S, Mayeux R. Dietary lipids and antioxidants in Parkinson’s disease: a population-based, case-control study. Ann Neurol. 1996;39:89–94.PubMedCrossRef Logroscino G, Marder K, Cote L, Tang MX, Shea S, Mayeux R. Dietary lipids and antioxidants in Parkinson’s disease: a population-based, case-control study. Ann Neurol. 1996;39:89–94.PubMedCrossRef
488.
Zurück zum Zitat Anderson C, Checkoway H, Franklin GM, Beresford S, Smith-Weller T, Swanson PD. Dietary factors in Parkinson’s disease: the role of food groups and specific foods. Mov Disord. 1999;14:21–7.PubMedCrossRef Anderson C, Checkoway H, Franklin GM, Beresford S, Smith-Weller T, Swanson PD. Dietary factors in Parkinson’s disease: the role of food groups and specific foods. Mov Disord. 1999;14:21–7.PubMedCrossRef
489.
Zurück zum Zitat Johnson CC, Gorell JM, Rybicki BA, Sanders K, Peterson EL. Adult nutrient intake as a risk factor for Parkinson’s disease. Int J Epidemiol. 1999;28:1102–9.PubMedCrossRef Johnson CC, Gorell JM, Rybicki BA, Sanders K, Peterson EL. Adult nutrient intake as a risk factor for Parkinson’s disease. Int J Epidemiol. 1999;28:1102–9.PubMedCrossRef
490.
Zurück zum Zitat Murakami K, Miyake Y, Sasaki S, Tanaka K, Fukushima W, Kiyohara C, et al. Dietary glycemic index is inversely associated with the risk of Parkinson’s disease: a case-control study in Japan. Nutrition. 2010;26:515–21.PubMedCrossRef Murakami K, Miyake Y, Sasaki S, Tanaka K, Fukushima W, Kiyohara C, et al. Dietary glycemic index is inversely associated with the risk of Parkinson’s disease: a case-control study in Japan. Nutrition. 2010;26:515–21.PubMedCrossRef
491.
Zurück zum Zitat Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A. Dietary intakes of fat and risk of Parkinson’s disease. Am J Epidemiol. 2003;157:1007–14.PubMedCrossRef Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A. Dietary intakes of fat and risk of Parkinson’s disease. Am J Epidemiol. 2003;157:1007–14.PubMedCrossRef
492.
Zurück zum Zitat Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H. Parkinson’s disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology. 2003;60:1761–6.PubMed Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H. Parkinson’s disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology. 2003;60:1761–6.PubMed
493.
Zurück zum Zitat Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H. Dietary fats, cholesterol and iron as risk factors for Parkinson’s disease. Parkinsonism Relat Disord. 2009;15:47–52.PubMedCrossRef Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H. Dietary fats, cholesterol and iron as risk factors for Parkinson’s disease. Parkinsonism Relat Disord. 2009;15:47–52.PubMedCrossRef
494.
Zurück zum Zitat de Lau LM, Bornebroek M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology. 2005;64:2040–5.PubMedCrossRef de Lau LM, Bornebroek M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology. 2005;64:2040–5.PubMedCrossRef
495.
Zurück zum Zitat Abbott RA, Cox M, Markus H, Tomkins A. Diet, body size and micronutrient status in Parkinson’s disease. Eur J Clin Nutr. 1992;46:879–84.PubMed Abbott RA, Cox M, Markus H, Tomkins A. Diet, body size and micronutrient status in Parkinson’s disease. Eur J Clin Nutr. 1992;46:879–84.PubMed
496.
Zurück zum Zitat King D, Playfer JR, Roberts NB. Concentrations of vitamins A, C and E in elderly patients with Parkinson’s disease. Postgrad Med J. 1992;68:634–7.PubMedCrossRef King D, Playfer JR, Roberts NB. Concentrations of vitamins A, C and E in elderly patients with Parkinson’s disease. Postgrad Med J. 1992;68:634–7.PubMedCrossRef
497.
Zurück zum Zitat Fernandez-Calle P, Jimenez-Jimenez FJ, Molina JA, Cabrera-Valdivia F, Vazquez A, Garcia Urra D, et al. Serum levels of ascorbic acid (vitamin C) in patients with Parkinson’s disease. J Neurol Sci. 1993;118:25–8.PubMedCrossRef Fernandez-Calle P, Jimenez-Jimenez FJ, Molina JA, Cabrera-Valdivia F, Vazquez A, Garcia Urra D, et al. Serum levels of ascorbic acid (vitamin C) in patients with Parkinson’s disease. J Neurol Sci. 1993;118:25–8.PubMedCrossRef
498.
Zurück zum Zitat Jimenez-Jimenez FJ, Molina JA, Fernandez-Calle P, Vazquez A, Cabrera-Valdivia F, Catalan MJ, et al. Serum levels of beta-carotene and other carotenoids in Parkinson’s disease. Neurosci Lett. 1993;157:103–6.PubMedCrossRef Jimenez-Jimenez FJ, Molina JA, Fernandez-Calle P, Vazquez A, Cabrera-Valdivia F, Catalan MJ, et al. Serum levels of beta-carotene and other carotenoids in Parkinson’s disease. Neurosci Lett. 1993;157:103–6.PubMedCrossRef
499.
Zurück zum Zitat Fernandez-Calle P, Molina JA, Jimenez-Jimenez FJ, Vazquez A, Pondal M, Garcia-Ruiz PJ, et al. Serum levels of alpha-tocopherol (vitamin E) in Parkinson’s disease. Neurology. 1992;42:1064–6.PubMed Fernandez-Calle P, Molina JA, Jimenez-Jimenez FJ, Vazquez A, Pondal M, Garcia-Ruiz PJ, et al. Serum levels of alpha-tocopherol (vitamin E) in Parkinson’s disease. Neurology. 1992;42:1064–6.PubMed
500.
Zurück zum Zitat Jimenez-Jimenez FJ, Molina JA, Fernandez-Calle P, Vazquez A, Pondal M, del Ser T, et al. Serum levels of vitamin A in Parkinson’s disease. J Neurol Sci. 1992;111:73–6.PubMedCrossRef Jimenez-Jimenez FJ, Molina JA, Fernandez-Calle P, Vazquez A, Pondal M, del Ser T, et al. Serum levels of vitamin A in Parkinson’s disease. J Neurol Sci. 1992;111:73–6.PubMedCrossRef
501.
Zurück zum Zitat Scheider WL, Hershey LA, Vena JE, Holmlund T, Marshall JR. Freudenheim. Dietary antioxidants and other dietary factors in the etiology of Parkinson’s disease. Mov Disord. 1997;12:190–6.PubMedCrossRef Scheider WL, Hershey LA, Vena JE, Holmlund T, Marshall JR. Freudenheim. Dietary antioxidants and other dietary factors in the etiology of Parkinson’s disease. Mov Disord. 1997;12:190–6.PubMedCrossRef
502.
Zurück zum Zitat de Rijk MC, Breteler MM, den Breeijen JH, Launer LJ, Grobbee DE, van der Meche FG, et al. Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch Neurol. 1997;54:762–5.PubMed de Rijk MC, Breteler MM, den Breeijen JH, Launer LJ, Grobbee DE, van der Meche FG, et al. Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch Neurol. 1997;54:762–5.PubMed
503.
Zurück zum Zitat Morens DM, Grandinetti A, Waslien CI, Park CB, Ross GW, White LR. Case-control study of idiopathic Parkinson’s disease and dietary vitamin E intake. Neurology. 1996;46:1270–4.PubMed Morens DM, Grandinetti A, Waslien CI, Park CB, Ross GW, White LR. Case-control study of idiopathic Parkinson’s disease and dietary vitamin E intake. Neurology. 1996;46:1270–4.PubMed
504.
Zurück zum Zitat Zhang SM, Hernan MA, Chen H, Spiegelman D, Willett WC, Ascherio A. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology. 2002;59:1161–9.PubMed Zhang SM, Hernan MA, Chen H, Spiegelman D, Willett WC, Ascherio A. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology. 2002;59:1161–9.PubMed
505.
Zurück zum Zitat Etminan M, Gill SS, Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis. Lancet Neurol. 2005;4:362–5.PubMedCrossRef Etminan M, Gill SS, Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis. Lancet Neurol. 2005;4:362–5.PubMedCrossRef
506.
Zurück zum Zitat The Parkinson Study Group N. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med. 1993;328:176–83.CrossRef The Parkinson Study Group N. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med. 1993;328:176–83.CrossRef
507.
Zurück zum Zitat Evatt ML, Delong MR, Khazai N, Rosen A, Triche S, Tangpricha V. Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008;65:1348–52.PubMedCrossRef Evatt ML, Delong MR, Khazai N, Rosen A, Triche S, Tangpricha V. Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008;65:1348–52.PubMedCrossRef
508.
Zurück zum Zitat Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Saaksjarvi K, Heliovaara M. Serum vitamin D and the risk of Parkinson disease. Arch Neurol. 2010;67:808–11.PubMedCrossRef Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Saaksjarvi K, Heliovaara M. Serum vitamin D and the risk of Parkinson disease. Arch Neurol. 2010;67:808–11.PubMedCrossRef
509.
Zurück zum Zitat Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Logroscino G, Willett WC, et al. Folate intake and risk of Parkinson’s disease. Am J Epidemiol. 2004;160:368–75.PubMedCrossRef Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Logroscino G, Willett WC, et al. Folate intake and risk of Parkinson’s disease. Am J Epidemiol. 2004;160:368–75.PubMedCrossRef
510.
Zurück zum Zitat de Lau LM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology. 2006;67:315–8.PubMedCrossRef de Lau LM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology. 2006;67:315–8.PubMedCrossRef
511.
Zurück zum Zitat Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich V, Lojacono N, et al. Dietary iron, animal fats, and risk of Parkinson’s disease. Mov Disord. 1998;13(Suppl 1):13–6.PubMed Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich V, Lojacono N, et al. Dietary iron, animal fats, and risk of Parkinson’s disease. Mov Disord. 1998;13(Suppl 1):13–6.PubMed
512.
Zurück zum Zitat Logroscino G, Gao X, Chen H, Wing A, Ascherio A. Dietary iron intake and risk of Parkinson’s disease. Am J Epidemiol. 2008;168:1381–8.PubMedCrossRef Logroscino G, Gao X, Chen H, Wing A, Ascherio A. Dietary iron intake and risk of Parkinson’s disease. Am J Epidemiol. 2008;168:1381–8.PubMedCrossRef
513.
Zurück zum Zitat Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. 1988;38:1237–44.PubMed Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. 1988;38:1237–44.PubMed
514.
Zurück zum Zitat Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62:436–46.PubMedCrossRef Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62:436–46.PubMedCrossRef
515.
Zurück zum Zitat Berendse HW, Booij J, Francot CM, Bergmans PL, Hijman R, Stoof JC, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson’s disease patients’ relatives with a decreased sense of smell. Ann Neurol. 2001;50:34–41.PubMedCrossRef Berendse HW, Booij J, Francot CM, Bergmans PL, Hijman R, Stoof JC, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson’s disease patients’ relatives with a decreased sense of smell. Ann Neurol. 2001;50:34–41.PubMedCrossRef
516.
Zurück zum Zitat Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol. 2004;56:173–81.PubMedCrossRef Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol. 2004;56:173–81.PubMedCrossRef
517.
Zurück zum Zitat Ponsen MM, Stoffers D, Wolters E, Booij J, Berendse HW. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2010;81:396–9.PubMedCrossRef Ponsen MM, Stoffers D, Wolters E, Booij J, Berendse HW. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2010;81:396–9.PubMedCrossRef
518.
Zurück zum Zitat Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, et al. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol. 2008;63:167–73.PubMedCrossRef Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, et al. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol. 2008;63:167–73.PubMedCrossRef
519.
Zurück zum Zitat Marras C, Goldman S, Smith A, Barney P, Aston D, Comyns K, et al. Smell identification ability in twin pairs discordant for Parkinson’s disease. Mov Disord. 2005;20:687–93.PubMedCrossRef Marras C, Goldman S, Smith A, Barney P, Aston D, Comyns K, et al. Smell identification ability in twin pairs discordant for Parkinson’s disease. Mov Disord. 2005;20:687–93.PubMedCrossRef
520.
Zurück zum Zitat Gagnon JF, Postuma RB, Mazza S, Doyon J, Montplaisir J. Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol. 2006;5:424–32.PubMedCrossRef Gagnon JF, Postuma RB, Mazza S, Doyon J, Montplaisir J. Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol. 2006;5:424–32.PubMedCrossRef
521.
Zurück zum Zitat Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology. 1996;46:388–93.PubMed Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology. 1996;46:388–93.PubMed
522.
Zurück zum Zitat Iranzo A, Molinuevo JL, Santamaria J, Serradell M, Marti MJ, Valldeoriola F, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 2006;5:572–7.PubMedCrossRef Iranzo A, Molinuevo JL, Santamaria J, Serradell M, Marti MJ, Valldeoriola F, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 2006;5:572–7.PubMedCrossRef
523.
Zurück zum Zitat Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009;72:1296–300.PubMed Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009;72:1296–300.PubMed
524.
Zurück zum Zitat Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology. 2010;75:494–9.PubMedCrossRef Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology. 2010;75:494–9.PubMedCrossRef
525.
Zurück zum Zitat Gamboa ET, Wolf A, Yahr MD, Harter DH, Duffy PE, Barden H, et al. Influenza virus antigen in postencephalitic parkinsonism brain. Detection by immunofluorescence. Arch Neurol. 1974;31:228–32.PubMed Gamboa ET, Wolf A, Yahr MD, Harter DH, Duffy PE, Barden H, et al. Influenza virus antigen in postencephalitic parkinsonism brain. Detection by immunofluorescence. Arch Neurol. 1974;31:228–32.PubMed
526.
Zurück zum Zitat Ravenholt RT, Foege WH. 1918 influenza, encephalitis lethargica, parkinsonism. Lancet. 1982;2:860–4.PubMedCrossRef Ravenholt RT, Foege WH. 1918 influenza, encephalitis lethargica, parkinsonism. Lancet. 1982;2:860–4.PubMedCrossRef
527.
Zurück zum Zitat Poskanzer DC, Schwab RS. Cohort analysis of Parkinson’s syndrome: evidence for a single etiology related to subclinical infection about 1920. J Chronic Dis. 1963;16:961–73.PubMedCrossRef Poskanzer DC, Schwab RS. Cohort analysis of Parkinson’s syndrome: evidence for a single etiology related to subclinical infection about 1920. J Chronic Dis. 1963;16:961–73.PubMedCrossRef
528.
Zurück zum Zitat Duvoisin RC, Yahr MD, Schweitzer MD, Merritt HH. Parkinsonism before and since the Epidemic of Encephalitis Lethargica. Arch Neurol. 1963;9:232–6.PubMed Duvoisin RC, Yahr MD, Schweitzer MD, Merritt HH. Parkinsonism before and since the Epidemic of Encephalitis Lethargica. Arch Neurol. 1963;9:232–6.PubMed
529.
Zurück zum Zitat Schwartz J, Elizan TS. Search for viral particles and virus-specific products in idiopathic Parkinson disease brain material. Ann Neurol. 1979;6:261–3.PubMedCrossRef Schwartz J, Elizan TS. Search for viral particles and virus-specific products in idiopathic Parkinson disease brain material. Ann Neurol. 1979;6:261–3.PubMedCrossRef
530.
Zurück zum Zitat Wetmur JG, Schwartz J, Elizan TS. Nucleic acid homology studies of viral nucleic acids in idiopathic Parkinson’s disease. Arch Neurol. 1979;36:462–4.PubMed Wetmur JG, Schwartz J, Elizan TS. Nucleic acid homology studies of viral nucleic acids in idiopathic Parkinson’s disease. Arch Neurol. 1979;36:462–4.PubMed
531.
Zurück zum Zitat Takahashi M, Yamada T, Nakajima S, Nakajima K, Yamamoto T, Okada H. The substantia nigra is a major target for neurovirulent influenza A virus. J Exp Med. 1995;181:2161–9.PubMedCrossRef Takahashi M, Yamada T, Nakajima S, Nakajima K, Yamamoto T, Okada H. The substantia nigra is a major target for neurovirulent influenza A virus. J Exp Med. 1995;181:2161–9.PubMedCrossRef
532.
Zurück zum Zitat Takahashi M, Yamada T. A possible role of influenza A virus infection for Parkinson’s disease. Adv Neurol. 2001;86:91–104.PubMed Takahashi M, Yamada T. A possible role of influenza A virus infection for Parkinson’s disease. Adv Neurol. 2001;86:91–104.PubMed
533.
Zurück zum Zitat Lai BC, Marion SA, Teschke K, Tsui JK. Occupational and environmental risk factors for Parkinson’s disease. Parkinsonism Relat Disord. 2002;8:297–309.PubMedCrossRef Lai BC, Marion SA, Teschke K, Tsui JK. Occupational and environmental risk factors for Parkinson’s disease. Parkinsonism Relat Disord. 2002;8:297–309.PubMedCrossRef
534.
Zurück zum Zitat Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson’s disease. Mov Disord. 1992;7:153–8.PubMedCrossRef Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson’s disease. Mov Disord. 1992;7:153–8.PubMedCrossRef
535.
Zurück zum Zitat Fiszer U, Tomik B, Grzesiowski P, Krygowska-Wajs A, Walory J, Michalowska M, et al. The antibodies against Bordetella pertussis in sera of patients with Parkinson’s disease and other non-neurological diseases. Acta Neurol Scand. 2004;110:113–7.PubMedCrossRef Fiszer U, Tomik B, Grzesiowski P, Krygowska-Wajs A, Walory J, Michalowska M, et al. The antibodies against Bordetella pertussis in sera of patients with Parkinson’s disease and other non-neurological diseases. Acta Neurol Scand. 2004;110:113–7.PubMedCrossRef
536.
Zurück zum Zitat Hubble JP, Cao T, Kjelstrom JA, Koller WC, Beaman BL. Nocardia species as an etiologic agent in Parkinson’s disease: serological testing in a case-control study. J Clin Microbiol. 1995;33:2768–9.PubMed Hubble JP, Cao T, Kjelstrom JA, Koller WC, Beaman BL. Nocardia species as an etiologic agent in Parkinson’s disease: serological testing in a case-control study. J Clin Microbiol. 1995;33:2768–9.PubMed
537.
Zurück zum Zitat Marttila RJ, Halonen P, Rinne UK. Influenza virus antibodies in Parkinsonism. Comparison of postencephalic and idiopathic Parkinson patients and matched controls. Arch Neurol. 1977;34:99–100.PubMed Marttila RJ, Halonen P, Rinne UK. Influenza virus antibodies in Parkinsonism. Comparison of postencephalic and idiopathic Parkinson patients and matched controls. Arch Neurol. 1977;34:99–100.PubMed
538.
Zurück zum Zitat Marttila RJ, Arstila P, Nikoskelainen J, Halonen PE, Rinne UK. Viral antibodies in the sera from patients with Parkinson disease. Eur Neurol. 1977;15:25–33.PubMedCrossRef Marttila RJ, Arstila P, Nikoskelainen J, Halonen PE, Rinne UK. Viral antibodies in the sera from patients with Parkinson disease. Eur Neurol. 1977;15:25–33.PubMedCrossRef
539.
Zurück zum Zitat Elizan TS, Madden DL, Noble GR, Herrmann KL, Gardner J, Schwartz J, et al. Viral antibodies in serum and CSF of Parkinsonian patients and controls. Arch Neurol. 1979;36:529–34.PubMed Elizan TS, Madden DL, Noble GR, Herrmann KL, Gardner J, Schwartz J, et al. Viral antibodies in serum and CSF of Parkinsonian patients and controls. Arch Neurol. 1979;36:529–34.PubMed
540.
Zurück zum Zitat Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson’s disease risk. Parkinsonism Relat Disord. 2006;12:185–9.PubMedCrossRef Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson’s disease risk. Parkinsonism Relat Disord. 2006;12:185–9.PubMedCrossRef
541.
Zurück zum Zitat Sasco AJ, Paffenbarger RS Jr. Measles infection and Parkinson’s disease. Am J Epidemiol. 1985;122:1017–31.PubMed Sasco AJ, Paffenbarger RS Jr. Measles infection and Parkinson’s disease. Am J Epidemiol. 1985;122:1017–31.PubMed
542.
Zurück zum Zitat Mattock C, Marmot M, Stern G. Could Parkinson’s disease follow intra-uterine influenza?: a speculative hypothesis. J Neurol Neurosurg Psychiatry. 1988;51:753–6.PubMedCrossRef Mattock C, Marmot M, Stern G. Could Parkinson’s disease follow intra-uterine influenza?: a speculative hypothesis. J Neurol Neurosurg Psychiatry. 1988;51:753–6.PubMedCrossRef
543.
Zurück zum Zitat Ebmeier KP, Mutch WJ, Calder SA, Crawford JR, Stewart L, Besson JO. Does idiopathic parkinsonism in Aberdeen follow intrauterine influenza? J Neurol Neurosurg Psychiatry. 1989;52:911–3.PubMedCrossRef Ebmeier KP, Mutch WJ, Calder SA, Crawford JR, Stewart L, Besson JO. Does idiopathic parkinsonism in Aberdeen follow intrauterine influenza? J Neurol Neurosurg Psychiatry. 1989;52:911–3.PubMedCrossRef
544.
Zurück zum Zitat Logroscino G. The role of early life environmental risk factors in Parkinson disease: what is the evidence? Environ Health Persp. 2005;113:1234–8.CrossRef Logroscino G. The role of early life environmental risk factors in Parkinson disease: what is the evidence? Environ Health Persp. 2005;113:1234–8.CrossRef
545.
Zurück zum Zitat Miura T, Shimura M, Kimura T. Season of birth in parkinsonism. Prog Biometeorol. 1987;6:157–62. Miura T, Shimura M, Kimura T. Season of birth in parkinsonism. Prog Biometeorol. 1987;6:157–62.
546.
Zurück zum Zitat Betemps EJ, Buncher CR. Birthplace as a risk factor in motor neurone disease and Parkinson’s disease. Int J Epidemiol. 1993;22:898–904.PubMedCrossRef Betemps EJ, Buncher CR. Birthplace as a risk factor in motor neurone disease and Parkinson’s disease. Int J Epidemiol. 1993;22:898–904.PubMedCrossRef
547.
Zurück zum Zitat Kurtzke JF, Goldberg ID. Parkinsonism death rates by race, sex, and geography. Neurology. 1988;38:1558–61.PubMed Kurtzke JF, Goldberg ID. Parkinsonism death rates by race, sex, and geography. Neurology. 1988;38:1558–61.PubMed
548.
Zurück zum Zitat Liu B, Gao HM, Hong JS. Parkinson’s disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Persp. 2003;111:1065–73.CrossRef Liu B, Gao HM, Hong JS. Parkinson’s disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Persp. 2003;111:1065–73.CrossRef
549.
Zurück zum Zitat McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord. 2004;10(Suppl 1):S3–7.PubMedCrossRef McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord. 2004;10(Suppl 1):S3–7.PubMedCrossRef
550.
Zurück zum Zitat McGeer PL, Yasojima K, McGeer EG. Inflammation in Parkinson’s disease. Adv Neurol. 2001;86:83–9.PubMed McGeer PL, Yasojima K, McGeer EG. Inflammation in Parkinson’s disease. Adv Neurol. 2001;86:83–9.PubMed
551.
Zurück zum Zitat Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson’s disease. Exp Neurol. 2007;205:295–312.PubMedCrossRef Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson’s disease. Exp Neurol. 2007;205:295–312.PubMedCrossRef
552.
Zurück zum Zitat Stypula G, Kunert-Radek J, Stepien H, Zylinska K, Pawlikowski M. Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson’s disease. Neuroimmunomodulation. 1996;3:131–4.PubMedCrossRef Stypula G, Kunert-Radek J, Stepien H, Zylinska K, Pawlikowski M. Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson’s disease. Neuroimmunomodulation. 1996;3:131–4.PubMedCrossRef
553.
Zurück zum Zitat Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand. 1999;100:34–41.PubMedCrossRef Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand. 1999;100:34–41.PubMedCrossRef
554.
Zurück zum Zitat Chen H, O’Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson’s disease. Am J Epidemiol. 2008;167:90–5.PubMedCrossRef Chen H, O’Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson’s disease. Am J Epidemiol. 2008;167:90–5.PubMedCrossRef
555.
Zurück zum Zitat Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson’s disease. J Neurochem. 2002;81:1285–97.PubMedCrossRef Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson’s disease. J Neurochem. 2002;81:1285–97.PubMedCrossRef
556.
Zurück zum Zitat Wang T, Pei Z, Zhang W, Liu B, Langenbach R, Lee C, et al. MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J. 2005;19:1134–6.PubMedCrossRef Wang T, Pei Z, Zhang W, Liu B, Langenbach R, Lee C, et al. MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J. 2005;19:1134–6.PubMedCrossRef
557.
Zurück zum Zitat Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol. 2003;60:1059–64.PubMedCrossRef Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol. 2003;60:1059–64.PubMedCrossRef
558.
Zurück zum Zitat Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease. Ann Neurol. 2005;58:963–7.PubMedCrossRef Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease. Ann Neurol. 2005;58:963–7.PubMedCrossRef
559.
Zurück zum Zitat Bornebroek M, de Lau LM, Haag MD, Koudstaal PJ, Hofman A, Stricker BH, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology. 2007;28:193–6.PubMedCrossRef Bornebroek M, de Lau LM, Haag MD, Koudstaal PJ, Hofman A, Stricker BH, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology. 2007;28:193–6.PubMedCrossRef
560.
Zurück zum Zitat Bower JH, Maraganore DM, Peterson BJ, Ahlskog JE, Rocca WA. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology. 2006;67:494–6.PubMedCrossRef Bower JH, Maraganore DM, Peterson BJ, Ahlskog JE, Rocca WA. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology. 2006;67:494–6.PubMedCrossRef
561.
Zurück zum Zitat Ton TG, Heckbert SR, Longstreth WT Jr, Rossing MA, Kukull WA, Franklin GM, et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson’s disease. Mov Disord. 2006;21:964–9.PubMedCrossRef Ton TG, Heckbert SR, Longstreth WT Jr, Rossing MA, Kukull WA, Franklin GM, et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson’s disease. Mov Disord. 2006;21:964–9.PubMedCrossRef
562.
Zurück zum Zitat Hernan MA, Logroscino G, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology. 2006;66:1097–9.PubMedCrossRef Hernan MA, Logroscino G, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology. 2006;66:1097–9.PubMedCrossRef
563.
Zurück zum Zitat Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology. 2010;74:995–1002.PubMedCrossRef Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology. 2010;74:995–1002.PubMedCrossRef
564.
Zurück zum Zitat Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord. 2003;18:414–8.PubMedCrossRef Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord. 2003;18:414–8.PubMedCrossRef
565.
Zurück zum Zitat Schuurman AG, van den Akker M, Ensinck KT, Metsemakers JF, Knottnerus JA, Leentjens AF, et al. Increased risk of Parkinson’s disease after depression: a retrospective cohort study. Neurology. 2002;58:1501–4.PubMed Schuurman AG, van den Akker M, Ensinck KT, Metsemakers JF, Knottnerus JA, Leentjens AF, et al. Increased risk of Parkinson’s disease after depression: a retrospective cohort study. Neurology. 2002;58:1501–4.PubMed
566.
Zurück zum Zitat Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord. 2000;15:669–77.PubMedCrossRef Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord. 2000;15:669–77.PubMedCrossRef
567.
Zurück zum Zitat Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson’s disease for patients with major affective disorder: a register study. Acta Psychiatr Scand. 2001;104:380–6.PubMedCrossRef Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson’s disease for patients with major affective disorder: a register study. Acta Psychiatr Scand. 2001;104:380–6.PubMedCrossRef
568.
Zurück zum Zitat Li X, Sundquist J, Hwang H, Sundquist K. Impact of psychiatric disorders on Parkinson’s disease: a nationwide follow-up study from Sweden. J Neurol. 2008;255:31–6.PubMedCrossRef Li X, Sundquist J, Hwang H, Sundquist K. Impact of psychiatric disorders on Parkinson’s disease: a nationwide follow-up study from Sweden. J Neurol. 2008;255:31–6.PubMedCrossRef
569.
Zurück zum Zitat Stern SL, Hurtig HI, Mendels J, Balaban D. Psychiatric illness in relatives of patients with Parkinson’s disease: a preliminary report. Am J Psychiatry. 1977;134:443–4.PubMed Stern SL, Hurtig HI, Mendels J, Balaban D. Psychiatric illness in relatives of patients with Parkinson’s disease: a preliminary report. Am J Psychiatry. 1977;134:443–4.PubMed
570.
Zurück zum Zitat Fahim S, van Duijn CM, Baker FM, Launer L, Breteler MM, Schudel WJ, et al. A study of familial aggregation of depression, dementia and Parkinson’s disease. Eur J Epidemiol. 1998;14:233–8.PubMedCrossRef Fahim S, van Duijn CM, Baker FM, Launer L, Breteler MM, Schudel WJ, et al. A study of familial aggregation of depression, dementia and Parkinson’s disease. Eur J Epidemiol. 1998;14:233–8.PubMedCrossRef
571.
Zurück zum Zitat Arabia G, Grossardt BR, Geda YE, Carlin JM, Bower JH, Ahlskog JE, et al. Increased risk of depressive and anxiety disorders in relatives of patients with Parkinson disease. Arch Gen Psychiatry. 2007;64:1385–92.PubMedCrossRef Arabia G, Grossardt BR, Geda YE, Carlin JM, Bower JH, Ahlskog JE, et al. Increased risk of depressive and anxiety disorders in relatives of patients with Parkinson disease. Arch Gen Psychiatry. 2007;64:1385–92.PubMedCrossRef
572.
Zurück zum Zitat Hofman A, Schulte W, Tanja TA, van Duijn CM, Haaxma R, Lameris AJ, et al. History of dementia and Parkinson’s disease in 1st-degree relatives of patients with Alzheimer’s disease. Neurology. 1989;39:1589–92.PubMed Hofman A, Schulte W, Tanja TA, van Duijn CM, Haaxma R, Lameris AJ, et al. History of dementia and Parkinson’s disease in 1st-degree relatives of patients with Alzheimer’s disease. Neurology. 1989;39:1589–92.PubMed
573.
Zurück zum Zitat Amaducci LA, Fratiglioni L, Rocca WA, Fieschi C, Livrea P, Pedone D, et al. Risk factors for clinically diagnosed Alzheimer’s disease: a case-control study of an Italian population. Neurology. 1986;36:922–31.PubMed Amaducci LA, Fratiglioni L, Rocca WA, Fieschi C, Livrea P, Pedone D, et al. Risk factors for clinically diagnosed Alzheimer’s disease: a case-control study of an Italian population. Neurology. 1986;36:922–31.PubMed
574.
Zurück zum Zitat van Duijn CM, Clayton D, Chandra V, Fratiglioni L, Graves AB, Heyman A, et al. Familial aggregation of Alzheimer’s disease and related disorders: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol. 1991;20(Suppl 2):S13–20.PubMed van Duijn CM, Clayton D, Chandra V, Fratiglioni L, Graves AB, Heyman A, et al. Familial aggregation of Alzheimer’s disease and related disorders: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol. 1991;20(Suppl 2):S13–20.PubMed
575.
Zurück zum Zitat Huff FJ, Auerbach J, Chakravarti A, Boller F. Risk of dementia in relatives of patients with Alzheimer’s disease. Neurology. 1988;38:786–90.PubMed Huff FJ, Auerbach J, Chakravarti A, Boller F. Risk of dementia in relatives of patients with Alzheimer’s disease. Neurology. 1988;38:786–90.PubMed
576.
Zurück zum Zitat Li G, Shen YC, Li YT, Chen CH, Zhau YW, Silverman JM. A case-control study of Alzheimer’s disease in China. Neurology. 1992;42:1481–8.PubMed Li G, Shen YC, Li YT, Chen CH, Zhau YW, Silverman JM. A case-control study of Alzheimer’s disease in China. Neurology. 1992;42:1481–8.PubMed
577.
Zurück zum Zitat Fratiglioni L, Ahlbom A, Viitanen M, Winblad B. Risk factors for late-onset Alzheimer’s disease: a population-based, case-control study. Ann Neurol. 1993;33:258–66.PubMedCrossRef Fratiglioni L, Ahlbom A, Viitanen M, Winblad B. Risk factors for late-onset Alzheimer’s disease: a population-based, case-control study. Ann Neurol. 1993;33:258–66.PubMedCrossRef
578.
Zurück zum Zitat Silverman JM, Raiford K, Edland S, Fillenbaum G, Morris JC, Clark CM, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part VI. Family history assessment: a multicenter study of first-degree relatives of Alzheimer’s disease probands and nondemented spouse controls. Neurology. 1994;44:1253–9.PubMed Silverman JM, Raiford K, Edland S, Fillenbaum G, Morris JC, Clark CM, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part VI. Family history assessment: a multicenter study of first-degree relatives of Alzheimer’s disease probands and nondemented spouse controls. Neurology. 1994;44:1253–9.PubMed
579.
Zurück zum Zitat Marder K, Tang MX, Alfaro B, Mejia H, Cote L, Louis E, et al. Risk of Alzheimer’s disease in relatives of Parkinson’s disease patients with and without dementia. Neurology. 1999;52:719–24.PubMed Marder K, Tang MX, Alfaro B, Mejia H, Cote L, Louis E, et al. Risk of Alzheimer’s disease in relatives of Parkinson’s disease patients with and without dementia. Neurology. 1999;52:719–24.PubMed
580.
Zurück zum Zitat Levy G, Louis ED, Mejia-Santana H, Cote L, Andrews H, Harris J, et al. Lack of familial aggregation of Parkinson disease and Alzheimer disease. Arch Neurol. 2004;61:1033–9.PubMedCrossRef Levy G, Louis ED, Mejia-Santana H, Cote L, Andrews H, Harris J, et al. Lack of familial aggregation of Parkinson disease and Alzheimer disease. Arch Neurol. 2004;61:1033–9.PubMedCrossRef
581.
Zurück zum Zitat Rosen AR, Steenland NK, Hanfelt J, Factor SA, Lah JJ, Levey AI. Evidence of shared risk for Alzheimer’s disease and Parkinson’s disease using family history. Neurogenetics. 2007;8:263–70.PubMedCrossRef Rosen AR, Steenland NK, Hanfelt J, Factor SA, Lah JJ, Levey AI. Evidence of shared risk for Alzheimer’s disease and Parkinson’s disease using family history. Neurogenetics. 2007;8:263–70.PubMedCrossRef
582.
Zurück zum Zitat Rocca WA, Bower JH, Ahlskog JE, Elbaz A, Grossardt BR, McDonnell SK, et al. Risk of cognitive impairment or dementia in relatives of patients with Parkinson disease. Arch Neurol. 2007;64:1458–64.PubMedCrossRef Rocca WA, Bower JH, Ahlskog JE, Elbaz A, Grossardt BR, McDonnell SK, et al. Risk of cognitive impairment or dementia in relatives of patients with Parkinson disease. Arch Neurol. 2007;64:1458–64.PubMedCrossRef
583.
Zurück zum Zitat Costello S, Bordelon Y, Bronstein J, Ritz B. Familial associations of Alzheimer disease and essential tremor with Parkinson disease. Eur J Neurol. 2010;17:871–8.PubMedCrossRef Costello S, Bordelon Y, Bronstein J, Ritz B. Familial associations of Alzheimer disease and essential tremor with Parkinson disease. Eur J Neurol. 2010;17:871–8.PubMedCrossRef
584.
Zurück zum Zitat Shahed J, Jankovic J. Exploring the relationship between essential tremor and Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:67–76.PubMedCrossRef Shahed J, Jankovic J. Exploring the relationship between essential tremor and Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:67–76.PubMedCrossRef
585.
Zurück zum Zitat Geraghty JJ, Jankovic J, Zetusky WJ. Association between essential tremor and Parkinson’s disease. Ann Neurol. 1985;17:329–33.PubMedCrossRef Geraghty JJ, Jankovic J, Zetusky WJ. Association between essential tremor and Parkinson’s disease. Ann Neurol. 1985;17:329–33.PubMedCrossRef
586.
587.
Zurück zum Zitat Rajput AH, Offord KP, Beard CM, Kurland LT. Essential tremor in Rochester, Minnesota: a 45-year study. J Neurol Neurosurg Psychiatry. 1984;47:466–70.PubMedCrossRef Rajput AH, Offord KP, Beard CM, Kurland LT. Essential tremor in Rochester, Minnesota: a 45-year study. J Neurol Neurosurg Psychiatry. 1984;47:466–70.PubMedCrossRef
588.
Zurück zum Zitat Larsson T, Sjogren T. Essential tremor: a clinical and genetic population study. Acta Psychiatr Scand Suppl. 1960;36:1–176.PubMed Larsson T, Sjogren T. Essential tremor: a clinical and genetic population study. Acta Psychiatr Scand Suppl. 1960;36:1–176.PubMed
589.
Zurück zum Zitat Cleeves L, Findley LJ, Koller W. Lack of association between essential tremor and Parkinson’s disease. Ann Neurol. 1988;24:23–6.PubMedCrossRef Cleeves L, Findley LJ, Koller W. Lack of association between essential tremor and Parkinson’s disease. Ann Neurol. 1988;24:23–6.PubMedCrossRef
590.
Zurück zum Zitat Louis ED, Levy G, Mejia-Santana H, Cote L, Andrews H, Harris J, et al. Risk of action tremor in relatives of tremor-dominant and postural instability gait disorder PD. Neurology. 2003;61:931–6.PubMed Louis ED, Levy G, Mejia-Santana H, Cote L, Andrews H, Harris J, et al. Risk of action tremor in relatives of tremor-dominant and postural instability gait disorder PD. Neurology. 2003;61:931–6.PubMed
591.
Zurück zum Zitat Rocca WA, Bower JH, Ahlskog JE, Elbaz A, Grossardt BR, McDonnell SK, et al. Increased risk of essential tremor in first-degree relatives of patients with Parkinson’s disease. Mov Disord. 2007;22:1607–14.PubMedCrossRef Rocca WA, Bower JH, Ahlskog JE, Elbaz A, Grossardt BR, McDonnell SK, et al. Increased risk of essential tremor in first-degree relatives of patients with Parkinson’s disease. Mov Disord. 2007;22:1607–14.PubMedCrossRef
592.
Zurück zum Zitat Benito-Leon J, Louis ED, Bermejo-Pareja F. Risk of incident Parkinson’s disease and parkinsonism in essential tremor: a population based study. J Neurol Neurosurg Psychiatry. 2009;80:423–5.PubMedCrossRef Benito-Leon J, Louis ED, Bermejo-Pareja F. Risk of incident Parkinson’s disease and parkinsonism in essential tremor: a population based study. J Neurol Neurosurg Psychiatry. 2009;80:423–5.PubMedCrossRef
593.
Zurück zum Zitat Westlund K, Hougen A. Cancer as a cause of death among patients with other cronic diseases. JAMA. 1956;162:1003. Westlund K, Hougen A. Cancer as a cause of death among patients with other cronic diseases. JAMA. 1956;162:1003.
594.
Zurück zum Zitat Pritchard PB III, Netsky MG. Prevalence of neoplasms and causes of death in paralysis agitans. A necropsy study. Neurology. 1973;23:215–22.PubMed Pritchard PB III, Netsky MG. Prevalence of neoplasms and causes of death in paralysis agitans. A necropsy study. Neurology. 1973;23:215–22.PubMed
595.
Zurück zum Zitat Harada H, Nishikawa S, Takahashi K. Epidemiology of Parkinson’s disease in a Japanese city. Arch Neurol. 1983;40:151–4.PubMed Harada H, Nishikawa S, Takahashi K. Epidemiology of Parkinson’s disease in a Japanese city. Arch Neurol. 1983;40:151–4.PubMed
596.
Zurück zum Zitat Jansson B, Jankovic J. Low cancer rates among patients with Parkinson’s disease. Ann Neurol. 1985;17:505–9.PubMedCrossRef Jansson B, Jankovic J. Low cancer rates among patients with Parkinson’s disease. Ann Neurol. 1985;17:505–9.PubMedCrossRef
597.
Zurück zum Zitat Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH. Occurrence of different cancers in patients with Parkinson’s disease. BMJ. 1995;310:1500–1.PubMed Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH. Occurrence of different cancers in patients with Parkinson’s disease. BMJ. 1995;310:1500–1.PubMed
598.
Zurück zum Zitat Raschetti R, Spila-Alegiani S, Vanacore N, Ancona C, Meco G. Mortality in a population-based cohort of patients treated with antiparkinsonian drugs. Acta Neurol Scand. 1998;97:20–6.PubMedCrossRef Raschetti R, Spila-Alegiani S, Vanacore N, Ancona C, Meco G. Mortality in a population-based cohort of patients treated with antiparkinsonian drugs. Acta Neurol Scand. 1998;97:20–6.PubMedCrossRef
599.
Zurück zum Zitat Vanacore N, Spila-Alegiani S, Raschetti R, Meco G. Mortality cancer risk in parkinsonian patients: a population-based study. Neurology. 1999;52:395–8.PubMed Vanacore N, Spila-Alegiani S, Raschetti R, Meco G. Mortality cancer risk in parkinsonian patients: a population-based study. Neurology. 1999;52:395–8.PubMed
600.
Zurück zum Zitat Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S. Mortality and cancer incidence in patients with Parkinson’s disease. J Neurol. 2000;247:429–34.PubMedCrossRef Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S. Mortality and cancer incidence in patients with Parkinson’s disease. J Neurol. 2000;247:429–34.PubMedCrossRef
601.
Zurück zum Zitat D’Amelio M, Ragonese P, Morgante L, Epifanio A, Callari G, Salemi G, et al. Tumor diagnosis preceding Parkinson’s disease: a case-control study. Mov Disord. 2004;19:807–11.PubMedCrossRef D’Amelio M, Ragonese P, Morgante L, Epifanio A, Callari G, Salemi G, et al. Tumor diagnosis preceding Parkinson’s disease: a case-control study. Mov Disord. 2004;19:807–11.PubMedCrossRef
602.
Zurück zum Zitat Elbaz A, Peterson BJ, Yang P, Van Gerpen JA, Bower JH, Maraganore DM, et al. Nonfatal cancer preceding Parkinson’s disease: a case-control study. Epidemiology. 2002;13:157–64.PubMedCrossRef Elbaz A, Peterson BJ, Yang P, Van Gerpen JA, Bower JH, Maraganore DM, et al. Nonfatal cancer preceding Parkinson’s disease: a case-control study. Epidemiology. 2002;13:157–64.PubMedCrossRef
603.
Zurück zum Zitat Elbaz A, Peterson BJ, Bower JH, Yang P, Maraganore DM, McDonnell SK, et al. Risk of cancer after the diagnosis of Parkinson’s disease: a historical cohort study. Mov Disord. 2005;20:719–25.PubMedCrossRef Elbaz A, Peterson BJ, Bower JH, Yang P, Maraganore DM, McDonnell SK, et al. Risk of cancer after the diagnosis of Parkinson’s disease: a historical cohort study. Mov Disord. 2005;20:719–25.PubMedCrossRef
604.
Zurück zum Zitat Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H. Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer. 2005;92:201–5.PubMedCrossRef Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H. Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer. 2005;92:201–5.PubMedCrossRef
605.
Zurück zum Zitat Olsen JH, Friis S, Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology. 2006;17:582–7.PubMedCrossRef Olsen JH, Friis S, Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology. 2006;17:582–7.PubMedCrossRef
606.
Zurück zum Zitat Becker C, Brobert GP, Johansson S, Jick SS, Meier CR. Cancer risk in association with Parkinson disease: a population-based study. Parkinsonism Relat Disord. 2010;16:186–90. Becker C, Brobert GP, Johansson S, Jick SS, Meier CR. Cancer risk in association with Parkinson disease: a population-based study. Parkinsonism Relat Disord. 2010;16:186–90.
607.
Zurück zum Zitat Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson’s disease. Cancer Causes Control. 2007;18:705–11.PubMedCrossRef Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson’s disease. Cancer Causes Control. 2007;18:705–11.PubMedCrossRef
608.
Zurück zum Zitat Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T. A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. Cancer Epidemiol Biomarkers Prev. 2007;16:1260–5.PubMedCrossRef Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T. A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. Cancer Epidemiol Biomarkers Prev. 2007;16:1260–5.PubMedCrossRef
609.
610.
Zurück zum Zitat Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Genetic determinants of hair color and Parkinson’s disease risk. Ann Neurol. 2009;65:76–82.PubMedCrossRef Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Genetic determinants of hair color and Parkinson’s disease risk. Ann Neurol. 2009;65:76–82.PubMedCrossRef
611.
Zurück zum Zitat Zanetti R, Loria D, Rosso S. Melanoma, Parkinson’s disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res. 2006;16:201–6.PubMedCrossRef Zanetti R, Loria D, Rosso S. Melanoma, Parkinson’s disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res. 2006;16:201–6.PubMedCrossRef
612.
Zurück zum Zitat Vermeij JD, Winogrodzka A, Trip J, Weber WE. Parkinson’s disease, levodopa-use and the risk of melanoma. Parkinsonism Relat Disord. 2009;15:551–3.PubMedCrossRef Vermeij JD, Winogrodzka A, Trip J, Weber WE. Parkinson’s disease, levodopa-use and the risk of melanoma. Parkinsonism Relat Disord. 2009;15:551–3.PubMedCrossRef
613.
Zurück zum Zitat Zanetti R, Rosso S, Loria DI. Parkinson’s disease and cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1081.PubMedCrossRef Zanetti R, Rosso S, Loria DI. Parkinson’s disease and cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1081.PubMedCrossRef
614.
Zurück zum Zitat Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology. 2009;73:1286–91.PubMedCrossRef Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology. 2009;73:1286–91.PubMedCrossRef
615.
Zurück zum Zitat Herrero Hernandez E. Pigmentation genes link Parkinson’s disease to melanoma, opening a window on both etiologies. Med Hypotheses. 2009;72:280–4.PubMedCrossRef Herrero Hernandez E. Pigmentation genes link Parkinson’s disease to melanoma, opening a window on both etiologies. Med Hypotheses. 2009;72:280–4.PubMedCrossRef
616.
Zurück zum Zitat Bajaj A, Driver JA, Schernhammer ES. Parkinson’s disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control. 2010;21:697–707.PubMedCrossRef Bajaj A, Driver JA, Schernhammer ES. Parkinson’s disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control. 2010;21:697–707.PubMedCrossRef
617.
Zurück zum Zitat West AB, Dawson VL, Dawson TM. To die or grow: Parkinson’s disease and cancer. Trends Neurosci. 2005;28:348–52.PubMedCrossRef West AB, Dawson VL, Dawson TM. To die or grow: Parkinson’s disease and cancer. Trends Neurosci. 2005;28:348–52.PubMedCrossRef
618.
Zurück zum Zitat Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology. 2007;69:1542–50.PubMedCrossRef Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology. 2007;69:1542–50.PubMedCrossRef
619.
Zurück zum Zitat D’Amelio M, Ragonese P, Sconzo G, Aridon P, Savettieri G. Parkinson’s disease and cancer: insights for pathogenesis from epidemiology. Ann N Y Acad Sci. 2009;1155:324–34.PubMedCrossRef D’Amelio M, Ragonese P, Sconzo G, Aridon P, Savettieri G. Parkinson’s disease and cancer: insights for pathogenesis from epidemiology. Ann N Y Acad Sci. 2009;1155:324–34.PubMedCrossRef
620.
Zurück zum Zitat Lacava G. Boxer’s Encephalopathy. J Sports Med Phys Fitness. 1963;168:87–92.PubMed Lacava G. Boxer’s Encephalopathy. J Sports Med Phys Fitness. 1963;168:87–92.PubMed
621.
Zurück zum Zitat Factor SA, Weiner WJ. Prior history of head trauma in Parkinson’s disease. Mov Disord. 1991;6:225–9.PubMedCrossRef Factor SA, Weiner WJ. Prior history of head trauma in Parkinson’s disease. Mov Disord. 1991;6:225–9.PubMedCrossRef
622.
623.
Zurück zum Zitat Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, Rocca WA. Head trauma preceding PD: a case-control study. Neurology. 2003;60:1610–5.PubMed Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, Rocca WA. Head trauma preceding PD: a case-control study. Neurology. 2003;60:1610–5.PubMed
624.
Zurück zum Zitat Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW. Head injury and Parkinson’s disease risk in twins. Ann Neurol. 2006;60:65–72.PubMedCrossRef Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW. Head injury and Parkinson’s disease risk in twins. Ann Neurol. 2006;60:65–72.PubMedCrossRef
625.
Zurück zum Zitat Maher NE, Golbe LI, Lazzarini AM, Mark MH, Currie LJ, Wooten GF, et al. Epidemiologic study of 203 sibling pairs with Parkinson’s disease: the GenePD study. Neurology. 2002;58:79–84.PubMed Maher NE, Golbe LI, Lazzarini AM, Mark MH, Currie LJ, Wooten GF, et al. Epidemiologic study of 203 sibling pairs with Parkinson’s disease: the GenePD study. Neurology. 2002;58:79–84.PubMed
626.
Zurück zum Zitat Williams DB, Annegers JF, Kokmen E, O’Brien PC, Kurland LT. Brain injury and neurologic sequelae: a cohort study of dementia, parkinsonism, and amyotrophic lateral sclerosis. Neurology. 1991;41:1554–7.PubMed Williams DB, Annegers JF, Kokmen E, O’Brien PC, Kurland LT. Brain injury and neurologic sequelae: a cohort study of dementia, parkinsonism, and amyotrophic lateral sclerosis. Neurology. 1991;41:1554–7.PubMed
627.
Zurück zum Zitat Rugbjerg K, Ritz B, Korbo L, Martinussen N, Olsen JH. Risk of Parkinson’s disease after hospital contact for head injury: population based case-control study. BMJ. 2008;337:a2494.PubMedCrossRef Rugbjerg K, Ritz B, Korbo L, Martinussen N, Olsen JH. Risk of Parkinson’s disease after hospital contact for head injury: population based case-control study. BMJ. 2008;337:a2494.PubMedCrossRef
628.
Zurück zum Zitat Spangenberg S, Hannerz H, Tuchsen F, Mikkelsen KL. A nationwide population study of severe head injury and Parkinson’s disease. Parkinsonism Relat Disord. 2009;15:12–4.PubMedCrossRef Spangenberg S, Hannerz H, Tuchsen F, Mikkelsen KL. A nationwide population study of severe head injury and Parkinson’s disease. Parkinsonism Relat Disord. 2009;15:12–4.PubMedCrossRef
629.
Zurück zum Zitat Pressley JC, Louis ED, Tang MX, Cote L, Cohen PD, Glied S, et al. The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology. 2003;60:87–93.PubMed Pressley JC, Louis ED, Tang MX, Cote L, Cohen PD, Glied S, et al. The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology. 2003;60:87–93.PubMed
630.
Zurück zum Zitat D’Amelio M, Ragonese P, Callari G, Di Benedetto N, Palmeri B, Terruso V, et al. Diabetes preceding Parkinson’s disease onset. A case-control study. Parkinsonism Relat Disord. 2009;15:660–4.PubMedCrossRef D’Amelio M, Ragonese P, Callari G, Di Benedetto N, Palmeri B, Terruso V, et al. Diabetes preceding Parkinson’s disease onset. A case-control study. Parkinsonism Relat Disord. 2009;15:660–4.PubMedCrossRef
631.
Zurück zum Zitat Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke. 2006;37:1184–8.PubMedCrossRef Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke. 2006;37:1184–8.PubMedCrossRef
632.
Zurück zum Zitat Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care. 2007;30:842–7.PubMedCrossRef Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care. 2007;30:842–7.PubMedCrossRef
633.
Zurück zum Zitat Driver JA, Smith A, Buring JE, Gaziano JM, Kurth T, Logroscino G. Prospective cohort study of type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care. 2008;31:2003–5.PubMedCrossRef Driver JA, Smith A, Buring JE, Gaziano JM, Kurth T, Logroscino G. Prospective cohort study of type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care. 2008;31:2003–5.PubMedCrossRef
634.
Zurück zum Zitat Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology. 2007;69:1688–95.PubMedCrossRef Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology. 2007;69:1688–95.PubMedCrossRef
635.
Zurück zum Zitat Becker C, Brobert GP, Johansson S, Jick SS, Meier CR. Diabetes in patients with idiopathic Parkinson’s disease. Diabetes Care. 2008;31:1808–12.PubMedCrossRef Becker C, Brobert GP, Johansson S, Jick SS, Meier CR. Diabetes in patients with idiopathic Parkinson’s disease. Diabetes Care. 2008;31:1808–12.PubMedCrossRef
636.
Zurück zum Zitat Becker C, Jick SS, Meier CR. Risk of stroke in patients with idiopathic Parkinson disease. Parkinsonism Relat Disord. 2009;16:31–5.PubMedCrossRef Becker C, Jick SS, Meier CR. Risk of stroke in patients with idiopathic Parkinson disease. Parkinsonism Relat Disord. 2009;16:31–5.PubMedCrossRef
637.
Zurück zum Zitat Okello E, Jiang X, Mohamed S, Zhao Q, Wang T. Combined statin/coenzyme Q10 as adjunctive treatment of chronic heart failure. Med Hypotheses. 2009;73:306–8.PubMedCrossRef Okello E, Jiang X, Mohamed S, Zhao Q, Wang T. Combined statin/coenzyme Q10 as adjunctive treatment of chronic heart failure. Med Hypotheses. 2009;73:306–8.PubMedCrossRef
638.
Zurück zum Zitat Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson’s disease. Mov Disord. 2007;22:377–81.PubMedCrossRef Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson’s disease. Mov Disord. 2007;22:377–81.PubMedCrossRef
639.
Zurück zum Zitat Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW. Low LDL cholesterol and increased risk of Parkinson’s disease: prospective results from Honolulu-Asia Aging Study. Mov Disord. 2008;23:1013–8.PubMedCrossRef Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW. Low LDL cholesterol and increased risk of Parkinson’s disease: prospective results from Honolulu-Asia Aging Study. Mov Disord. 2008;23:1013–8.PubMedCrossRef
640.
Zurück zum Zitat de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum cholesterol levels and the risk of Parkinson’s disease. Am J Epidemiol. 2006;164:998–1002.PubMedCrossRef de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum cholesterol levels and the risk of Parkinson’s disease. Am J Epidemiol. 2006;164:998–1002.PubMedCrossRef
641.
Zurück zum Zitat Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. Total cholesterol and the risk of Parkinson disease. Neurology. 2008;70:1972–9.PubMedCrossRef Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. Total cholesterol and the risk of Parkinson disease. Neurology. 2008;70:1972–9.PubMedCrossRef
642.
Zurück zum Zitat Becker C, Meier CR. Statins and the risk of Parkinson disease: an update on the controversy. Expert Opin Drug Saf. 2009;8:261–71.PubMedCrossRef Becker C, Meier CR. Statins and the risk of Parkinson disease: an update on the controversy. Expert Opin Drug Saf. 2009;8:261–71.PubMedCrossRef
643.
Zurück zum Zitat Becker C, Jick SS, Meier CR. Use of statins and the risk of Parkinson’s disease: a retrospective case-control study in the UK. Drug Saf. 2008;31:399–407.PubMedCrossRef Becker C, Jick SS, Meier CR. Use of statins and the risk of Parkinson’s disease: a retrospective case-control study in the UK. Drug Saf. 2008;31:399–407.PubMedCrossRef
644.
Zurück zum Zitat Shulman LM. Is there a connection between estrogen and Parkinson’s disease? Parkinsonism Relat Disord. 2002;8:289–95.PubMedCrossRef Shulman LM. Is there a connection between estrogen and Parkinson’s disease? Parkinsonism Relat Disord. 2002;8:289–95.PubMedCrossRef
645.
Zurück zum Zitat Marder K, Tang MX, Alfaro B, Mejia H, Cote L, Jacobs D, et al. Postmenopausal estrogen use and Parkinson’s disease with and without dementia. Neurology. 1998;50:1141–3.PubMed Marder K, Tang MX, Alfaro B, Mejia H, Cote L, Jacobs D, et al. Postmenopausal estrogen use and Parkinson’s disease with and without dementia. Neurology. 1998;50:1141–3.PubMed
646.
Zurück zum Zitat Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S. The effect of estrogen replacement on early Parkinson’s disease. Neurology. 1999;52:1417–21.PubMed Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S. The effect of estrogen replacement on early Parkinson’s disease. Neurology. 1999;52:1417–21.PubMed
647.
Zurück zum Zitat Benedetti MD, Maraganore DM, Bower JH, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson’s disease: an exploratory case-control study. Mov Disord. 2001;16:830–7.PubMedCrossRef Benedetti MD, Maraganore DM, Bower JH, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson’s disease: an exploratory case-control study. Mov Disord. 2001;16:830–7.PubMedCrossRef
648.
Zurück zum Zitat Ragonese P, D’Amelio M, Salemi G, Aridon P, Gammino M, Epifanio A, et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology. 2004;62:2010–4.PubMed Ragonese P, D’Amelio M, Salemi G, Aridon P, Gammino M, Epifanio A, et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology. 2004;62:2010–4.PubMed
649.
Zurück zum Zitat Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol. 2004;61:886–8.PubMedCrossRef Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol. 2004;61:886–8.PubMedCrossRef
650.
Zurück zum Zitat Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease. Neurology. 2003;60:790–5.PubMed Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease. Neurology. 2003;60:790–5.PubMed
651.
Zurück zum Zitat Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson’s disease. Mov Disord. 2009;24:1359–65.PubMedCrossRef Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson’s disease. Mov Disord. 2009;24:1359–65.PubMedCrossRef
652.
Zurück zum Zitat Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology. 2008;70:200–9.PubMedCrossRef Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology. 2008;70:200–9.PubMedCrossRef
653.
Zurück zum Zitat Frigerio R, Breteler MM, de Lau LM, Sanft KR, Bower JH, Ahlskog JE, et al. Number of children and risk of Parkinson’s disease. Mov Disord. 2007;22:632–9.PubMedCrossRef Frigerio R, Breteler MM, de Lau LM, Sanft KR, Bower JH, Ahlskog JE, et al. Number of children and risk of Parkinson’s disease. Mov Disord. 2007;22:632–9.PubMedCrossRef
654.
Zurück zum Zitat Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78:6858–62.PubMedCrossRef Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78:6858–62.PubMedCrossRef
655.
Zurück zum Zitat Church WH, Ward VL. Uric acid is reduced in the substantia nigra in Parkinson’s disease: effect on dopamine oxidation. Brain Res Bull. 1994;33:419–25.PubMedCrossRef Church WH, Ward VL. Uric acid is reduced in the substantia nigra in Parkinson’s disease: effect on dopamine oxidation. Brain Res Bull. 1994;33:419–25.PubMedCrossRef
656.
Zurück zum Zitat Tohgi H, Abe T, Takahashi S, Kikuchi T. The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson’s disease. J Neural Transm Park Dis Dement Sect. 1993;6:119–26.PubMedCrossRef Tohgi H, Abe T, Takahashi S, Kikuchi T. The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson’s disease. J Neural Transm Park Dis Dement Sect. 1993;6:119–26.PubMedCrossRef
657.
Zurück zum Zitat Ahlskog JE, Uitti RJ, Low PA, Tyce GM, Nickander KK, Petersen RC, et al. No evidence for systemic oxidant stress in Parkinson’s or Alzheimer’s disease. Mov Disord. 1995;10:566–73.PubMedCrossRef Ahlskog JE, Uitti RJ, Low PA, Tyce GM, Nickander KK, Petersen RC, et al. No evidence for systemic oxidant stress in Parkinson’s or Alzheimer’s disease. Mov Disord. 1995;10:566–73.PubMedCrossRef
658.
Zurück zum Zitat Annanmaki T, Muuronen A, Murros K. Low plasma uric acid level in Parkinson’s disease. Mov Disord. 2007;22:1133–7.PubMedCrossRef Annanmaki T, Muuronen A, Murros K. Low plasma uric acid level in Parkinson’s disease. Mov Disord. 2007;22:1133–7.PubMedCrossRef
659.
Zurück zum Zitat Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson’s disease. Am J Epidemiol. 1996;144:480–4.PubMed Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson’s disease. Am J Epidemiol. 1996;144:480–4.PubMed
660.
Zurück zum Zitat de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol. 2005;58:797–800.PubMedCrossRef de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol. 2005;58:797–800.PubMedCrossRef
661.
Zurück zum Zitat Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson’s disease. Am J Epidemiol. 2007;166:561–7.PubMedCrossRef Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson’s disease. Am J Epidemiol. 2007;166:561–7.PubMedCrossRef
662.
Zurück zum Zitat Chen H, Mosley TH, Alonso A, Huang X. Plasma urate and Parkinson’s disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2009;169:1064–9.PubMedCrossRef Chen H, Mosley TH, Alonso A, Huang X. Plasma urate and Parkinson’s disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2009;169:1064–9.PubMedCrossRef
663.
Zurück zum Zitat Alonso A, Rodriguez LA, Logroscino G, Hernan MA. Gout and risk of Parkinson disease: a prospective study. Neurology. 2007;69:1696–700.PubMedCrossRef Alonso A, Rodriguez LA, Logroscino G, Hernan MA. Gout and risk of Parkinson disease: a prospective study. Neurology. 2007;69:1696–700.PubMedCrossRef
664.
Zurück zum Zitat De Vera M, Rahman MM, Rankin J, Kopec J, Gao X, Choi H. Gout and the risk of Parkinson’s disease: a cohort study. Arthritis Rheum. 2008;59:1549–54.PubMedCrossRef De Vera M, Rahman MM, Rankin J, Kopec J, Gao X, Choi H. Gout and the risk of Parkinson’s disease: a cohort study. Arthritis Rheum. 2008;59:1549–54.PubMedCrossRef
665.
Zurück zum Zitat Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65:716–23.PubMedCrossRef Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65:716–23.PubMedCrossRef
666.
Zurück zum Zitat Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009;66:1460–8.PubMedCrossRef Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009;66:1460–8.PubMedCrossRef
667.
Zurück zum Zitat Bronstein J, Carvey P, Chen H, Cory-Slechta D, DiMonte D, Duda J, et al. Meeting report: Consensus statement–Parkinson’s disease and the environment: Collaborative on Health and the Environment and Parkinson’s Action Network (CHE PAN) Conference 26–28 June 2007. Environ Health Persp. 2009;117:117–21. Bronstein J, Carvey P, Chen H, Cory-Slechta D, DiMonte D, Duda J, et al. Meeting report: Consensus statement–Parkinson’s disease and the environment: Collaborative on Health and the Environment and Parkinson’s Action Network (CHE PAN) Conference 26–28 June 2007. Environ Health Persp. 2009;117:117–21.
668.
Zurück zum Zitat Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology. 2001;57:1032–5.PubMed Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology. 2001;57:1032–5.PubMed
669.
Zurück zum Zitat Lemay S, Chouinard S, Blanchet P, Masson H, Soland V, Beuter A, et al. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:31–9.PubMedCrossRef Lemay S, Chouinard S, Blanchet P, Masson H, Soland V, Beuter A, et al. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:31–9.PubMedCrossRef
670.
Zurück zum Zitat Xu K, Bastia E, Schwarzschild M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson’s disease. Pharmacol Ther. 2005;105:267–310.PubMedCrossRef Xu K, Bastia E, Schwarzschild M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson’s disease. Pharmacol Ther. 2005;105:267–310.PubMedCrossRef
671.
Zurück zum Zitat Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology. 2003;61:297–303.PubMed Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology. 2003;61:297–303.PubMed
672.
Zurück zum Zitat Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, et al. Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord. 2008;23:2177–85.PubMedCrossRef Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, et al. Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord. 2008;23:2177–85.PubMedCrossRef
673.
Zurück zum Zitat LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63:295–302.PubMedCrossRef LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63:295–302.PubMedCrossRef
674.
Zurück zum Zitat Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70:2233–40.PubMedCrossRef Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70:2233–40.PubMedCrossRef
675.
Zurück zum Zitat Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, et al. Significant linkage of Parkinson disease to chromosome 2q36-37. Am J Hum Genet. 2003;72:1053–7.PubMedCrossRef Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, et al. Significant linkage of Parkinson disease to chromosome 2q36-37. Am J Hum Genet. 2003;72:1053–7.PubMedCrossRef
Metadaten
Titel
Epidemiology and etiology of Parkinson’s disease: a review of the evidence
verfasst von
Karin Wirdefeldt
Hans-Olov Adami
Philip Cole
Dimitrios Trichopoulos
Jack Mandel
Publikationsdatum
01.06.2011
Verlag
Springer Netherlands
Erschienen in
European Journal of Epidemiology / Ausgabe Sonderheft 1/2011
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-011-9581-6